@prefix : <https://w3id.org/skgo/pham#> .
@prefix dc: <http://purl.org/dc/elements/1.1/> .
@prefix ns: <http://www.w3.org/2003/06/sw-vocab-status/ns#> .
@prefix owl: <http://www.w3.org/2002/07/owl#> .
@prefix phm: <https://w3id.org/SKGO/phm##> .
@prefix rdf: <http://www.w3.org/1999/02/22-rdf-syntax-ns#> .
@prefix wot: <http://xmlns.com/wot/0.1/> .
@prefix xml: <http://www.w3.org/XML/1998/namespace> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .
@prefix bibo: <http://purl.org/ontology/bibo/> .
@prefix foaf: <http://xmlns.com/foaf/0.1/> .
@prefix rdfs: <http://www.w3.org/2000/01/rdf-schema#> .
@prefix skos: <http://www.w3.org/2004/02/skos/core#> .
@prefix vann: <http://purl.org/vocab/vann/> .
@prefix terms: <http://purl.org/dc/terms/> .
@prefix terms1: <http://ns.nature.com/terms/> .
@base <https://w3id.org/skgo/pham> .

<https://w3id.org/skgo/pham> rdf:type owl:Ontology ;
                              owl:imports terms1: ,
                                          bibo: ,
                                          foaf: ;
                              dc:creator "Zeynep Say, Aysegul Say, Sahar Vahdati, Said Fathalla"^^xsd:string ;
                              terms:license "Creative Commons Attribution 3.0 (CC BY 3.0)"^^xsd:string ;
                              owl:versionInfo "2.0"^^xsd:string ;
                              skos:definition """PharmSci is an Ontology for describing Pharmaceutical Science research.
The aim of building ontology is to help Pharmaceutical Science researchers to find scientific research close to their work or their research topic. Ontology covers the study design for the pharmaceutical science research which is a Clinical Study includes experimental and non-experimental studies."""^^xsd:string .

#################################################################
#    Annotation properties
#################################################################

###  http://purl.org/dc/elements/1.1/contributor
dc:contributor rdf:type owl:AnnotationProperty .


###  http://purl.org/dc/elements/1.1/coverage
dc:coverage rdf:type owl:AnnotationProperty .


###  http://purl.org/dc/elements/1.1/creator
dc:creator rdf:type owl:AnnotationProperty .


###  http://purl.org/dc/elements/1.1/format
dc:format rdf:type owl:AnnotationProperty .


###  http://purl.org/dc/elements/1.1/identifier
dc:identifier rdf:type owl:AnnotationProperty .


###  http://purl.org/dc/elements/1.1/language
dc:language rdf:type owl:AnnotationProperty .


###  http://purl.org/dc/elements/1.1/publisher
dc:publisher rdf:type owl:AnnotationProperty .


###  http://purl.org/dc/elements/1.1/relation
dc:relation rdf:type owl:AnnotationProperty .


###  http://purl.org/dc/elements/1.1/rights
dc:rights rdf:type owl:AnnotationProperty .


###  http://purl.org/dc/elements/1.1/source
dc:source rdf:type owl:AnnotationProperty .


###  http://purl.org/dc/elements/1.1/subject
dc:subject rdf:type owl:AnnotationProperty .


###  http://purl.org/dc/elements/1.1/type
dc:type rdf:type owl:AnnotationProperty .


###  http://purl.org/dc/terms/abstract
terms:abstract rdf:type owl:AnnotationProperty ;
               rdfs:subPropertyOf dc:description .


###  http://purl.org/dc/terms/accessRights
terms:accessRights rdf:type owl:AnnotationProperty ;
                   rdfs:subPropertyOf dc:rights ;
                   rdfs:range terms:RightsStatement .


###  http://purl.org/dc/terms/alternative
terms:alternative rdf:type owl:AnnotationProperty ;
                  rdfs:subPropertyOf dc:title ;
                  rdfs:range rdfs:Literal .


###  http://purl.org/dc/terms/available
terms:available rdf:type owl:AnnotationProperty ;
                rdfs:subPropertyOf dc:date ;
                rdfs:range rdfs:Literal .


###  http://purl.org/dc/terms/bibliographicCitation
terms:bibliographicCitation rdf:type owl:AnnotationProperty ;
                            rdfs:subPropertyOf dc:identifier ;
                            rdfs:range rdfs:Literal ;
                            rdfs:domain terms:BibliographicResource .


###  http://purl.org/dc/terms/conformsTo
terms:conformsTo rdf:type owl:AnnotationProperty ;
                 rdfs:subPropertyOf dc:relation ;
                 rdfs:range terms:Standard .


###  http://purl.org/dc/terms/contributor
terms:contributor rdf:type owl:AnnotationProperty ;
                  rdfs:subPropertyOf dc:contributor ;
                  rdfs:range terms:Agent .


###  http://purl.org/dc/terms/coverage
terms:coverage rdf:type owl:AnnotationProperty ;
               rdfs:subPropertyOf dc:coverage ;
               rdfs:range terms:LocationPeriodOrJurisdiction .


###  http://purl.org/dc/terms/created
terms:created rdf:type owl:AnnotationProperty ;
              rdfs:subPropertyOf dc:date ;
              rdfs:range rdfs:Literal .


###  http://purl.org/dc/terms/creator
terms:creator rdfs:subPropertyOf dc:creator ;
              rdfs:range terms:Agent ,
                         <http://www.w3.org/2000/10/swap/pim/contact#Person> .


###  http://purl.org/dc/terms/date
terms:date rdf:type owl:AnnotationProperty ;
           rdfs:subPropertyOf dc:date ;
           rdfs:range rdfs:Literal .


###  http://purl.org/dc/terms/dateAccepted
terms:dateAccepted rdf:type owl:AnnotationProperty ;
                   rdfs:subPropertyOf dc:date ;
                   rdfs:range rdfs:Literal .


###  http://purl.org/dc/terms/dateCopyrighted
terms:dateCopyrighted rdf:type owl:AnnotationProperty ;
                      rdfs:subPropertyOf dc:date ;
                      rdfs:range rdfs:Literal .


###  http://purl.org/dc/terms/dateSubmitted
terms:dateSubmitted rdf:type owl:AnnotationProperty ;
                    rdfs:subPropertyOf dc:date ;
                    rdfs:range rdfs:Literal .


###  http://purl.org/dc/terms/description
terms:description rdfs:subPropertyOf dc:description ;
                  rdfs:range xsd:string ;
                  rdfs:domain <https://w3id.org/ScienceOnto/phm#ResearchStatement> .


###  http://purl.org/dc/terms/extent
terms:extent rdf:type owl:AnnotationProperty ;
             rdfs:subPropertyOf dc:format ;
             rdfs:range terms:SizeOrDuration .


###  http://purl.org/dc/terms/format
terms:format rdf:type owl:AnnotationProperty ;
             rdfs:subPropertyOf dc:format ;
             rdfs:range terms:MediaTypeOrExtent .


###  http://purl.org/dc/terms/hasFormat
terms:hasFormat rdf:type owl:AnnotationProperty ;
                rdfs:subPropertyOf dc:relation .


###  http://purl.org/dc/terms/hasPart
terms:hasPart rdf:type owl:AnnotationProperty ;
              rdfs:subPropertyOf dc:relation .


###  http://purl.org/dc/terms/hasVersion
terms:hasVersion rdf:type owl:AnnotationProperty ;
                 rdfs:subPropertyOf dc:relation .


###  http://purl.org/dc/terms/identifier
terms:identifier rdfs:subPropertyOf dc:identifier ;
                 rdfs:range rdfs:Literal .


###  http://purl.org/dc/terms/isFormatOf
terms:isFormatOf rdf:type owl:AnnotationProperty ;
                 rdfs:subPropertyOf dc:relation .


###  http://purl.org/dc/terms/isPartOf
terms:isPartOf rdf:type owl:AnnotationProperty ;
               rdfs:subPropertyOf dc:relation .


###  http://purl.org/dc/terms/isReferencedBy
terms:isReferencedBy rdf:type owl:AnnotationProperty ;
                     rdfs:subPropertyOf dc:relation .


###  http://purl.org/dc/terms/isReplacedBy
terms:isReplacedBy rdf:type owl:AnnotationProperty ;
                   rdfs:subPropertyOf dc:relation .


###  http://purl.org/dc/terms/isRequiredBy
terms:isRequiredBy rdf:type owl:AnnotationProperty ;
                   rdfs:subPropertyOf dc:relation .


###  http://purl.org/dc/terms/isVersionOf
terms:isVersionOf rdf:type owl:AnnotationProperty ;
                  rdfs:subPropertyOf dc:relation .


###  http://purl.org/dc/terms/issued
terms:issued rdf:type owl:AnnotationProperty ;
             rdfs:subPropertyOf dc:date ;
             rdfs:range rdfs:Literal .


###  http://purl.org/dc/terms/language
terms:language rdf:type owl:AnnotationProperty ;
               rdfs:subPropertyOf dc:language ;
               rdfs:range terms:LinguisticSystem .


###  http://purl.org/dc/terms/license
terms:license rdf:type owl:AnnotationProperty ;
              rdfs:subPropertyOf dc:rights ;
              rdfs:range terms:LicenseDocument .


###  http://purl.org/dc/terms/medium
terms:medium rdf:type owl:AnnotationProperty ;
             rdfs:subPropertyOf dc:format ;
             rdfs:range terms:PhysicalMedium .


###  http://purl.org/dc/terms/modified
terms:modified rdf:type owl:AnnotationProperty ;
               rdfs:subPropertyOf dc:date ;
               rdfs:range rdfs:Literal .


###  http://purl.org/dc/terms/publisher
terms:publisher rdf:type owl:AnnotationProperty ;
                rdfs:subPropertyOf dc:publisher ;
                rdfs:range terms:Agent .


###  http://purl.org/dc/terms/references
terms:references rdf:type owl:AnnotationProperty ;
                 rdfs:subPropertyOf dc:relation .


###  http://purl.org/dc/terms/relation
terms:relation rdf:type owl:AnnotationProperty ;
               rdfs:subPropertyOf dc:relation .


###  http://purl.org/dc/terms/replaces
terms:replaces rdf:type owl:AnnotationProperty ;
               rdfs:subPropertyOf dc:relation .


###  http://purl.org/dc/terms/requires
terms:requires rdf:type owl:AnnotationProperty ;
               rdfs:subPropertyOf dc:relation .


###  http://purl.org/dc/terms/rights
terms:rights rdf:type owl:AnnotationProperty ;
             rdfs:subPropertyOf dc:rights ;
             rdfs:range terms:RightsStatement .


###  http://purl.org/dc/terms/source
terms:source rdf:type owl:AnnotationProperty ;
             rdfs:subPropertyOf dc:source .


###  http://purl.org/dc/terms/spatial
terms:spatial rdf:type owl:AnnotationProperty ;
              rdfs:subPropertyOf dc:coverage ;
              rdfs:range terms:Location .


###  http://purl.org/dc/terms/subject
terms:subject rdf:type owl:AnnotationProperty ;
              rdfs:subPropertyOf dc:subject .


###  http://purl.org/dc/terms/tableOfContents
terms:tableOfContents rdf:type owl:AnnotationProperty ;
                      rdfs:subPropertyOf dc:description .


###  http://purl.org/dc/terms/temporal
terms:temporal rdf:type owl:AnnotationProperty ;
               rdfs:subPropertyOf dc:coverage ;
               rdfs:range terms:PeriodOfTime .


###  http://purl.org/dc/terms/title
terms:title rdfs:subPropertyOf dc:title ;
            rdfs:range rdfs:Literal .


###  http://purl.org/dc/terms/type
terms:type rdf:type owl:AnnotationProperty ;
           rdfs:subPropertyOf dc:type ;
           rdfs:range rdfs:Class .


###  http://purl.org/dc/terms/valid
terms:valid rdf:type owl:AnnotationProperty ;
            rdfs:subPropertyOf dc:date ;
            rdfs:range rdfs:Literal .


#################################################################
#    Datatypes
#################################################################

###  http://purl.org/dc/terms/Box
terms:Box rdf:type rdfs:Datatype .


###  http://purl.org/dc/terms/ISO3166
terms:ISO3166 rdf:type rdfs:Datatype .


###  http://purl.org/dc/terms/ISO639-2
terms:ISO639-2 rdf:type rdfs:Datatype .


###  http://purl.org/dc/terms/ISO639-3
terms:ISO639-3 rdf:type rdfs:Datatype .


###  http://purl.org/dc/terms/Period
terms:Period rdf:type rdfs:Datatype .


###  http://purl.org/dc/terms/Point
terms:Point rdf:type rdfs:Datatype .


###  http://purl.org/dc/terms/RFC1766
terms:RFC1766 rdf:type rdfs:Datatype .


###  http://purl.org/dc/terms/RFC3066
terms:RFC3066 rdf:type rdfs:Datatype .


###  http://purl.org/dc/terms/RFC4646
terms:RFC4646 rdf:type rdfs:Datatype .


###  http://purl.org/dc/terms/RFC5646
terms:RFC5646 rdf:type rdfs:Datatype .


###  http://purl.org/dc/terms/URI
terms:URI rdf:type rdfs:Datatype .


###  http://purl.org/dc/terms/W3CDTF
terms:W3CDTF rdf:type rdfs:Datatype .


###  http://www.w3.org/2001/XMLSchema#date
xsd:date rdf:type rdfs:Datatype .


###  http://www.w3.org/2001/XMLSchema#gYear
xsd:gYear rdf:type rdfs:Datatype .


#################################################################
#    Object Properties
#################################################################

###  http://ns.nature.com/terms/relation
terms1:relation rdfs:subPropertyOf owl:topObjectProperty .


###  http://purl.org/dc/terms/alternative
terms:alternative rdf:type owl:ObjectProperty ;
                  rdfs:subPropertyOf terms:title .


###  http://purl.org/dc/terms/coverage
terms:coverage rdf:type owl:ObjectProperty .


###  http://purl.org/dc/terms/creator
terms:creator rdf:type owl:ObjectProperty ;
              rdfs:subPropertyOf terms:contributor ;
              rdfs:domain bibo:Article .


###  http://purl.org/dc/terms/hasPart
terms:hasPart rdfs:subPropertyOf terms:relation .


###  http://purl.org/dc/terms/isPartOf
terms:isPartOf rdfs:subPropertyOf terms:relation .


###  http://purl.org/dc/terms/isReferencedBy
terms:isReferencedBy rdfs:subPropertyOf terms:relation .


###  http://purl.org/dc/terms/isVersionOf
terms:isVersionOf rdfs:subPropertyOf terms:relation .


###  http://purl.org/dc/terms/publisher
terms:publisher rdfs:domain terms1:Publication .


###  http://purl.org/dc/terms/references
terms:references rdfs:subPropertyOf terms:relation .


###  http://purl.org/dc/terms/title
terms:title rdfs:domain [ rdf:type owl:Class ;
                          owl:unionOf ( terms1:Publication
                                        bibo:Article
                                      )
                        ] .


###  http://purl.org/dc/terms/type
terms:type rdf:type owl:ObjectProperty .


###  https://w3id.org/skgo/pham#addressesStudy
:addressesStudy rdf:type owl:ObjectProperty ;
                rdfs:subPropertyOf owl:topObjectProperty ;
                rdf:type owl:AsymmetricProperty ,
                         owl:IrreflexiveProperty ;
                rdfs:domain terms1:Publication ;
                rdfs:range :ClinicalStudy ;
                dc:description "To give attention to or deal with a research or study."@en ;
                rdfs:label "addressesStudy"@en .


###  https://w3id.org/skgo/pham#examinedBy
:examinedBy rdf:type owl:ObjectProperty ;
            rdfs:subPropertyOf owl:topObjectProperty ;
            rdf:type owl:AsymmetricProperty ,
                     owl:ReflexiveProperty ;
            rdfs:domain [ rdf:type owl:Class ;
                          owl:unionOf ( :Hypothesis
                                        :levels_of_mdr1_mRNA
                                      )
                        ] ;
            rdfs:range :Multidrug_resistance_to_cancer_cells ;
            dc:description "To look at or consider a statement carefully and in detail in order to explore and discover."@en ;
            rdfs:label "examinedBy"@en .


###  https://w3id.org/skgo/pham#hasBlotAnalysis
:hasBlotAnalysis rdf:type owl:ObjectProperty ;
                 rdfs:subPropertyOf owl:topObjectProperty ;
                 rdf:type owl:AsymmetricProperty ,
                          owl:IrreflexiveProperty ;
                 rdfs:domain :Multidrug_resistance_to_cancer_cells ;
                 rdfs:range :BlotAnalysis ;
                 dc:description "Experiment uses as a method for the transfer of protein, RNA or DNA molecules."@en ;
                 rdfs:label "useBlotAnalysis"@en .


###  https://w3id.org/skgo/pham#hasClinicalProblem
:hasClinicalProblem rdf:type owl:ObjectProperty ;
                    rdfs:subPropertyOf owl:topObjectProperty ;
                    rdf:type owl:AsymmetricProperty ,
                             owl:IrreflexiveProperty ;
                    rdfs:domain :Treatment ;
                    rdfs:range :ClinicalProblem ;
                    dc:description "Problem or a difficulty, disorder, condition occurs in Clinical Study."@en ;
                    rdfs:label "hasClinicalProblem"@en .


###  https://w3id.org/skgo/pham#hasDisease
:hasDisease rdf:type owl:ObjectProperty ;
            rdfs:subPropertyOf owl:topObjectProperty ;
            rdf:type owl:AsymmetricProperty ,
                     owl:IrreflexiveProperty ;
            rdfs:domain :Patient ;
            rdfs:range :Disease ;
            dc:description "Person who shows a definite pathological process having a characteristic set of signs and symptoms."@en ;
            rdfs:label "hasDisease"@en .


###  https://w3id.org/skgo/pham#hasExperiment
:hasExperiment rdf:type owl:ObjectProperty ;
               rdfs:subPropertyOf owl:topObjectProperty ;
               rdf:type owl:AsymmetricProperty ,
                        owl:IrreflexiveProperty ;
               rdfs:domain :ClinicalStudy ;
               rdfs:range :Multidrug_resistance_to_cancer_cells ;
               dc:description "Study has a procedure done in order to discover or demonstrate some fact or general truth"@en ;
               rdfs:label "hasExperiment"@en .


###  https://w3id.org/skgo/pham#hasExperimentKit
:hasExperimentKit rdf:type owl:ObjectProperty ;
                  rdfs:subPropertyOf owl:topObjectProperty ;
                  rdf:type owl:AsymmetricProperty ,
                           owl:IrreflexiveProperty ;
                  rdfs:domain :Multidrug_resistance_to_cancer_cells ;
                  rdfs:range :ExperimentKit ;
                  dc:description "Identification of the kit/biologicals used in the experiment."@en ;
                  rdfs:label "hasExperimentKit"@en .


###  https://w3id.org/skgo/pham#hasExperimentMaterial
:hasExperimentMaterial rdf:type owl:ObjectProperty ;
                       rdfs:subPropertyOf owl:topObjectProperty ;
                       rdf:type owl:AsymmetricProperty ,
                                owl:IrreflexiveProperty ;
                       rdfs:domain :Multidrug_resistance_to_cancer_cells ;
                       rdfs:range :ExperimentMaterial ;
                       dc:description "Experiment has materials are culture collections and chemicals used for executing of an experiment."@en ;
                       rdfs:label "hasExperimentMaterial"@en .


###  https://w3id.org/skgo/pham#hasExperimentMethod
:hasExperimentMethod rdf:type owl:ObjectProperty ;
                     rdfs:subPropertyOf owl:topObjectProperty ;
                     rdf:type owl:AsymmetricProperty ,
                              owl:IrreflexiveProperty ;
                     rdfs:domain :Multidrug_resistance_to_cancer_cells ;
                     rdfs:range :Antibody-mediated_cytolysis_experiment ;
                     dc:description "An experiment has method is a way to solve a scientific task by executing a scientific experiment."@en ;
                     rdfs:label "hasExperimentMethod"@en .


###  https://w3id.org/skgo/pham#hasExperimentalSetting
:hasExperimentalSetting rdf:type owl:ObjectProperty ;
                        rdfs:subPropertyOf owl:topObjectProperty ;
                        rdf:type owl:AsymmetricProperty ,
                                 owl:IrreflexiveProperty ;
                        rdfs:domain :Multidrug_resistance_to_cancer_cells ;
                        rdfs:range :ExperimentSetting ;
                        dc:description "Experiment identifies the designed experiment involves the investigator assigning some or all conditions to subjects."@en ;
                        rdfs:label "hasExperimentSetting"@en .


###  https://w3id.org/skgo/pham#hasHypothesis
:hasHypothesis rdf:type owl:ObjectProperty ;
               rdfs:subPropertyOf owl:topObjectProperty ;
               rdf:type owl:AsymmetricProperty ,
                        owl:IrreflexiveProperty ;
               rdfs:domain :ClinicalStudy ;
               rdfs:range :levels_of_mdr1_mRNA ;
               dc:description "Referencing a claim, focus, goal or hypothes is supported by the study findings and examined by the study experiment."@en ;
               rdfs:label "hasResearchStatement"@en .


###  https://w3id.org/skgo/pham#hasInvestigation
:hasInvestigation rdf:type owl:ObjectProperty ;
                  rdfs:subPropertyOf owl:topObjectProperty ;
                  rdf:type owl:AsymmetricProperty ,
                           owl:IrreflexiveProperty ;
                  rdfs:domain :ClinicalStudy ;
                  rdfs:range :Investigation ;
                  dc:description "Study which acts or processes of examining."@en ;
                  rdfs:label "hasInvestigation"@en .


###  https://w3id.org/skgo/pham#hasProtein
:hasProtein rdf:type owl:ObjectProperty ;
            rdfs:subPropertyOf owl:topObjectProperty ;
            rdf:type owl:AsymmetricProperty ,
                     owl:IrreflexiveProperty ;
            rdfs:domain :Cell ;
            rdfs:range :Gene ;
            dc:description "Referencing any of a group of complex organic macromolecules ."@en ;
            rdfs:label "hasProtein"@en .


###  https://w3id.org/skgo/pham#hasStudyDesign
:hasStudyDesign rdf:type owl:ObjectProperty ;
                rdfs:subPropertyOf owl:topObjectProperty ;
                rdf:type owl:AsymmetricProperty ,
                         owl:IrreflexiveProperty ;
                rdfs:domain :ClinicalStudy ;
                rdfs:range :StudyDesign ;
                dc:description "Clinical Study defines the study design for the trials and experiments, as well as observational studies in medical, clinical and other types of research involving human beings."@en ;
                rdfs:label "hasStudyDesign"@en .


###  https://w3id.org/skgo/pham#hasTreatment
:hasTreatment rdf:type owl:ObjectProperty ;
              rdfs:subPropertyOf owl:topObjectProperty ;
              rdf:type owl:AsymmetricProperty ,
                       owl:IrreflexiveProperty ;
              rdfs:domain [ rdf:type owl:Class ;
                            owl:unionOf ( :Antibody-mediated_cytolysis_experiment
                                          :Multidrug_resistance_to_cancer_cells
                                        )
                          ] ;
              rdfs:range :Treatment ;
              dc:description "Defining a period in a clinical study during which subjects receive therapeutic treatment."@en ;
              rdfs:label "useTreatment"@en .


###  https://w3id.org/skgo/pham#has_Treatment
:has_Treatment rdf:type owl:ObjectProperty ;
               rdfs:subPropertyOf owl:topObjectProperty ;
               rdf:type owl:AsymmetricProperty ,
                        owl:IrreflexiveProperty ;
               rdfs:domain :Disease ;
               rdfs:range :Treatment ;
               dc:description "Disease that has a therapeutic treatment."@en ;
               rdfs:label "hasTreatment"@en .


###  https://w3id.org/skgo/pham#investigate
:investigate rdf:type owl:ObjectProperty ;
             rdfs:subPropertyOf owl:topObjectProperty ;
             rdf:type owl:AsymmetricProperty ,
                      owl:ReflexiveProperty ;
             rdfs:domain :ClinicalStudy ;
             rdfs:range :Disease ;
             dc:description "To observe or inquire into in detail; examine systematically."@en ;
             rdfs:label "investigate"@en .


###  https://w3id.org/skgo/pham#investigatesProblem
:investigatesProblem rdf:type owl:ObjectProperty ;
                     rdfs:subPropertyOf owl:topObjectProperty ;
                     rdf:type owl:AsymmetricProperty ,
                              owl:IrreflexiveProperty ;
                     rdfs:domain :ClinicalStudy ;
                     rdfs:range :ClinicalProblem ;
                     dc:description "To examine an issue, problem, statement of research or study."@en ;
                     rdfs:label "investigatesProblem"@en .


###  https://w3id.org/skgo/pham#isClinicalTrial
:isClinicalTrial rdf:type owl:ObjectProperty ;
                 rdfs:subPropertyOf owl:topObjectProperty ;
                 rdf:type owl:SymmetricProperty ,
                          owl:ReflexiveProperty ;
                 rdfs:domain :Patient ;
                 rdfs:range :ClinicalTrial ;
                 dc:description "Patients are chosen as Clinical Trial for Clinical Study."@en ;
                 rdfs:label "isClinicalTrial"@en ;
                 skos:definition "Patients are chosen as Clinical Trial for Clinical Study."@en .


###  https://w3id.org/skgo/pham#obtainedfrom
:obtainedfrom rdf:type owl:ObjectProperty ,
                       owl:AsymmetricProperty ,
                       owl:IrreflexiveProperty ;
              rdfs:domain [ rdf:type owl:Class ;
                            owl:unionOf ( :ExperimentKit
                                          :ExperimentMaterial
                                        )
                          ] ;
              rdfs:range foaf:Organization ;
              dc:description "Get, acquire, or secure something."@en ;
              rdfs:label "obtainedfrom"@en .


###  https://w3id.org/skgo/pham#obtainedfromPatient
:obtainedfromPatient rdf:type owl:ObjectProperty ;
                     rdfs:subPropertyOf owl:topObjectProperty ;
                     rdf:type owl:AsymmetricProperty ,
                              owl:IrreflexiveProperty ;
                     rdfs:domain :Specimen ;
                     rdfs:range :Patient ;
                     dc:description "Get, acquire, or secure specimen from patient."@en ;
                     rdfs:label "obtainedfromPatient"@en .


###  https://w3id.org/skgo/pham#performsExperiment
:performsExperiment rdf:type owl:ObjectProperty ;
                    rdfs:subPropertyOf owl:topObjectProperty ;
                    rdf:type owl:AsymmetricProperty ,
                             owl:IrreflexiveProperty ;
                    rdfs:domain :ClinicalStudy ;
                    rdfs:range :Multidrug_resistance_to_cancer_cells ;
                    dc:description "Clinical Study performs particular Experiment."@en ;
                    rdfs:label "performsExperiment"@en .


###  https://w3id.org/skgo/pham#refersExperiment
:refersExperiment rdf:type owl:ObjectProperty ;
                  rdfs:subPropertyOf owl:topObjectProperty ;
                  rdf:type owl:AsymmetricProperty ,
                           owl:IrreflexiveProperty ;
                  rdfs:domain :Investigation ;
                  rdfs:range :Multidrug_resistance_to_cancer_cells ;
                  dc:description "To relate investigation to a particular Experiment."@en ;
                  rdfs:label "refersExperiment"@en .


###  https://w3id.org/skgo/pham#resistantTo
:resistantTo rdf:type owl:ObjectProperty ;
             rdfs:subPropertyOf owl:topObjectProperty ;
             rdf:type owl:AsymmetricProperty ,
                      owl:IrreflexiveProperty ;
             rdfs:domain :Cell ;
             rdfs:range :Drug ;
             dc:description "Cell definitions resistant to drugs."@en ;
             rdfs:label "resistantTo"@en .


###  https://w3id.org/skgo/pham#testOn
:testOn rdf:type owl:ObjectProperty ;
        rdfs:subPropertyOf owl:topObjectProperty ;
        rdf:type owl:AsymmetricProperty ,
                 owl:IrreflexiveProperty ;
        rdfs:domain :Drug ;
        rdfs:range :ClinicalTrial ;
        dc:description "To prove; to try a substance; to determine the chemical nature of a substance on Patient."@en ;
        rdfs:label "testOn"@en .


###  https://w3id.org/skgo/pham#useAssay
:useAssay rdf:type owl:ObjectProperty ;
          rdfs:subPropertyOf owl:topObjectProperty ;
          rdf:type owl:AsymmetricProperty ,
                   owl:IrreflexiveProperty ;
          rdfs:domain :Multidrug_resistance_to_cancer_cells ;
          rdfs:range :Assay ;
          dc:description "Method referencing a assay to carry out experiments for the purpose of testing the effect of a perturbing agent in a biological model system."@en ;
          rdfs:label "useAssay"@en .


###  https://w3id.org/skgo/pham#useCellLine
:useCellLine rdf:type owl:ObjectProperty ;
             rdfs:subPropertyOf owl:topObjectProperty ;
             rdf:type owl:AsymmetricProperty ,
                      owl:IrreflexiveProperty ;
             rdfs:domain [ rdf:type owl:Class ;
                           owl:unionOf ( :ExperimentMaterial
                                         :Multidrug_resistance_to_cancer_cells
                                       )
                         ] ;
             rdfs:range :CellLine .


###  https://w3id.org/skgo/pham#useDrug
:useDrug rdf:type owl:ObjectProperty ;
         rdfs:subPropertyOf owl:topObjectProperty ;
         rdf:type owl:AsymmetricProperty ,
                  owl:IrreflexiveProperty ;
         rdfs:domain [ rdf:type owl:Class ;
                       owl:unionOf ( :ExperimentMaterial
                                     :Multidrug_resistance_to_cancer_cells
                                     :Treatment
                                   )
                     ] ;
         rdfs:range :Drug .


###  https://w3id.org/skgo/pham#useGene
:useGene rdf:type owl:ObjectProperty ;
         rdfs:subPropertyOf owl:topObjectProperty ;
         rdf:type owl:AsymmetricProperty ,
                  owl:IrreflexiveProperty ;
         rdfs:domain [ rdf:type owl:Class ;
                       owl:unionOf ( :ExperimentMaterial
                                     :Multidrug_resistance_to_cancer_cells
                                   )
                     ] ;
         rdfs:range :Gene .


###  https://w3id.org/skgo/pham#useProbe
:useProbe rdf:type owl:ObjectProperty ;
          rdfs:subPropertyOf owl:topObjectProperty ;
          rdf:type owl:AsymmetricProperty ,
                   owl:IrreflexiveProperty ;
          rdfs:domain [ rdf:type owl:Class ;
                        owl:unionOf ( :ExperimentMaterial
                                      :Multidrug_resistance_to_cancer_cells
                                    )
                      ] ;
          rdfs:range :Probe .


###  https://w3id.org/skgo/pham#useReagent
:useReagent rdf:type owl:ObjectProperty ;
            rdfs:subPropertyOf owl:topObjectProperty ;
            rdf:type owl:AsymmetricProperty ,
                     owl:IrreflexiveProperty ;
            rdfs:domain :Multidrug_resistance_to_cancer_cells ;
            rdfs:range :Reagent .


###  https://w3id.org/skgo/pham#useSpecimen
:useSpecimen rdf:type owl:ObjectProperty ;
             rdfs:subPropertyOf owl:topObjectProperty ;
             rdf:type owl:AsymmetricProperty ,
                      owl:IrreflexiveProperty ;
             rdfs:domain [ rdf:type owl:Class ;
                           owl:unionOf ( :ExperimentMaterial
                                         :Treatment
                                       )
                         ] ;
             rdfs:range :Specimen .


###  https://w3id.org/skgo/pham#useStatisticalAnalysis
:useStatisticalAnalysis rdf:type owl:ObjectProperty ;
                        rdfs:subPropertyOf owl:topObjectProperty ;
                        rdf:type owl:AsymmetricProperty ,
                                 owl:IrreflexiveProperty ;
                        rdfs:domain :ClinicalStudy ;
                        rdfs:range :StatisticalAnalysis .


#################################################################
#    Data properties
#################################################################

###  http://ns.nature.com/terms/name
terms1:name rdfs:domain [ rdf:type owl:Class ;
                          owl:unionOf ( terms1:Contributor
                                        terms1:Publisher
                                        :ClinicalStudy
                                        :Multidrug_resistance_to_cancer_cells
                                      )
                        ] .


###  http://purl.org/dc/terms/abstract
terms:abstract rdf:type owl:DatatypeProperty ;
               rdfs:subPropertyOf terms:description .


###  http://purl.org/dc/terms/alternative
terms:alternative rdf:type owl:DatatypeProperty .


###  http://purl.org/dc/terms/bibliographicCitation
terms:bibliographicCitation rdf:type owl:DatatypeProperty ;
                            rdfs:subPropertyOf terms:identifier .


###  http://purl.org/dc/terms/identifier
terms:identifier rdf:type owl:DatatypeProperty .


###  http://purl.org/dc/terms/title
terms:title rdf:type owl:DatatypeProperty .


###  http://purl.org/ontology/bibo/abstract
bibo:abstract rdfs:domain [ rdf:type owl:Class ;
                            owl:unionOf ( bibo:Article
                                          rdfs:Resource
                                        )
                          ] ;
              dc:description "A summary of the resource."@en .


###  https://w3id.org/skgo/pham#assayTitle
:assayTitle rdf:type owl:DatatypeProperty ;
            rdfs:subPropertyOf owl:topDataProperty ;
            rdfs:domain :Assay ;
            rdfs:range rdfs:Literal ;
            dc:description "Title of the assay."@en ;
            rdfs:label "assayTitle"@en .


###  https://w3id.org/skgo/pham#failureReason
:failureReason rdf:type owl:DatatypeProperty ;
               rdfs:subPropertyOf owl:topDataProperty ;
               rdfs:domain :Treatment ;
               rdfs:range xsd:string ;
               dc:description "The reasons or causes of a condition or  a fact of not achieving the desired end or ends."@en ;
               rdfs:label "failureReason"@en .


###  https://w3id.org/skgo/pham#hasAssayMethod
:hasAssayMethod rdf:type owl:DatatypeProperty ;
                rdfs:subPropertyOf owl:topDataProperty ;
                rdfs:domain :Assay ;
                rdfs:range rdfs:Literal .


###  https://w3id.org/skgo/pham#hasDrugEffects
:hasDrugEffects rdf:type owl:DatatypeProperty ;
                rdfs:subPropertyOf owl:topDataProperty ;
                rdfs:domain :Drug ;
                rdfs:range rdfs:Literal .


###  https://w3id.org/skgo/pham#hasEligibilityCriteria
:hasEligibilityCriteria rdf:type owl:DatatypeProperty ;
                        rdfs:subPropertyOf owl:topDataProperty ;
                        rdfs:domain [ rdf:type owl:Class ;
                                      owl:unionOf ( :ClinicalTrial
                                                    :Patient
                                                  )
                                    ] ;
                        rdfs:range rdfs:Literal .


###  https://w3id.org/skgo/pham#hasEvidence
:hasEvidence rdf:type owl:DatatypeProperty ;
             rdfs:subPropertyOf owl:topDataProperty ;
             rdfs:domain :ClinicalStudy ;
             rdfs:range rdfs:Literal ;
             dc:description "Information, including verifiable facts and data that support a practice or belief."@en ;
             rdfs:label "hasEvidence"@en .


###  https://w3id.org/skgo/pham#hasExperimentalResult
:hasExperimentalResult rdf:type owl:DatatypeProperty ;
                       rdfs:subPropertyOf owl:topDataProperty ;
                       rdfs:domain :Multidrug_resistance_to_cancer_cells ;
                       rdfs:range rdfs:Literal .


###  https://w3id.org/skgo/pham#hasFindings
:hasFindings rdf:type owl:DatatypeProperty ;
             rdfs:subPropertyOf owl:topDataProperty ;
             rdfs:domain :ClinicalStudy ;
             rdfs:range rdfs:Literal .


###  https://w3id.org/skgo/pham#hasLimitations
:hasLimitations rdf:type owl:DatatypeProperty ;
                rdfs:subPropertyOf owl:topDataProperty ;
                rdfs:domain :ClinicalStudy ;
                rdfs:range rdfs:Literal ;
                dc:description "Conditions or restrictions of research study."@en ;
                rdfs:label "hasLimitations"@en .


###  https://w3id.org/skgo/pham#hasMutationResult
:hasMutationResult rdf:type owl:DatatypeProperty ;
                   rdfs:subPropertyOf owl:topDataProperty ;
                   rdfs:domain :ClinicalProblem ;
                   rdfs:range rdfs:Literal .


###  https://w3id.org/skgo/pham#hasOverexpressionGene
:hasOverexpressionGene rdf:type owl:DatatypeProperty ;
                       rdfs:subPropertyOf owl:topDataProperty ;
                       rdfs:domain :ClinicalProblem ;
                       rdfs:range rdfs:Literal ;
                       dc:description "The Gene that has overexpression which leads to the abundant target protein expression subsequently."@en ;
                       rdfs:label "hasOverexpressionGene"@en .


###  https://w3id.org/skgo/pham#hasProblemSolution
:hasProblemSolution rdf:type owl:DatatypeProperty ;
                    rdfs:subPropertyOf owl:topDataProperty ;
                    rdfs:domain :ClinicalProblem ;
                    rdfs:range rdfs:Literal ;
                    dc:description "Problem has the answer  or the explanation for something."@en ;
                    rdfs:label "hasProblemSolution"@en .


###  https://w3id.org/skgo/pham#hasSuggestion
:hasSuggestion rdf:type owl:DatatypeProperty ;
               rdfs:subPropertyOf owl:topDataProperty ;
               rdfs:domain :ClinicalStudy ;
               rdfs:range rdfs:Literal .


###  https://w3id.org/skgo/pham#hasTargetingMethod
:hasTargetingMethod rdf:type owl:DatatypeProperty ;
                    rdfs:subPropertyOf owl:topDataProperty ;
                    rdfs:domain :ClinicalProblem ;
                    rdfs:range rdfs:Literal ;
                    dc:description "The process of having proteins contain certain signals such that the proteins are directed specifically towards certain cellular locations"@en ;
                    rdfs:label "hasTargetingMethod"@en .


###  https://w3id.org/skgo/pham#hasTissueLocalization
:hasTissueLocalization rdf:type owl:DatatypeProperty ;
                       rdfs:subPropertyOf owl:topDataProperty ;
                       rdfs:domain :ClinicalProblem ;
                       rdfs:range xsd:string .


###  https://w3id.org/skgo/pham#hasTitle
:hasTitle rdf:type owl:DatatypeProperty ;
          rdfs:subPropertyOf owl:topDataProperty ;
          rdfs:domain [ rdf:type owl:Class ;
                        owl:unionOf ( :ClinicalStudy
                                      :Multidrug_resistance_to_cancer_cells
                                    )
                      ] ;
          rdfs:range rdfs:Literal ;
          dc:description "A name that describes something."@en ;
          rdfs:label "hasTitle"@en .


###  https://w3id.org/skgo/pham#name
:name rdf:type owl:DatatypeProperty ;
      rdfs:subPropertyOf owl:topDataProperty ;
      rdfs:domain [ rdf:type owl:Class ;
                    owl:unionOf ( :Disease
                                  :Drug
                                  :Multidrug_resistance_to_cancer_cells
                                )
                  ] ;
      rdfs:range xsd:string ;
      dc:description "A word or words by which an entity is designated and distinguished from others."@en .


###  https://w3id.org/skgo/pham#treatmentOutcome
:treatmentOutcome rdf:type owl:DatatypeProperty ;
                  rdfs:subPropertyOf owl:topDataProperty ;
                  rdfs:domain :Treatment ;
                  rdfs:range rdfs:Literal ;
                  dc:description "A final product or end result of treatment."@en ;
                  rdfs:label "treatmentOutcome"@en .


#################################################################
#    Classes
#################################################################

###  http://ns.nature.com/terms/Publication
terms1:Publication dc:description "The :Publication class groups together all individuals (or part of) created as the result of the publishing process. Note that we are not referring here to the physical artefacts, but just their abstract counterparts."@en .


###  http://ns.nature.com/terms/Publisher
terms1:Publisher dc:description "The :Publisher class represents organizations involved in the publishing business."@en .


###  http://purl.org/dc/dcam/VocabularyEncodingScheme
<http://purl.org/dc/dcam/VocabularyEncodingScheme> rdf:type owl:Class .


###  http://purl.org/dc/dcmitype/Collection
<http://purl.org/dc/dcmitype/Collection> rdf:type owl:Class .


###  http://purl.org/dc/terms/AgentClass
terms:AgentClass rdf:type owl:Class ;
                 rdfs:subClassOf rdfs:Class .


###  http://purl.org/dc/terms/BibliographicResource
terms:BibliographicResource rdf:type owl:Class .


###  http://purl.org/dc/terms/Frequency
terms:Frequency rdf:type owl:Class .


###  http://purl.org/dc/terms/LicenseDocument
terms:LicenseDocument rdf:type owl:Class ;
                      rdfs:subClassOf terms:RightsStatement .


###  http://purl.org/dc/terms/LinguisticSystem
terms:LinguisticSystem rdf:type owl:Class .


###  http://purl.org/dc/terms/MethodOfAccrual
terms:MethodOfAccrual rdf:type owl:Class .


###  http://purl.org/dc/terms/MethodOfInstruction
terms:MethodOfInstruction rdf:type owl:Class .


###  http://purl.org/dc/terms/PhysicalResource
terms:PhysicalResource rdf:type owl:Class .


###  http://purl.org/dc/terms/Policy
terms:Policy rdf:type owl:Class .


###  http://purl.org/dc/terms/ProvenanceStatement
terms:ProvenanceStatement rdf:type owl:Class .


###  http://purl.org/dc/terms/RightsStatement
terms:RightsStatement rdf:type owl:Class .


###  http://purl.org/dc/terms/Standard
terms:Standard rdf:type owl:Class .


###  http://www.w3.org/2000/10/swap/pim/contact#Person
<http://www.w3.org/2000/10/swap/pim/contact#Person> rdf:type owl:Class .


###  https://w3id.org/skgo/pham#Antibody-mediated_cytolysis_experiment
:Antibody-mediated_cytolysis_experiment rdf:type owl:Class ;
                                        dc:description "An experimental method is a way to solve a scientific task by executing a scientific experiment."@en ;
                                        rdfs:label "ExperimentMethod"@en .


###  https://w3id.org/skgo/pham#Assay
:Assay rdf:type owl:Class ;
       dc:description "A set of instructions, methodology, operations, required reagents, instruments to carry out experiments for the purpose of testing the effect of a perturbing agent in a biological model system."@en ;
       rdfs:label "Assay"@en .


###  https://w3id.org/skgo/pham#AssayKit
:AssayKit rdf:type owl:Class ;
          rdfs:subClassOf :Assay .


###  https://w3id.org/skgo/pham#AssayMethod
:AssayMethod rdf:type owl:Class ;
             rdfs:subClassOf :Assay .


###  https://w3id.org/skgo/pham#BlotAnalysis
:BlotAnalysis rdf:type owl:Class ;
              dc:description "The transfer of protein, RNA or DNA molecules from a thick acrylamide or agarose gel to a paper like membrane by capilliarity or an electric field, preserving the spatial arrangement."@en ;
              rdfs:label "BlotAnalysis"@en .


###  https://w3id.org/skgo/pham#Calculations
:Calculations rdf:type owl:Class .


###  https://w3id.org/skgo/pham#Cell
:Cell rdf:type owl:Class ;
      dc:description "A material entity of anatomical origin (part of or deriving from an organism) that has as its parts a maximally connected cell compartment surrounded by a plasma membrane."@en ;
      rdfs:label "Cell"@en .


###  https://w3id.org/skgo/pham#CellLine
:CellLine rdf:type owl:Class ;
          rdfs:subClassOf :ExperimentMaterial ;
          rdfs:label "CellLine"@en ;
          skos:definition "The term 'line' is used when a culture has undergone an intentional experimental process to establish a more uniform and stable population of cells."@en .


###  https://w3id.org/skgo/pham#Chemical
:Chemical rdf:type owl:Class ;
          rdfs:subClassOf :ExperimentMaterial ;
          rdfs:label "Chemical"@en ;
          skos:definition "A substance composed of chemical elements."@en .


###  https://w3id.org/skgo/pham#ClinicalProblem
:ClinicalProblem rdf:type owl:Class ;
                 dc:description "A difficulty, disorder, or condition needing resolution."@en ;
                 rdfs:label "ClinicalProblem"@en .


###  https://w3id.org/skgo/pham#ClinicalStudy
:ClinicalStudy rdf:type owl:Class ;
               dc:description "A research study involving human subjects designed to answer specific questions about the safety and efficacy of a biomedical intervention (drug, treatment, device), or new ways of using a known drug, treatment or device."@en ;
               rdfs:label "ClinicalStudy"@en .


###  https://w3id.org/skgo/pham#ClinicalTrial
:ClinicalTrial rdf:type owl:Class ;
               dc:description "Clinical trial an experiment performed on human beings in order to evaluate the comparative efficacy of two or more therapies."@en ;
               rdfs:label "ClinicalTrial"@en .


###  https://w3id.org/skgo/pham#Disease
:Disease rdf:type owl:Class ;
         dc:description "A definite pathological process having a characteristic set of signs and symptoms. It may affect the whole body or any of its parts, and its etiology, pathology, and prognosis may be known or unknown."@en ;
         rdfs:label "Disease"@en .


###  https://w3id.org/skgo/pham#Drug
:Drug rdf:type owl:Class ;
      rdfs:subClassOf :ExperimentMaterial ;
      rdfs:label "Drug"@en ;
      skos:definition "Therapeutic agent; any substance, other than food, used in the prevention, diagnosis, alleviation, treatment, or cure of disease. For types or classifications of drugs, see the specific name."@en .


###  https://w3id.org/skgo/pham#EasternBlotting
:EasternBlotting rdf:type owl:Class ;
                 rdfs:subClassOf :BlotAnalysis .


###  https://w3id.org/skgo/pham#ExperimentKit
:ExperimentKit rdf:type owl:Class ;
               dc:description "The title of the kit/biologicals used in the experiment."@en ;
               rdfs:label "ExperimentKit"@en .


###  https://w3id.org/skgo/pham#ExperimentMaterial
:ExperimentMaterial rdf:type owl:Class ;
                    dc:description "Materials are culture collections and chemicals used for executing of an experiment."@en ;
                    rdfs:label "ExperimentMaterial"@en .


###  https://w3id.org/skgo/pham#ExperimentSetting
:ExperimentSetting rdf:type owl:Class ;
                   dc:description "A designed experiment involves the investigator assigning (preferably randomly) some or all conditions to subjects."@en ;
                   rdfs:label "ExperimentSetting"@en .


###  https://w3id.org/skgo/pham#ExperimentalStudy
:ExperimentalStudy rdf:type owl:Class ;
                   rdfs:subClassOf :StudyDesign .


###  https://w3id.org/skgo/pham#Exvivo
:Exvivo rdf:type owl:Class ;
        rdfs:subClassOf :ExperimentSetting ;
        dc:description "Outside the living body; denoting removal of an organ (e.g., the kidney) for reparative surgery, after which it is returned to the original site."@en ;
        rdfs:label "Exvivo"@en .


###  https://w3id.org/skgo/pham#Gene
:Gene rdf:type owl:Class ;
      rdfs:subClassOf :ExperimentMaterial ;
      rdfs:label "Gene"@en ;
      skos:definition "One of the biologic units of heredity, self-reproducing, and located at a definite position (locus) on a particular chromosome."@en .


###  https://w3id.org/skgo/pham#Hypothesis
:Hypothesis rdf:type owl:Class ;
            dc:description "A supposition that appears to explain a group of phenomena and is advanced as a bases for further investigation."@en ;
            rdfs:label "Hypothesis"@en .


###  https://w3id.org/skgo/pham#Insilico
:Insilico rdf:type owl:Class ;
          rdfs:subClassOf :ExperimentSetting ;
          dc:description "The mimicking or modeling of biological processes within computer hardware and software."@en ;
          rdfs:label "Insilico"@en .


###  https://w3id.org/skgo/pham#Investigation
:Investigation rdf:type owl:Class ;
               dc:description "Investigation is the process of carrying out a plan or procedure so as to discover facts or information about the object of study."@en ;
               rdfs:label "Investigation"@en .


###  https://w3id.org/skgo/pham#Invitro
:Invitro rdf:type owl:Class ;
         rdfs:subClassOf :ExperimentSetting ;
         dc:description "In an artificial environment, referring to a process or reaction occurring therein, as in a test tube or culture media."@en ;
         rdfs:label "Invitro"@en .


###  https://w3id.org/skgo/pham#Invivo
:Invivo rdf:type owl:Class ;
        rdfs:subClassOf :ExperimentSetting ;
        dc:description "Biological processes or experiments occurring in the living organism."@en ;
        rdfs:label "Invivo"@en .


###  https://w3id.org/skgo/pham#Multidrug_resistance_to_cancer_cells
:Multidrug_resistance_to_cancer_cells rdf:type owl:Class ;
                                      dc:description "A procedure done in order to discover or demonstrate some fact or general truth."@en ;
                                      rdfs:label "Experiment"@en .


###  https://w3id.org/skgo/pham#NorthernBlotting
:NorthernBlotting rdf:type owl:Class ;
                  rdfs:subClassOf :BlotAnalysis ;
                  dc:description "A technique used to detect a specific mRNA sequence, which consists of electrophoresing RNA fragments, transferring those fragments to a membrane, then adding a labelled nucleic acid probe to the milieu."@en ;
                  rdfs:label "NorthernBlotting"@en .


###  https://w3id.org/skgo/pham#ObservationalStudy
:ObservationalStudy rdf:type owl:Class ;
                    rdfs:subClassOf :StudyDesign .


###  https://w3id.org/skgo/pham#Patient
:Patient rdf:type owl:Class ;
         dc:description "A person who is under medical care or treatment."@en ;
         rdfs:label "Patient"@en .


###  https://w3id.org/skgo/pham#Probe
:Probe rdf:type owl:Class ;
       rdfs:subClassOf :ExperimentMaterial ;
       rdfs:label "Probe"@en ;
       skos:definition "A radioactive or chemiluminescent DNA or RNA fragment used to detect the presence of a complementary fragment."@en .


###  https://w3id.org/skgo/pham#Reagent
:Reagent rdf:type owl:Class ;
         rdfs:subClassOf :ExperimentMaterial ;
         rdfs:label "Reagent"@en ;
         skos:definition "A substance used to produce a chemical reaction so as to detect, measure, or produce other substances."@en .


###  https://w3id.org/skgo/pham#ReviewStudy
:ReviewStudy rdf:type owl:Class ;
             rdfs:subClassOf :StudyDesign ;
             dc:description "Reviews are a type of literature review that uses systematic methods to collect secondary data, critically appraise research studies, and synthesize findings qualitatively or quantitatively."@en ;
             rdfs:label "ReviewStudyDesign"@en .


###  https://w3id.org/skgo/pham#SouthernBlotting
:SouthernBlotting rdf:type owl:Class ;
                  rdfs:subClassOf :BlotAnalysis ;
                  dc:description "A technique for the detection of specific DNA fragments that have been separated by polyacrylamide-gel electrophoresis, transferred to a nitrocellulose or other type of paper or nylon membrane, and detected by hybridization and visualization with a labeled probe."@en ;
                  rdfs:label "SouthernBlotting"@en .


###  https://w3id.org/skgo/pham#Specimen
:Specimen rdf:type owl:Class ;
          rdfs:subClassOf :ExperimentMaterial ;
          rdfs:label "Specimen"@en ;
          skos:definition "A small sample or part taken to show the nature of the whole, such as a small quantity of urine for urinalysis or a small fragment of tissue for microscopic study."@en .


###  https://w3id.org/skgo/pham#StatisticalAnalysis
:StatisticalAnalysis rdf:type owl:Class .


###  https://w3id.org/skgo/pham#Study
:Study rdf:type owl:Class .


###  https://w3id.org/skgo/pham#StudyDesign
:StudyDesign rdf:type owl:Class ;
             dc:description "Study design is the formulation of trials and experiments, as well as observational studies in medical, clinical and other types of research involving human beings."@en ;
             rdfs:label "StudyDesign"@en .


###  https://w3id.org/skgo/pham#Treatment
:Treatment rdf:type owl:Class ;
           dc:description "A period in a clinical study during which subjects receive therapeutic treatment or an action or administration of therapeutic agents to produce an effect that is intended to alter or stop a pathologic process."@en ;
           rdfs:label "Treatment"@en .


###  https://w3id.org/skgo/pham#WesternBlotting
:WesternBlotting rdf:type owl:Class ;
                 rdfs:subClassOf :BlotAnalysis ;
                 dc:description "A laboratory procedure for the detection or identification of proteins or peptides that have been separated by gel electrophoresis and transferred onto nitrocellulose or other type of paper or nylon membrane."@en ;
                 rdfs:label "WesternBlotting"@en .


###  https://w3id.org/skgo/pham#levels_of_mdr1_mRNA
:levels_of_mdr1_mRNA rdf:type owl:Class ;
                     dc:description "It is a claim, focus, goal or hypothes is supported by the study findings and examined by the study experiment."@en ;
                     rdfs:label "ResearchStatement"@en .


#################################################################
#    Individuals
#################################################################

###  http://purl.org/dc/aboutdcmi#DCMI
<http://purl.org/dc/aboutdcmi#DCMI> rdf:type owl:NamedIndividual .


###  http://purl.org/dc/terms/
terms: rdf:type owl:NamedIndividual ;
       terms:modified "2012-06-14"^^xsd:date ;
       terms:publisher <http://purl.org/dc/aboutdcmi#DCMI> ;
       terms:title "DCMI Metadata Terms - other"@en .


###  http://purl.org/dc/terms/Agent
terms:Agent rdf:type owl:NamedIndividual ,
                     terms:AgentClass .


###  http://purl.org/dc/terms/AgentClass
terms:AgentClass rdf:type owl:NamedIndividual .


###  http://purl.org/dc/terms/BibliographicResource
terms:BibliographicResource rdf:type owl:NamedIndividual .


###  http://purl.org/dc/terms/Box
terms:Box rdf:type owl:NamedIndividual .


###  http://purl.org/dc/terms/DCMIType
terms:DCMIType rdf:type owl:NamedIndividual ,
                        <http://purl.org/dc/dcam/VocabularyEncodingScheme> ;
               terms:hasVersion <http://dublincore.org/usage/terms/history/#DCMIType-005> ;
               terms:issued "2000-07-11"^^xsd:date ;
               terms:modified "2012-06-14"^^xsd:date ;
               rdfs:comment "The set of classes specified by the DCMI Type Vocabulary, used to categorize the nature or genre of the resource."@en ;
               rdfs:isDefinedBy terms: ;
               rdfs:label "DCMI Type Vocabulary"@en ;
               rdfs:seeAlso <http://purl.org/dc/dcmitype/> .


###  http://purl.org/dc/terms/DDC
terms:DDC rdf:type owl:NamedIndividual ,
                   <http://purl.org/dc/dcam/VocabularyEncodingScheme> ;
          terms:hasVersion <http://dublincore.org/usage/terms/history/#DDC-003> ;
          terms:issued "2000-07-11"^^xsd:date ;
          terms:modified "2008-01-14"^^xsd:date ;
          rdfs:comment "The set of conceptual resources specified by the Dewey Decimal Classification."@en ;
          rdfs:isDefinedBy terms: ;
          rdfs:label "DDC"@en ;
          rdfs:seeAlso <http://www.oclc.org/dewey/> .


###  http://purl.org/dc/terms/FileFormat
terms:FileFormat rdf:type owl:NamedIndividual .


###  http://purl.org/dc/terms/Frequency
terms:Frequency rdf:type owl:NamedIndividual .


###  http://purl.org/dc/terms/IMT
terms:IMT rdf:type owl:NamedIndividual ,
                   <http://purl.org/dc/dcam/VocabularyEncodingScheme> ;
          terms:hasVersion <http://dublincore.org/usage/terms/history/#IMT-004> ;
          terms:issued "2000-07-11"^^xsd:date ;
          terms:modified "2008-01-14"^^xsd:date ;
          rdfs:comment "The set of media types specified by the Internet Assigned Numbers Authority."@en ;
          rdfs:isDefinedBy terms: ;
          rdfs:label "IMT"@en ;
          rdfs:seeAlso <http://www.iana.org/assignments/media-types/> .


###  http://purl.org/dc/terms/ISO3166
terms:ISO3166 rdf:type owl:NamedIndividual .


###  http://purl.org/dc/terms/ISO639-2
terms:ISO639-2 rdf:type owl:NamedIndividual .


###  http://purl.org/dc/terms/ISO639-3
terms:ISO639-3 rdf:type owl:NamedIndividual .


###  http://purl.org/dc/terms/Jurisdiction
terms:Jurisdiction rdf:type owl:NamedIndividual .


###  http://purl.org/dc/terms/LCC
terms:LCC rdf:type owl:NamedIndividual ,
                   <http://purl.org/dc/dcam/VocabularyEncodingScheme> ;
          terms:hasVersion <http://dublincore.org/usage/terms/history/#LCC-003> ;
          terms:issued "2000-07-11"^^xsd:date ;
          terms:modified "2008-01-14"^^xsd:date ;
          rdfs:comment "The set of conceptual resources specified by the Library of Congress Classification."@en ;
          rdfs:isDefinedBy terms: ;
          rdfs:label "LCC"@en ;
          rdfs:seeAlso <http://lcweb.loc.gov/catdir/cpso/lcco/lcco.html> .


###  http://purl.org/dc/terms/LCSH
terms:LCSH rdf:type owl:NamedIndividual ,
                    <http://purl.org/dc/dcam/VocabularyEncodingScheme> ;
           terms:hasVersion <http://dublincore.org/usage/terms/history/#LCSH-003> ;
           terms:issued "2000-07-11"^^xsd:date ;
           terms:modified "2008-01-14"^^xsd:date ;
           rdfs:comment "The set of labeled concepts specified by the Library of Congress Subject Headings."@en ;
           rdfs:isDefinedBy terms: ;
           rdfs:label "LCSH"@en .


###  http://purl.org/dc/terms/LicenseDocument
terms:LicenseDocument rdf:type owl:NamedIndividual .


###  http://purl.org/dc/terms/LinguisticSystem
terms:LinguisticSystem rdf:type owl:NamedIndividual .


###  http://purl.org/dc/terms/Location
terms:Location rdf:type owl:NamedIndividual .


###  http://purl.org/dc/terms/LocationPeriodOrJurisdiction
terms:LocationPeriodOrJurisdiction rdf:type owl:NamedIndividual .


###  http://purl.org/dc/terms/MESH
terms:MESH rdf:type owl:NamedIndividual ,
                    <http://purl.org/dc/dcam/VocabularyEncodingScheme> ;
           terms:hasVersion <http://dublincore.org/usage/terms/history/#MESH-003> ;
           terms:issued "2000-07-11"^^xsd:date ;
           terms:modified "2008-01-14"^^xsd:date ;
           rdfs:comment "The set of labeled concepts specified by the Medical Subject Headings."@en ;
           rdfs:isDefinedBy terms: ;
           rdfs:label "MeSH"@en ;
           rdfs:seeAlso <http://www.nlm.nih.gov/mesh/meshhome.html> .


###  http://purl.org/dc/terms/MediaType
terms:MediaType rdf:type owl:NamedIndividual .


###  http://purl.org/dc/terms/MediaTypeOrExtent
terms:MediaTypeOrExtent rdf:type owl:NamedIndividual .


###  http://purl.org/dc/terms/MethodOfAccrual
terms:MethodOfAccrual rdf:type owl:NamedIndividual .


###  http://purl.org/dc/terms/MethodOfInstruction
terms:MethodOfInstruction rdf:type owl:NamedIndividual .


###  http://purl.org/dc/terms/NLM
terms:NLM rdf:type owl:NamedIndividual ,
                   <http://purl.org/dc/dcam/VocabularyEncodingScheme> ;
          terms:hasVersion <http://dublincore.org/usage/terms/history/#NLM-002> ;
          terms:issued "2005-06-13"^^xsd:date ;
          terms:modified "2008-01-14"^^xsd:date ;
          rdfs:comment "The set of conceptual resources specified by the National Library of Medicine Classification."@en ;
          rdfs:isDefinedBy terms: ;
          rdfs:label "NLM"@en ;
          rdfs:seeAlso <http://wwwcf.nlm.nih.gov/class/> .


###  http://purl.org/dc/terms/Period
terms:Period rdf:type owl:NamedIndividual .


###  http://purl.org/dc/terms/PeriodOfTime
terms:PeriodOfTime rdf:type owl:NamedIndividual .


###  http://purl.org/dc/terms/PhysicalMedium
terms:PhysicalMedium rdf:type owl:NamedIndividual .


###  http://purl.org/dc/terms/PhysicalResource
terms:PhysicalResource rdf:type owl:NamedIndividual .


###  http://purl.org/dc/terms/Point
terms:Point rdf:type owl:NamedIndividual .


###  http://purl.org/dc/terms/Policy
terms:Policy rdf:type owl:NamedIndividual .


###  http://purl.org/dc/terms/ProvenanceStatement
terms:ProvenanceStatement rdf:type owl:NamedIndividual .


###  http://purl.org/dc/terms/RFC1766
terms:RFC1766 rdf:type owl:NamedIndividual .


###  http://purl.org/dc/terms/RFC3066
terms:RFC3066 rdf:type owl:NamedIndividual .


###  http://purl.org/dc/terms/RFC4646
terms:RFC4646 rdf:type owl:NamedIndividual .


###  http://purl.org/dc/terms/RFC5646
terms:RFC5646 rdf:type owl:NamedIndividual .


###  http://purl.org/dc/terms/RightsStatement
terms:RightsStatement rdf:type owl:NamedIndividual .


###  http://purl.org/dc/terms/SizeOrDuration
terms:SizeOrDuration rdf:type owl:NamedIndividual .


###  http://purl.org/dc/terms/Standard
terms:Standard rdf:type owl:NamedIndividual .


###  http://purl.org/dc/terms/TGN
terms:TGN rdf:type owl:NamedIndividual ,
                   <http://purl.org/dc/dcam/VocabularyEncodingScheme> ;
          terms:hasVersion <http://dublincore.org/usage/terms/history/#TGN-003> ;
          terms:issued "2000-07-11"^^xsd:date ;
          terms:modified "2008-01-14"^^xsd:date ;
          rdfs:comment "The set of places specified by the Getty Thesaurus of Geographic Names."@en ;
          rdfs:isDefinedBy terms: ;
          rdfs:label "TGN"@en ;
          rdfs:seeAlso <http://www.getty.edu/research/tools/vocabulary/tgn/index.html> .


###  http://purl.org/dc/terms/UDC
terms:UDC rdf:type owl:NamedIndividual ,
                   <http://purl.org/dc/dcam/VocabularyEncodingScheme> ;
          terms:hasVersion <http://dublincore.org/usage/terms/history/#UDC-003> ;
          terms:issued "2000-07-11"^^xsd:date ;
          terms:modified "2008-01-14"^^xsd:date ;
          rdfs:comment "The set of conceptual resources specified by the Universal Decimal Classification."@en ;
          rdfs:isDefinedBy terms: ;
          rdfs:label "UDC"@en ;
          rdfs:seeAlso <http://www.udcc.org/> .


###  http://purl.org/dc/terms/URI
terms:URI rdf:type owl:NamedIndividual .


###  http://purl.org/dc/terms/W3CDTF
terms:W3CDTF rdf:type owl:NamedIndividual .


###  http://purl.org/dc/terms/abstract
terms:abstract rdf:type owl:NamedIndividual .


###  http://purl.org/dc/terms/accessRights
terms:accessRights rdf:type owl:NamedIndividual .


###  http://purl.org/dc/terms/accrualMethod
terms:accrualMethod rdf:type owl:NamedIndividual .


###  http://purl.org/dc/terms/accrualPeriodicity
terms:accrualPeriodicity rdf:type owl:NamedIndividual .


###  http://purl.org/dc/terms/accrualPolicy
terms:accrualPolicy rdf:type owl:NamedIndividual .


###  http://purl.org/dc/terms/alternative
terms:alternative rdf:type owl:NamedIndividual .


###  http://purl.org/dc/terms/audience
terms:audience rdf:type owl:NamedIndividual .


###  http://purl.org/dc/terms/available
terms:available rdf:type owl:NamedIndividual .


###  http://purl.org/dc/terms/bibliographicCitation
terms:bibliographicCitation rdf:type owl:NamedIndividual .


###  http://purl.org/dc/terms/conformsTo
terms:conformsTo rdf:type owl:NamedIndividual .


###  http://purl.org/dc/terms/contributor
terms:contributor rdf:type owl:NamedIndividual .


###  http://purl.org/dc/terms/coverage
terms:coverage rdf:type owl:NamedIndividual .


###  http://purl.org/dc/terms/created
terms:created rdf:type owl:NamedIndividual .


###  http://purl.org/dc/terms/creator
terms:creator rdf:type owl:NamedIndividual .


###  http://purl.org/dc/terms/date
terms:date rdf:type owl:NamedIndividual .


###  http://purl.org/dc/terms/dateAccepted
terms:dateAccepted rdf:type owl:NamedIndividual .


###  http://purl.org/dc/terms/dateCopyrighted
terms:dateCopyrighted rdf:type owl:NamedIndividual .


###  http://purl.org/dc/terms/dateSubmitted
terms:dateSubmitted rdf:type owl:NamedIndividual .


###  http://purl.org/dc/terms/description
terms:description rdf:type owl:NamedIndividual .


###  http://purl.org/dc/terms/educationLevel
terms:educationLevel rdf:type owl:NamedIndividual .


###  http://purl.org/dc/terms/extent
terms:extent rdf:type owl:NamedIndividual .


###  http://purl.org/dc/terms/format
terms:format rdf:type owl:NamedIndividual .


###  http://purl.org/dc/terms/hasFormat
terms:hasFormat rdf:type owl:NamedIndividual .


###  http://purl.org/dc/terms/hasPart
terms:hasPart rdf:type owl:NamedIndividual .


###  http://purl.org/dc/terms/hasVersion
terms:hasVersion rdf:type owl:NamedIndividual .


###  http://purl.org/dc/terms/identifier
terms:identifier rdf:type owl:NamedIndividual .


###  http://purl.org/dc/terms/instructionalMethod
terms:instructionalMethod rdf:type owl:NamedIndividual .


###  http://purl.org/dc/terms/isFormatOf
terms:isFormatOf rdf:type owl:NamedIndividual .


###  http://purl.org/dc/terms/isPartOf
terms:isPartOf rdf:type owl:NamedIndividual .


###  http://purl.org/dc/terms/isReferencedBy
terms:isReferencedBy rdf:type owl:NamedIndividual .


###  http://purl.org/dc/terms/isReplacedBy
terms:isReplacedBy rdf:type owl:NamedIndividual .


###  http://purl.org/dc/terms/isRequiredBy
terms:isRequiredBy rdf:type owl:NamedIndividual .


###  http://purl.org/dc/terms/isVersionOf
terms:isVersionOf rdf:type owl:NamedIndividual .


###  http://purl.org/dc/terms/issued
terms:issued rdf:type owl:NamedIndividual .


###  http://purl.org/dc/terms/language
terms:language rdf:type owl:NamedIndividual .


###  http://purl.org/dc/terms/license
terms:license rdf:type owl:NamedIndividual .


###  http://purl.org/dc/terms/mediator
terms:mediator rdf:type owl:NamedIndividual .


###  http://purl.org/dc/terms/medium
terms:medium rdf:type owl:NamedIndividual .


###  http://purl.org/dc/terms/modified
terms:modified rdf:type owl:NamedIndividual .


###  http://purl.org/dc/terms/provenance
terms:provenance rdf:type owl:NamedIndividual .


###  http://purl.org/dc/terms/publisher
terms:publisher rdf:type owl:NamedIndividual .


###  http://purl.org/dc/terms/references
terms:references rdf:type owl:NamedIndividual .


###  http://purl.org/dc/terms/relation
terms:relation rdf:type owl:NamedIndividual .


###  http://purl.org/dc/terms/replaces
terms:replaces rdf:type owl:NamedIndividual .


###  http://purl.org/dc/terms/requires
terms:requires rdf:type owl:NamedIndividual .


###  http://purl.org/dc/terms/rights
terms:rights rdf:type owl:NamedIndividual .


###  http://purl.org/dc/terms/rightsHolder
terms:rightsHolder rdf:type owl:NamedIndividual .


###  http://purl.org/dc/terms/source
terms:source rdf:type owl:NamedIndividual .


###  http://purl.org/dc/terms/spatial
terms:spatial rdf:type owl:NamedIndividual .


###  http://purl.org/dc/terms/subject
terms:subject rdf:type owl:NamedIndividual .


###  http://purl.org/dc/terms/tableOfContents
terms:tableOfContents rdf:type owl:NamedIndividual .


###  http://purl.org/dc/terms/temporal
terms:temporal rdf:type owl:NamedIndividual .


###  http://purl.org/dc/terms/title
terms:title rdf:type owl:NamedIndividual .


###  http://purl.org/dc/terms/type
terms:type rdf:type owl:NamedIndividual .


###  http://purl.org/dc/terms/valid
terms:valid rdf:type owl:NamedIndividual .


###  https://w3id.org/skgo/pham#A._T._FoJo
:A._T._FoJo rdf:type owl:NamedIndividual ,
                     foaf:Person ;
            rdfs:label "A. T. Fojo" .


###  https://w3id.org/skgo/pham#ABCA2
:ABCA2 rdf:type owl:NamedIndividual ,
                :Gene ;
       rdfs:label "ABCA2"@en .


###  https://w3id.org/skgo/pham#ABC_genes
:ABC_genes rdf:type owl:NamedIndividual ,
                    :Gene ;
           rdfs:label "ABC_genes"@en .


###  https://w3id.org/skgo/pham#ABC_transporters_and_in_vitro_MDR
:ABC_transporters_and_in_vitro_MDR rdf:type owl:NamedIndividual ,
                                            :Multidrug_resistance_to_cancer_cells ;
                                   :hasExperimentMethod :antibody-mediated_cytolysis_experiment ;
                                   :useDrug :CAVE ,
                                            :Cyclosporine ,
                                            :Cytarabine ,
                                            :Daunorubicin ,
                                            :Epirubicin ,
                                            :Etoposide ,
                                            :IL-2 ,
                                            :Mitoxantrone ,
                                            :Paclitaxel ,
                                            :VAD ,
                                            :Vindesine ,
                                            <https://w3id.org/skgo/pham#CAV/EP> ;
                                   rdfs:label "ABC_transporters_and_in_vitro_MDR"@en .


###  https://w3id.org/skgo/pham#ABC_transporters_as_multidrug_resistance_mechanisms_and_the_development_of_chemosensitizers_for_their_reversal
:ABC_transporters_as_multidrug_resistance_mechanisms_and_the_development_of_chemosensitizers_for_their_reversal rdf:type owl:NamedIndividual ,
                                                                                                                         terms1:Publication ,
                                                                                                                         bibo:Article ;
                                                                                                                :addressesStudy :The_physiological_functions_and_structures_of_ABC_transporters ;
                                                                                                                terms1:publicationYear "2005"^^xsd:gYear ;
                                                                                                                bibo:abstract """One of the major problems related with anticancer chemotherapy is resistance against anticancer drugs. The ATP-binding cassette (ABC) transporters are a family of transporter proteins that are responsible for drug resistance and a low bioavailability of drugs by pumping a variety of drugs out cells at the expense of ATP hydrolysis. One strategy for reversal of the resistance of tumor cells
expressing ABC transporters is combined use of anticancer drugs with chemosensitizers. In this review, the physiological functions and structures of ABC transporters, and the development of chemosensitizers are described focusing on well-known proteins including P-glycoprotein, multidrug resistance associated protein, and breast cancer resistance protein."""^^rdfs:Literal ;
                                                                                                                terms:creator :Cheol-Hee_Choi ;
                                                                                                                terms:publisher :Cancer_Cell_International ;
                                                                                                                terms:title """ABC transporters as multidrug resistance mechanisms and the
development of chemosensitizers for their reversal"""^^rdfs:Literal .


###  https://w3id.org/skgo/pham#ABC_transporters_in_human_cancers
:ABC_transporters_in_human_cancers rdf:type owl:NamedIndividual ,
                                            :ClinicalStudy ;
                                   :investigate :Breast_Cancer ,
                                                :Leukaemia ,
                                                :Lung_cancer ,
                                                :Non_Smallcell_Lung_Cancer ,
                                                :Small_Cell_Lung_Cancer ;
                                   :investigatesProblem :Drug_Resistance ;
                                   :performsExperiment :multidrug_resistance_to_cancer_cells ;
                                   terms1:name "MULTIDRUG RESISTANCE IN CANCER" ;
                                   rdfs:label "ABC transporters in human cancers"@en .


###  https://w3id.org/skgo/pham#ADE
:ADE rdf:type owl:NamedIndividual ,
              :Drug ;
     rdfs:label "ADE"@en .


###  https://w3id.org/skgo/pham#ALL
:ALL rdf:type owl:NamedIndividual ,
              :Disease ;
     rdfs:label "ALL"@en .


###  https://w3id.org/skgo/pham#AML
:AML rdf:type owl:NamedIndividual ,
              :Disease ;
     rdfs:label "AML"@en .


###  https://w3id.org/skgo/pham#AML_sample
:AML_sample rdf:type owl:NamedIndividual ,
                     :Specimen ;
            :obtainedfromPatient :Phase_III_clinical_trials_with_ABC_transporter_inhibitors ;
            rdfs:label "AML_sample"@en .


###  https://w3id.org/skgo/pham#ARUN_K._RISHI
:ARUN_K._RISHI rdf:type owl:NamedIndividual ,
                        foaf:Person ;
               rdfs:label "Arun k. Rishi" .


###  https://w3id.org/skgo/pham#A_multidrug_resistance_transporter_from_human_MCF-7_breast_cancer_cells
:A_multidrug_resistance_transporter_from_human_MCF-7_breast_cancer_cells rdf:type owl:NamedIndividual ,
                                                                                  terms1:Publication ,
                                                                                  bibo:Article ;
                                                                         :addressesStudy <https://w3id.org/skgo/pham#Differentially_overexpressed_in_MCF-7/AdrVp_cells_compared_with_MCF-7_cells> ;
                                                                         terms1:publicationYear "1998"^^xsd:gYear ;
                                                                         bibo:abstract """MCF-7yAdrVp is a multidrug-resistant human breast cancer subline that displays an ATP-dependent reduction in the intracellular accumulation of anthracycline anticancer drugs in the absence of overexpression of known multidrug resistance transporters such as P glycoprotein or the multidrug resistance protein. RNA fingerprinting led to the identification of a 2.4-kb mRNA that is overexpressed in
MCF-7yAdrVp cells relative to parental MCF-7 cells. The mRNA encodes a 663-aa member of the ATP-binding cassette superfamily of transporters that we term breast cancer resistance protein (BCRP). Enforced expression of the full-length
BCRP cDNA in MCF-7 breast cancer cells confers resistance to mitoxantrone, doxorubicin, and daunorubicin, reduces daunorubicin accumulation and retention, and causes an ATP-dependent enhancement of the efflux of rhodamine 123
in the cloned transfected cells. BCRP is a xenobiotic transporter that appears to play a major role in the multidrug resistance phenotype of MCF-7yAdrVp human breast cancer cells."""@en ;
                                                                         terms:creator :ARUN_K._RISHI ,
                                                                                       :DOUGLAS_D._ROSS ,
                                                                                       :L._AUSTIN_DOYLE ,
                                                                                       :LYNNE_V._ABRUZZO ,
                                                                                       :TAMMY_KROGMANN ,
                                                                                       :WEIDONG_YANG ,
                                                                                       :YONGMING_GAO ;
                                                                         terms:publisher :Proc._Nati._Acad._Sci._USA ;
                                                                         terms:title "A multidrug resistance transporter from human MCF-7 breast cancer cells"^^rdfs:Literal .


###  https://w3id.org/skgo/pham#Accumulation_Bioassay
:Accumulation_Bioassay rdf:type owl:NamedIndividual ,
                                :Assay ;
                       rdfs:label "Accumulation_Bioassay"@en .


###  https://w3id.org/skgo/pham#Actinomycin_D
:Actinomycin_D rdf:type owl:NamedIndividual ,
                        :Drug ;
               rdfs:label "Actinomycin_D"@en .


###  https://w3id.org/skgo/pham#Acute_lymphoblastic_leukemia
:Acute_lymphoblastic_leukemia rdf:type owl:NamedIndividual ,
                                       :Disease ;
                              rdfs:label "Acute_lymphoblastic_leukemia"@en .


###  https://w3id.org/skgo/pham#Adrenocortical_Cancer
:Adrenocortical_Cancer rdf:type owl:NamedIndividual ,
                                :Disease ;
                       rdfs:label "Adrenocortical_Cancer"@en .


###  https://w3id.org/skgo/pham#Advanced_and_recurrent_breast_cancer_sample
:Advanced_and_recurrent_breast_cancer_sample rdf:type owl:NamedIndividual ,
                                                      :Specimen ;
                                             :obtainedfromPatient :Phase_III_clinical_trials_with_ABC_transporter_inhibitors ;
                                             rdfs:label "Advanced_and_recurrent_breast_cancer_sample"@en .


###  https://w3id.org/skgo/pham#American_Type_Culture_Collection
:American_Type_Culture_Collection rdf:type owl:NamedIndividual ,
                                           foaf:Organization .


###  https://w3id.org/skgo/pham#Analysis_of_leukemic_blast_MDR_function
:Analysis_of_leukemic_blast_MDR_function rdf:type owl:NamedIndividual ,
                                                  :ClinicalStudy ;
                                         :investigate :AML ,
                                                      :Leukaemia ;
                                         :investigatesProblem :Multidrug_resistance_MDR_efflux_pumps_capable_of_eliminating_chemotherapeutic_drugs_from_tumor_cells ;
                                         :performsExperiment :Zosuquidar_AML_experiments ;
                                         rdfs:label "Analysis_of_leukemic_blast_MDR_function"@en .


###  https://w3id.org/skgo/pham#Anthracyclines-doxorubucin_daunorubicin_epirubicin
:Anthracyclines-doxorubucin_daunorubicin_epirubicin rdf:type owl:NamedIndividual ,
                                                             :Drug ;
                                                    rdfs:label "Anthracyclines-doxorubucin_daunorubicin_epirubicin"@en .


###  https://w3id.org/skgo/pham#Anthranilic-acid-based_drug
:Anthranilic-acid-based_drug rdf:type owl:NamedIndividual ,
                                      :Drug ;
                             rdfs:label "Anthranilic-acid-based_drug"@en .


###  https://w3id.org/skgo/pham#AssayKit
:AssayKit rdf:type owl:NamedIndividual ;
          foaf:name "AssayKit"@en .


###  https://w3id.org/skgo/pham#AssayKit15
:AssayKit15 rdf:type owl:NamedIndividual .


###  https://w3id.org/skgo/pham#AssayKit16
:AssayKit16 rdf:type owl:NamedIndividual .


###  https://w3id.org/skgo/pham#AssayKit17
:AssayKit17 rdf:type owl:NamedIndividual .


###  https://w3id.org/skgo/pham#AssayKit18
:AssayKit18 rdf:type owl:NamedIndividual .


###  https://w3id.org/skgo/pham#AssayKit19
:AssayKit19 rdf:type owl:NamedIndividual .


###  https://w3id.org/skgo/pham#AssayKit2
:AssayKit2 rdf:type owl:NamedIndividual .


###  https://w3id.org/skgo/pham#AssayKit20
:AssayKit20 rdf:type owl:NamedIndividual .


###  https://w3id.org/skgo/pham#AssayKit3
:AssayKit3 rdf:type owl:NamedIndividual .


###  https://w3id.org/skgo/pham#AssayKit4
:AssayKit4 rdf:type owl:NamedIndividual .


###  https://w3id.org/skgo/pham#AssayKit5
:AssayKit5 rdf:type owl:NamedIndividual .


###  https://w3id.org/skgo/pham#AssayKit6
:AssayKit6 rdf:type owl:NamedIndividual .


###  https://w3id.org/skgo/pham#AssayKit7
:AssayKit7 rdf:type owl:NamedIndividual .


###  https://w3id.org/skgo/pham#AssayKit8
:AssayKit8 rdf:type owl:NamedIndividual .


###  https://w3id.org/skgo/pham#AssayKit9
:AssayKit9 rdf:type owl:NamedIndividual .


###  https://w3id.org/skgo/pham#AssayMethod
:AssayMethod rdf:type owl:NamedIndividual ;
             foaf:name "AssayMethod"@en .


###  https://w3id.org/skgo/pham#Asuka_Mizutani
:Asuka_Mizutani rdf:type owl:NamedIndividual ,
                         foaf:Person ;
                rdfs:label "Asuka Mizutani" .


###  https://w3id.org/skgo/pham#BBR3390
:BBR3390 rdf:type owl:NamedIndividual ,
                  :Drug ;
         rdfs:label "BBR3390"@en .


###  https://w3id.org/skgo/pham#BCRP
:BCRP rdf:type owl:NamedIndividual ,
               :Gene ;
      rdfs:label "BCRP"@en .


###  https://w3id.org/skgo/pham#BD_Biosciences_La_Jolla_CA
:BD_Biosciences_La_Jolla_CA rdf:type owl:NamedIndividual ,
                                     foaf:Organization .


###  https://w3id.org/skgo/pham#BH3_profiling
:BH3_profiling rdf:type owl:NamedIndividual ,
                        :Multidrug_resistance_to_cancer_cells ;
               :hasExperimentMethod :BH3_profiling_method ;
               :useCellLine :Gastrointestinal_stromal_tumour_GIST_cell_lines ,
                            :Melanoma ,
                            :Pancreatic_cancer_cell_lines ,
                            <https://w3id.org/skgo/pham#ERBB2amplified_breast_cancer_cell_lines> ;
               :useDrug :Bevacizumab ,
                        :Bortezomib ,
                        :Cetuximab ,
                        :Crizotinib ,
                        :Dasatinib ,
                        :Gefitinib ,
                        :Nilotinib ,
                        :Trastuzumab ,
                        :Vemurafenib ;
               rdfs:label "BH3_profiling"@en .


###  https://w3id.org/skgo/pham#BH3_profiling_method
:BH3_profiling_method rdf:type owl:NamedIndividual ,
                               :Antibody-mediated_cytolysis_experiment ;
                      :useAssay :Functional_Assay ;
                      rdfs:label "BH3_profiling_method"@en .


###  https://w3id.org/skgo/pham#Bevacizumab
:Bevacizumab rdf:type owl:NamedIndividual ,
                      :Drug ;
             rdfs:label "Bevacizumab"@en .


###  https://w3id.org/skgo/pham#Blast_populations_in_the_two_bioassays
:Blast_populations_in_the_two_bioassays rdf:type owl:NamedIndividual ,
                                                 :StatisticalAnalysis ;
                                        rdfs:label "Blast populations in the two bioassays"@en ;
                                        skos:definition "P-gp accumulation ratio, P-gp efflux ratio, percent unimpeded efflux for total MDR activity, percent efflux in the presence of zosuquidar, and percent inhibition of efflux by zosuquidar"@en .


###  https://w3id.org/skgo/pham#Bone_marrow_aspirates
:Bone_marrow_aspirates rdf:type owl:NamedIndividual ,
                                :Specimen ;
                       :obtainedfrom <https://w3id.org/skgo/pham#50_patients_with_newly_diagnosed_AML> ;
                       rdfs:label "Bone_marrow_aspirates"@en .


###  https://w3id.org/skgo/pham#Bortezomib
:Bortezomib rdf:type owl:NamedIndividual ,
                     :Drug ;
            rdfs:label "Bortezomib"@en .


###  https://w3id.org/skgo/pham#Branimir_I._Sikic
:Branimir_I._Sikic rdf:type owl:NamedIndividual ,
                            foaf:Person ;
                   rdfs:label "Branimir I. Sikic" .


###  https://w3id.org/skgo/pham#Breast_Cancer
:Breast_Cancer rdf:type owl:NamedIndividual ,
                        :Disease ;
               rdfs:label "Breast_Cancer"@en .


###  https://w3id.org/skgo/pham#Breast_cancer_samples
:Breast_cancer_samples rdf:type owl:NamedIndividual ,
                                :Specimen ;
                       :obtainedfromPatient :Patient_with_adrenocortical_cancer_and_breast_cancer ;
                       rdfs:label "Breast_cancer_samples"@en .


###  https://w3id.org/skgo/pham#CAVE
:CAVE rdf:type owl:NamedIndividual ,
               :Drug ;
      rdfs:label "CAVE"@en .


###  https://w3id.org/skgo/pham#CCL_127__PC12
:CCL_127__PC12 rdf:type owl:NamedIndividual ,
                        :CellLine ;
               rdfs:label "CCL_127__PC12"@en .


###  https://w3id.org/skgo/pham#CI1033
:CI1033 rdf:type owl:NamedIndividual ,
                 :Drug ;
        rdfs:label "CI1033"@en .


###  https://w3id.org/skgo/pham#CLONTECH
:CLONTECH rdf:type owl:NamedIndividual ,
                   foaf:Organization .


###  https://w3id.org/skgo/pham#CML
:CML rdf:type owl:NamedIndividual ,
              :Disease ;
     rdfs:label "CML"@en .


###  https://w3id.org/skgo/pham#Caitriona_Holohan
:Caitriona_Holohan rdf:type owl:NamedIndividual ,
                            foaf:Person ;
                   rdfs:label "Caitriona Holohan" .


###  https://w3id.org/skgo/pham#Cancer_Cell_International
:Cancer_Cell_International rdf:type owl:NamedIndividual ,
                                    terms1:Publisher .


###  https://w3id.org/skgo/pham#Cancer_chemotherapy_doxorubicin_vinblastine
:Cancer_chemotherapy_doxorubicin_vinblastine rdf:type owl:NamedIndividual ,
                                                      :Treatment ;
                                             :useDrug :Actinomycin_D ,
                                                      :Doxorubicin ,
                                                      :Mitomycin_C ,
                                                      :Vincristine ;
                                             :useSpecimen :Peripheral_blood_lymphocytes ;
                                             :treatmentOutcome "Vinca alkaloid, doxorubicin, or actinomycin D might not be effective in the therapy of pheochromocytoma."@en ;
                                             rdfs:label "Cancer_chemotherapy_doxorubicin_vinblastine"@en .


###  https://w3id.org/skgo/pham#Cancer_drug_resistance_an_evolving_paradigm
:Cancer_drug_resistance_an_evolving_paradigm rdf:type owl:NamedIndividual ,
                                                      terms1:Publication ,
                                                      bibo:Article ;
                                             :addressesStudy :Mechanisms_that_enable_the_survival_of_cancer_cells_during_drug_treatment ;
                                             bibo:abstract """Resistance to chemotherapy and molecularly targeted therapies is a major
problem facing current cancer research. The mechanisms of resistance to classical cytotoxic chemotherapeutics and to therapies that are designed to be selective for specific molecular targets share many features, such as alterations in the drug target, activation of prosurvival pathways and ineffective induction of cell death. With the increasing arsenal of anticancer agents, improving preclinical models and the advent of powerful high-throughput screening techniques, there are now unprecedented opportunities to understand and overcome drug
resistance through the clinical assessment of rational therapeutic drug combinations and the use of predictive biomarkers to enable patient stratification."""@en ;
                                             terms:creator :Caitriona_Holohan ,
                                                           :Daniel_B._Longley ,
                                                           :Patrick_G._Johnston ,
                                                           :Sandra_Van_Schaeybroeck ;
                                             terms:publisher :Macmillan_Magazines_Ltd ;
                                             terms:title "Cancer drug resistance: an evolving paradigm"@en .


###  https://w3id.org/skgo/pham#Carboplatin
:Carboplatin rdf:type owl:NamedIndividual ,
                      :Drug ;
             rdfs:label "Carboplatin"@en .


###  https://w3id.org/skgo/pham#Catherine_Booth-Genthe
:Catherine_Booth-Genthe rdf:type owl:NamedIndividual ,
                                 foaf:Person ;
                        rdfs:label "Catherine Booth Genthe" .


###  https://w3id.org/skgo/pham#Cetuximab
:Cetuximab rdf:type owl:NamedIndividual ,
                    :Drug ;
           rdfs:label "Cetuximab"@en .


###  https://w3id.org/skgo/pham#Chemotherapy
:Chemotherapy rdf:type owl:NamedIndividual ,
                       :Treatment ;
              rdfs:label "Chemotherapy"@en .


###  https://w3id.org/skgo/pham#Chemotherapy_with_targeted_inhibitors_of_Pgp-mediated_drug_transport
:Chemotherapy_with_targeted_inhibitors_of_Pgp-mediated_drug_transport rdf:type owl:NamedIndividual ,
                                                                               :Treatment ;
                                                                      :useSpecimen :AML_sample ,
                                                                                   :Advanced_and_recurrent_breast_cancer_sample ,
                                                                                   :NSCLC_sample ,
                                                                                   :Poor-risk_acute_leukaemia_samples ,
                                                                                   :Refractory_AML_high-risk_MDS_sample ,
                                                                                   :Relapsed_and_refractory_AML_sample ;
                                                                      rdfs:label "Chemotherapy_with_targeted_inhibitors_of_Pgp-mediated_drug_transport"@en .


###  https://w3id.org/skgo/pham#Cheol-Hee_Choi
:Cheol-Hee_Choi rdf:type owl:NamedIndividual ,
                         foaf:Person ;
                rdfs:label "Cheol Hee Choi" .


###  https://w3id.org/skgo/pham#ClinicalProblemSolution1
:ClinicalProblemSolution1 rdf:type owl:NamedIndividual .


###  https://w3id.org/skgo/pham#ClinicalProblemSolution10
:ClinicalProblemSolution10 rdf:type owl:NamedIndividual .


###  https://w3id.org/skgo/pham#ClinicalProblemSolution11
:ClinicalProblemSolution11 rdf:type owl:NamedIndividual .


###  https://w3id.org/skgo/pham#ClinicalProblemSolution12
:ClinicalProblemSolution12 rdf:type owl:NamedIndividual .


###  https://w3id.org/skgo/pham#ClinicalProblemSolution13
:ClinicalProblemSolution13 rdf:type owl:NamedIndividual .


###  https://w3id.org/skgo/pham#ClinicalProblemSolution14
:ClinicalProblemSolution14 rdf:type owl:NamedIndividual .


###  https://w3id.org/skgo/pham#ClinicalProblemSolution15
:ClinicalProblemSolution15 rdf:type owl:NamedIndividual .


###  https://w3id.org/skgo/pham#ClinicalProblemSolution16
:ClinicalProblemSolution16 rdf:type owl:NamedIndividual .


###  https://w3id.org/skgo/pham#ClinicalProblemSolution17
:ClinicalProblemSolution17 rdf:type owl:NamedIndividual .


###  https://w3id.org/skgo/pham#ClinicalProblemSolution18
:ClinicalProblemSolution18 rdf:type owl:NamedIndividual .


###  https://w3id.org/skgo/pham#ClinicalProblemSolution19
:ClinicalProblemSolution19 rdf:type owl:NamedIndividual .


###  https://w3id.org/skgo/pham#ClinicalProblemSolution2
:ClinicalProblemSolution2 rdf:type owl:NamedIndividual .


###  https://w3id.org/skgo/pham#ClinicalProblemSolution20
:ClinicalProblemSolution20 rdf:type owl:NamedIndividual .


###  https://w3id.org/skgo/pham#ClinicalProblemSolution3
:ClinicalProblemSolution3 rdf:type owl:NamedIndividual .


###  https://w3id.org/skgo/pham#ClinicalProblemSolution4
:ClinicalProblemSolution4 rdf:type owl:NamedIndividual .


###  https://w3id.org/skgo/pham#ClinicalProblemSolution5
:ClinicalProblemSolution5 rdf:type owl:NamedIndividual .


###  https://w3id.org/skgo/pham#ClinicalProblemSolution6
:ClinicalProblemSolution6 rdf:type owl:NamedIndividual .


###  https://w3id.org/skgo/pham#ClinicalProblemSolution7
:ClinicalProblemSolution7 rdf:type owl:NamedIndividual .


###  https://w3id.org/skgo/pham#ClinicalProblemSolution8
:ClinicalProblemSolution8 rdf:type owl:NamedIndividual .


###  https://w3id.org/skgo/pham#ClinicalProblemSolution9
:ClinicalProblemSolution9 rdf:type owl:NamedIndividual .


###  https://w3id.org/skgo/pham#Clonogenic_survival_assays
:Clonogenic_survival_assays rdf:type owl:NamedIndividual ,
                                     :Assay ;
                            rdfs:label "Clonogenic_survival_assays"@en .


###  https://w3id.org/skgo/pham#Colchicine
:Colchicine rdf:type owl:NamedIndividual ,
                     :Drug ;
            rdfs:label "Colchicine"@en .


###  https://w3id.org/skgo/pham#Colerectal_cancer
:Colerectal_cancer rdf:type owl:NamedIndividual ,
                            :Disease ;
                   rdfs:label "Colerectal_cancer"@en .


###  https://w3id.org/skgo/pham#Colon_Tumor
:Colon_Tumor rdf:type owl:NamedIndividual ,
                      :Disease ;
             rdfs:label "Colerectal_cancer"@en .


###  https://w3id.org/skgo/pham#Colon_carcinoma
:Colon_carcinoma rdf:type owl:NamedIndividual ,
                          :CellLine ;
                 :obtainedfrom :National_Cancer_Institute ;
                 rdfs:label "Colon_carcinoma"@en .


###  https://w3id.org/skgo/pham#Crizotinib
:Crizotinib rdf:type owl:NamedIndividual ,
                     :Drug ;
            rdfs:label "Crizotinib"@en .


###  https://w3id.org/skgo/pham#Cyclosporine
:Cyclosporine rdf:type owl:NamedIndividual ,
                       :Drug ;
              rdfs:label "Cyclosporine"@en .


###  https://w3id.org/skgo/pham#Cytarabine
:Cytarabine rdf:type owl:NamedIndividual ,
                     :Drug ;
            rdfs:label "Cytarabine"@en .


###  https://w3id.org/skgo/pham#D._G._POPLACK
:D._G._POPLACK rdf:type owl:NamedIndividual ,
                        foaf:Person ;
               rdfs:label "D. G. Poplack" .


###  https://w3id.org/skgo/pham#D._J._SLAMON
:D._J._SLAMON rdf:type owl:NamedIndividual ,
                       foaf:Person ;
              rdfs:label "D. J. Slamon" .


###  https://w3id.org/skgo/pham#DOUGLAS_D._ROSS
:DOUGLAS_D._ROSS rdf:type owl:NamedIndividual ,
                          foaf:Person ;
                 rdfs:label "Douglas D. Ross" .


###  https://w3id.org/skgo/pham#Daniel_B._Longley
:Daniel_B._Longley rdf:type owl:NamedIndividual ,
                            foaf:Person ;
                   rdfs:label "Daniel B. Longley" .


###  https://w3id.org/skgo/pham#Dasatinib
:Dasatinib rdf:type owl:NamedIndividual ,
                    :Drug ;
           rdfs:label "Dasatinib"@en .


###  https://w3id.org/skgo/pham#Daunomycin
:Daunomycin rdf:type owl:NamedIndividual ,
                     :Drug ;
            owl:sameAs :Daunorubicin ;
            rdfs:label "Daunomycin"@en .


###  https://w3id.org/skgo/pham#Daunorubicin
:Daunorubicin rdf:type owl:NamedIndividual ,
                       :Drug ;
              rdfs:label "Daunorubicin"@en .


###  https://w3id.org/skgo/pham#Delta_RNA_Fingerprinting_kit
:Delta_RNA_Fingerprinting_kit rdf:type owl:NamedIndividual ,
                                       :ExperimentKit ;
                              :obtainedfrom :CLONTECH ;
                              rdfs:label "Delta_RNA_Fingerprinting_kit"@en .


###  https://w3id.org/skgo/pham#Describe_various_approaches_to_combating_multidrug-resistant_cancer
:Describe_various_approaches_to_combating_multidrug-resistant_cancer rdf:type owl:NamedIndividual ,
                                                                              :levels_of_mdr1_mRNA ;
                                                                     terms:description "The most common of these mechanisms, one that relies on drug efflux from cancer cells mediated by ATP-binding cassette (ABC) transporters." ;
                                                                     rdfs:label "Describe_various_approaches_to_combating_multidrug-resistant_cancer"@en .


###  https://w3id.org/skgo/pham#DiOC2
:DiOC2 rdf:type owl:NamedIndividual ,
                :Reagent ;
       :obtainedfrom :Invitrogen ;
       rdfs:label "DiOC2"@en .


###  https://w3id.org/skgo/pham#Different_Efflux_Transporter_Aff_inity_and_Metabolism_of_99mTc-2-Methoxyisobutylisonitrile_and_99mTc-Tetrofosmin_for_Multidrug_Resistance_Monitoring_in_Cancer
:Different_Efflux_Transporter_Aff_inity_and_Metabolism_of_99mTc-2-Methoxyisobutylisonitrile_and_99mTc-Tetrofosmin_for_Multidrug_Resistance_Monitoring_in_Cancer rdf:type owl:NamedIndividual ,
                                                                                                                                                                         terms1:Publication ,
                                                                                                                                                                         bibo:Article ;
                                                                                                                                                                :addressesStudy :Multidrug_Resistance_Monitoring_in_Cancer ;
                                                                                                                                                                terms1:publicationYear "2018"@en ;
                                                                                                                                                                bibo:abstract """Background Little is known about the affinity and stability of
99mTc-labeled 2-methoxyisobutylisonitrile (99mTc-MIBI) and
tetrofosmin (99mTc-TF) for imaging of multiple drug resistance
transporters in cancer. We examined the affinity of 99mTc-labeled
compounds for these transporters and their stability.
Methods 99mTc-MIBI and 99mTc-TF were incubated in vesicles
expressing P-glycoprotein (MDR1), multidrug resistanceassociated
protein (MRP)14, or breast cancer resistance protein
with and without verapamil (MDR1 inhibitor) or MK-
571 (MRP inhibitor). Time activity curves of 99mTc-labeled
compounds were established using SK-N-SH neuroblastoma,
SK-MEL-28 melanoma, and PC-3 prostate adenocarcinoma
cell lines, and transporter expression of multiple drug resistance
was measured in these cells. The stability was evaluated.
Results In vesicles, 99mTc-labeled compounds had affinity for
MDR1 and MRP1. 99mTc-TF had additional affinity for
MRP2 and MRP3. In SK-N-SH cells expressing MDR1 and
MRP1, MK-571 produced the highest uptake of both 99mTclabeled
compounds. 99mTc-MIBI uptake with inhibitors was
higher than 99mTc-TF uptake with inhibitors. 99mTc-TF was
taken up more in SK-MEL-28 cells expressing MRP1 and
MRP2 than PC-3 cells expressing MRP1 and MRP3. 99mTc-
MIBI was metabolized, whereas 99mTc-TF had high stability.
Conclusion 99mTc-MIBI is exported via MDR1 and MRP1
(MRP1 > MDR1) at greater levels and more quickly compared
to 99mTc-TF, which is exported via MDR1 and MRP13
(MRP1 > MDR1; MRP1, 2 >MRP3). Because 99mTc-MIBI
is metabolized, clinical imaging for monitoring MDR and
shorter examination times may be possible with an earlier scanning
time on late phase imaging. 99mTc-TF has high stability
and accurately reflects the function of MDR1 and MRP13."""@en ;
                                                                                                                                                                terms:creator :Asuka_Mizutani ,
                                                                                                                                                                              :Ikumi_Tamai ,
                                                                                                                                                                              :Kazuki_Fukuchi ,
                                                                                                                                                                              :Keiichi_Kawai ,
                                                                                                                                                                              :Kodai_Nishi ,
                                                                                                                                                                              :Masato_Kobayashi ,
                                                                                                                                                                              :Ryuichi_Nishii ,
                                                                                                                                                                              :Takafumi_Tsujiuchi ,
                                                                                                                                                                              :Takeo_Nakanishi ,
                                                                                                                                                                              :Yuya_Okui ;
                                                                                                                                                                terms:publisher <https://w3id.org/skgo/pham#Springer_Science+Business_Media_LLC> ;
                                                                                                                                                                terms:title "Different Efflux Transporter Aff inity and Metabolism of 99mTc-2-Methoxyisobutylisonitrile and 99mTc-Tetrofosmin for Multidrug Resistance Monitoring in Cancer"@en .


###  https://w3id.org/skgo/pham#Differential_inhibition_of_various_transporters_by_two_structurally_similar_MDR_modulators
:Differential_inhibition_of_various_transporters_by_two_structurally_similar_MDR_modulators rdf:type owl:NamedIndividual ,
                                                                                                     :Treatment ;
                                                                                            :useDrug :Daunorubicin ,
                                                                                                     :Leukotriene_C4 ,
                                                                                                     :Taurocholate ;
                                                                                            :treatmentOutcome """There was increased intracellular
accumulation of doxorubicin as was evidenced using
confocal microscopy and reduced toxicity compared to the
free (unencapsulated) doxorubicin."""@en ;
                                                                                            rdfs:label "Differential_inhibition_of_various_transporters_by_two_structurally_similar_MDR_modulators"@en .


###  https://w3id.org/skgo/pham#Doxorubicin
:Doxorubicin rdf:type owl:NamedIndividual ,
                      :Drug ;
             rdfs:label "Doxorubicin"@en .


###  https://w3id.org/skgo/pham#Drosophila_white_gene
:Drosophila_white_gene rdf:type owl:NamedIndividual ,
                                :Gene ;
                       rdfs:label "Drosophila_white_gene"@en .


###  https://w3id.org/skgo/pham#Drug_Resistance
:Drug_Resistance rdf:type owl:NamedIndividual ,
                          :ClinicalProblem ;
                 :hasMutationResult "Dubin-Johnson syndrome" ;
                 :hasTissueLocalization "Liver, kidney, intestine, adrenal glands, pancreas, lung, ovary" ;
                 :name "Drug Resistance" ;
                 rdfs:label "Drug_Resistance"@en .


###  https://w3id.org/skgo/pham#Drug_efflux_from_cancer_cells_mediated_by_ATP-binding_cassette_ABC_transporters
:Drug_efflux_from_cancer_cells_mediated_by_ATP-binding_cassette_ABC_transporters rdf:type owl:NamedIndividual ,
                                                                                          :ClinicalStudy ;
                                                                                 :investigate :AML ,
                                                                                              :Breast_Cancer ,
                                                                                              :Leukaemia ,
                                                                                              :Lung_cancer ,
                                                                                              :Myeloma ;
                                                                                 :performsExperiment :ABC_transporters_and_in_vitro_MDR ;
                                                                                 terms1:name "Targeting multidrug resistance in cancer" ;
                                                                                 rdfs:label "Drug_efflux_from_cancer_cells_mediated_by_ATP-binding_cassette_ABC_transporters"@en .


###  https://w3id.org/skgo/pham#Drug_resistance_and_its_role_in_clinical_oncology
:Drug_resistance_and_its_role_in_clinical_oncology rdf:type owl:NamedIndividual ,
                                                            :levels_of_mdr1_mRNA ;
                                                   terms:description "Cellular mechanisms of multidrug resistance and ATP-binding cassette (ABC) transporters" ;
                                                   rdfs:label "Drug_resistance_and_its_role_in_clinical_oncology"@en .


###  https://w3id.org/skgo/pham#EasternBlotting
:EasternBlotting rdf:type owl:NamedIndividual ;
                 foaf:name "EasternBlotting"@en .


###  https://w3id.org/skgo/pham#Eastern_Blot_Analysis
:Eastern_Blot_Analysis rdf:type owl:NamedIndividual ,
                                :EasternBlotting ;
                       rdfs:label "Eastern_Blot_Analysis"@en .


###  https://w3id.org/skgo/pham#Efflux_Bioassay
:Efflux_Bioassay rdf:type owl:NamedIndividual ,
                          :Assay ;
                 rdfs:label "Efflux_Bioassay"@en .


###  https://w3id.org/skgo/pham#Elisabeth_Paietta
:Elisabeth_Paietta rdf:type owl:NamedIndividual ,
                            foaf:Person ;
                   rdfs:label "Elisabeth Paietta" .


###  https://w3id.org/skgo/pham#Endogenous_and_exogenous_substrates_for_ABC_transporters
:Endogenous_and_exogenous_substrates_for_ABC_transporters rdf:type owl:NamedIndividual ,
                                                                   :Multidrug_resistance_to_cancer_cells ;
                                                          :useDrug :Actinomycin_D ,
                                                                   :Anthracyclines-doxorubucin_daunorubicin_epirubicin ,
                                                                   :Colchicine ,
                                                                   :Methotrexate ,
                                                                   :Podophyllotoxin-etoposide_teniposide ;
                                                          :useGene :MRP1 ,
                                                                   :MRP2 ,
                                                                   :MRP3 ,
                                                                   :MRP4 ,
                                                                   :MRP5 ,
                                                                   :MRP6 ,
                                                                   :MRP7 ,
                                                                   :MRP8 ,
                                                                   :mdr1 ;
                                                          rdfs:label "Endogenous_and_exogenous_substrates_for_ABC_transporters"@en .


###  https://w3id.org/skgo/pham#Epirubicin
:Epirubicin rdf:type owl:NamedIndividual ,
                     :Drug ;
            rdfs:label "Epirubicin"@en .


###  https://w3id.org/skgo/pham#Etoposide
:Etoposide rdf:type owl:NamedIndividual ,
                    :Drug ;
           rdfs:label "Etoposide"@en .


###  https://w3id.org/skgo/pham#European_Journal_of_Pharmaceutical_Sciences
:European_Journal_of_Pharmaceutical_Sciences rdf:type owl:NamedIndividual ,
                                                      terms1:Publisher .


###  https://w3id.org/skgo/pham#Evidence17
:Evidence17 rdf:type owl:NamedIndividual .


###  https://w3id.org/skgo/pham#Evidence18
:Evidence18 rdf:type owl:NamedIndividual .


###  https://w3id.org/skgo/pham#Evidence19
:Evidence19 rdf:type owl:NamedIndividual .


###  https://w3id.org/skgo/pham#Evidence2
:Evidence2 rdf:type owl:NamedIndividual .


###  https://w3id.org/skgo/pham#Evidence20
:Evidence20 rdf:type owl:NamedIndividual .


###  https://w3id.org/skgo/pham#Evidence3
:Evidence3 rdf:type owl:NamedIndividual .


###  https://w3id.org/skgo/pham#Evidence4
:Evidence4 rdf:type owl:NamedIndividual .


###  https://w3id.org/skgo/pham#Evidence5
:Evidence5 rdf:type owl:NamedIndividual .


###  https://w3id.org/skgo/pham#Evidence6
:Evidence6 rdf:type owl:NamedIndividual .


###  https://w3id.org/skgo/pham#Evidence7
:Evidence7 rdf:type owl:NamedIndividual .


###  https://w3id.org/skgo/pham#Evidence8
:Evidence8 rdf:type owl:NamedIndividual .


###  https://w3id.org/skgo/pham#Evidence9
:Evidence9 rdf:type owl:NamedIndividual .


###  https://w3id.org/skgo/pham#Evidence_of_a_Role_for_Functional_Heterogeneity_in_Multidrug_Resistance_Transporters_in_Clinical_Trials_of_P-Glycoprotein_Modulation_in_Acute_Myeloid_Leukemia
:Evidence_of_a_Role_for_Functional_Heterogeneity_in_Multidrug_Resistance_Transporters_in_Clinical_Trials_of_P-Glycoprotein_Modulation_in_Acute_Myeloid_Leukemia rdf:type owl:NamedIndividual ,
                                                                                                                                                                         terms1:Publication ,
                                                                                                                                                                         bibo:Article ;
                                                                                                                                                                :addressesStudy :Analysis_of_leukemic_blast_MDR_function ;
                                                                                                                                                                bibo:abstract """Background: Multidrug resistance (MDR) transporter proteins such as P-glycoprotein (P-gp) efflux a variety
of chemotherapeutic drugs from acute myeloid leukemia (AML) blasts leading to clinical drug resistance.
Methods: This study examined heterogeneity of MDR functional efflux by AML blasts using two flow cytometry
bioassays. Bone marrow specimens (N = 50) from elderly patients with newly diagnosed AML were analyzed
for CD34+ blasts with MDR efflux function. Efflux was measured with a fluorescent dye (DiOC2) as a
surrogate for oncology drugs that are substrates for MDR efflux. P-gp-mediated efflux was differentiated from
non-P-gp MDR activities using zosuquidar, a highly selective P-gp modulator. The bioassays included a
zosuquidar-dependent DiOC2 accumulation bioassay that measured only P-gp. The second method, termed the
efflux bioassay, could detect P-gp and other non-P-gp efflux depending on bioassay culture conditions.
Results: Sixty-two percent of the specimens were considered positive for blasts with P-gp function, and
26% of such P-gp-positive specimens also exhibited zosuquidar-resistant (i.e., non-P-gp) MDR efflux activity;
37% of P-gp-negative AML blast specimens displayed zosuquidar-resistant MDR function in the efflux
bioassay.
Conclusions: These results confirm the heterogeneous nature of MDR efflux pumps in AML blasts, and provide
support for the hypothesis that non-P-gp MDR contributed to negative results with zosuquidar in AML trials
like ECOG-ACRIN E3999."""@en ;
                                                                                                                                                                dc:title """Evidence of a Role for Functional Heterogeneity in
Multidrug Resistance Transporters in Clinical Trials of
P-Glycoprotein Modulation in Acute Myeloid Leukemia"""@en ;
                                                                                                                                                                terms:creator :Branimir_I._Sikic ,
                                                                                                                                                                              :Elisabeth_Paietta ,
                                                                                                                                                                              :John_F._Marcelletti ,
                                                                                                                                                                              :Larry_D._Cripe ;
                                                                                                                                                                terms:publisher :International_Clinical_Cytometry_Society .


###  https://w3id.org/skgo/pham#ExperimentalStudy
:ExperimentalStudy rdf:type owl:NamedIndividual ;
                   foaf:name "ExperimentalStudy"@en .


###  https://w3id.org/skgo/pham#Experimental_Study
:Experimental_Study rdf:type owl:NamedIndividual ,
                             :ExperimentalStudy ;
                    rdfs:label "Experimental Study"@en .


###  https://w3id.org/skgo/pham#Expression_of_a_multidrug-resistance_gene
:Expression_of_a_multidrug-resistance_gene rdf:type owl:NamedIndividual ,
                                                    :ClinicalStudy ;
                                           :investigate :Adrenocortical_Cancer ,
                                                        :Colon_Tumor ,
                                                        :Neuroblastoma ,
                                                        :Neuroepithelioma ,
                                                        :Pheochromocytoma ,
                                                        :Rhabdomyosarcoma ;
                                           :investigatesProblem :Multiple_chemotherapeutic_agents ;
                                           :performsExperiment :mdr1_gene_expression ;
                                           terms1:name "Expression of a multidrug-resistance gene in human tumors and tissues" ;
                                           :hasSuggestion "Some cases of colon cancer, increased expression of the mdr1 gene might be involved in the intrinsic resistance of these tumors to chemotherapeutic agents." ;
                                           rdfs:label "Expression_of_a_multidrug-resistance_gene"@en .


###  https://w3id.org/skgo/pham#Expression_of_a_multidrug-resistance_gene_in_human_tumors_and_tissues
:Expression_of_a_multidrug-resistance_gene_in_human_tumors_and_tissues rdf:type owl:NamedIndividual ,
                                                                                terms1:Publication ,
                                                                                bibo:Article ;
                                                                       :addressesStudy :Expression_of_a_multidrug-resistance_gene ;
                                                                       terms1:publicationYear "1987"^^xsd:gYear ;
                                                                       bibo:abstract """The identification and cloning of a segment of a human multidrug resistance gene (mdrl) was reported recently. To examine the molecular basis of one type of multidrug resistance, we have prepared RNA from human tumors and normal tissues and measured their content of mdrl RNA. We find that the mdrl gene is expressed at a very high level in the adrenal gland; at a high level in the kidney; at
intermediate levels in the lung, liver, lower jejunum, colon, and rectum; and at low levels in many other tissues. The mdrl gene is also expressed in several human tumors, including many but not all tumors derived from the adrenal gland and the colon. In addition, increased expression was detected in a few tumors at the time of relapse following initial chemotherapy. Although controlled clinical studies will be required, our results suggest that measurement of mdrl RNA may prove to be a valuable tool in the design of chemotherapy protocols.""" ;
                                                                       terms:creator :D._G._POPLACK ,
                                                                                     :D._J._SLAMON ,
                                                                                     :I._PASTAN ,
                                                                                     :K._UEDA ,
                                                                                     :M._M._GOTTESMAN ;
                                                                       terms:publisher :Proc._Nati._Acad._Sci._USA ;
                                                                       terms:title "Expression of a multidrug-resistance gene in human tumors and tissues"^^rdfs:Literal .


###  https://w3id.org/skgo/pham#Finding1
:Finding1 rdf:type owl:NamedIndividual .


###  https://w3id.org/skgo/pham#Finding10
:Finding10 rdf:type owl:NamedIndividual .


###  https://w3id.org/skgo/pham#Finding11
:Finding11 rdf:type owl:NamedIndividual .


###  https://w3id.org/skgo/pham#Finding12
:Finding12 rdf:type owl:NamedIndividual .


###  https://w3id.org/skgo/pham#Finding13
:Finding13 rdf:type owl:NamedIndividual .


###  https://w3id.org/skgo/pham#Finding14
:Finding14 rdf:type owl:NamedIndividual .


###  https://w3id.org/skgo/pham#Finding15
:Finding15 rdf:type owl:NamedIndividual .


###  https://w3id.org/skgo/pham#Finding16
:Finding16 rdf:type owl:NamedIndividual .


###  https://w3id.org/skgo/pham#Finding17
:Finding17 rdf:type owl:NamedIndividual .


###  https://w3id.org/skgo/pham#Finding18
:Finding18 rdf:type owl:NamedIndividual .


###  https://w3id.org/skgo/pham#Finding19
:Finding19 rdf:type owl:NamedIndividual .


###  https://w3id.org/skgo/pham#Finding2
:Finding2 rdf:type owl:NamedIndividual .


###  https://w3id.org/skgo/pham#Finding20
:Finding20 rdf:type owl:NamedIndividual .


###  https://w3id.org/skgo/pham#Finding3
:Finding3 rdf:type owl:NamedIndividual .


###  https://w3id.org/skgo/pham#Finding4
:Finding4 rdf:type owl:NamedIndividual .


###  https://w3id.org/skgo/pham#Finding5
:Finding5 rdf:type owl:NamedIndividual .


###  https://w3id.org/skgo/pham#Finding6
:Finding6 rdf:type owl:NamedIndividual .


###  https://w3id.org/skgo/pham#Finding7
:Finding7 rdf:type owl:NamedIndividual .


###  https://w3id.org/skgo/pham#Finding8
:Finding8 rdf:type owl:NamedIndividual .


###  https://w3id.org/skgo/pham#Finding9
:Finding9 rdf:type owl:NamedIndividual .


###  https://w3id.org/skgo/pham#Flavopiridol
:Flavopiridol rdf:type owl:NamedIndividual ,
                       :Drug ;
              rdfs:label "Flavopiridol"@en .


###  https://w3id.org/skgo/pham#Fluorochrome-labeled_anti-CD_antibodies
:Fluorochrome-labeled_anti-CD_antibodies rdf:type owl:NamedIndividual ,
                                                  :Reagent ;
                                         :obtainedfrom :BD_Biosciences_La_Jolla_CA ;
                                         rdfs:label "Fluorochrome-labeled_anti-CD_antibodies"@en .


###  https://w3id.org/skgo/pham#Fluorouracil
:Fluorouracil rdf:type owl:NamedIndividual ,
                       :Drug ;
              rdfs:label "Fluorouracil"@en .


###  https://w3id.org/skgo/pham#Functional_Assay
:Functional_Assay rdf:type owl:NamedIndividual ,
                           :Assay ;
                  rdfs:label "Functional_Assay"@en .


###  https://w3id.org/skgo/pham#Functional_Bioassay
:Functional_Bioassay rdf:type owl:NamedIndividual ,
                              :Assay ;
                     rdfs:label "Functional_Bioassay"@en .


###  https://w3id.org/skgo/pham#Functions_of_ABC_transporters_in_Chemotherapy
:Functions_of_ABC_transporters_in_Chemotherapy rdf:type owl:NamedIndividual ,
                                                        :Treatment ;
                                               :useSpecimen :Breast_cancer_samples ;
                                               :failureReason "PGP expression increased after therapy and was associated with a greater likelihood of treatment failure." ;
                                               :treatmentOutcome "Toxicity" ;
                                               rdfs:label "Functions_of_ABC_transporters_in_Chemotherapy"@en .


###  https://w3id.org/skgo/pham#Gastrointestinal_stromal_tumour_GIST_cell_lines
:Gastrointestinal_stromal_tumour_GIST_cell_lines rdf:type owl:NamedIndividual ,
                                                          :CellLine ;
                                                 rdfs:label "Gastrointestinal_stromal_tumour_GIST_cell_lines"@en .


###  https://w3id.org/skgo/pham#Gefitinib
:Gefitinib rdf:type owl:NamedIndividual ,
                    :Drug ;
           rdfs:label "Gefitinib"@en .


###  https://w3id.org/skgo/pham#Gergely_Szakcs
:Gergely_Szakcs rdf:type owl:NamedIndividual ,
                          foaf:Person .


###  https://w3id.org/skgo/pham#Growth_inhibition_assays
:Growth_inhibition_assays rdf:type owl:NamedIndividual ,
                                   :Assay ;
                          rdfs:label "Growth_inhibition_assays"@en .


###  https://w3id.org/skgo/pham#HTB_10_HTB_11_HTB_38
:HTB_10_HTB_11_HTB_38 rdf:type owl:NamedIndividual ,
                               :CellLine ;
                      rdfs:label "HTB_10_HTB_11_HTB_38"@en .


###  https://w3id.org/skgo/pham#Head_and_neck_cancer
:Head_and_neck_cancer rdf:type owl:NamedIndividual ,
                               :Disease ;
                      rdfs:label "Head_and_neck_cancer"@en .


###  https://w3id.org/skgo/pham#High-risk_MDS_sample
:High-risk_MDS_sample rdf:type owl:NamedIndividual ,
                               :Specimen ;
                      rdfs:label "High-risk_MDS_sample"@en .


###  https://w3id.org/skgo/pham#I._PASTAN
:I._PASTAN rdf:type owl:NamedIndividual ,
                    foaf:Person .


###  https://w3id.org/skgo/pham#IL-2
:IL-2 rdf:type owl:NamedIndividual ,
               :Drug ;
      rdfs:label "IL-2"@en .


###  https://w3id.org/skgo/pham#Iamivudine
:Iamivudine rdf:type owl:NamedIndividual ,
                     :Drug ;
            rdfs:label "Iamivudine"@en .


###  https://w3id.org/skgo/pham#Idarubicine
:Idarubicine rdf:type owl:NamedIndividual ,
                      :Drug ;
             rdfs:label "Idarubicine"@en .


###  https://w3id.org/skgo/pham#Idarubicinol
:Idarubicinol rdf:type owl:NamedIndividual ,
                       :Drug ;
              rdfs:label "Idarubicinol"@en .


###  https://w3id.org/skgo/pham#Identification_of_the_BCRP_gene-Functional_configuration_of_BCRP
:Identification_of_the_BCRP_gene-Functional_configuration_of_BCRP rdf:type owl:NamedIndividual ,
                                                                           :ClinicalStudy ;
                                                                  :hasStudyDesign :Review_Study ;
                                                                  :investigate :AML ;
                                                                  :performsExperiment <https://w3id.org/skgo/pham#BCRP_substrate/inhibitors> ;
                                                                  rdfs:label "Identification_of_the_BCRP_gene-Functional_configuration_of_BCRP"@en .


###  https://w3id.org/skgo/pham#Ifosfamide
:Ifosfamide rdf:type owl:NamedIndividual ,
                     :Drug ;
            rdfs:label "Ifosfamide"@en .


###  https://w3id.org/skgo/pham#Ikumi_Tamai
:Ikumi_Tamai rdf:type owl:NamedIndividual ,
                      foaf:Person .


###  https://w3id.org/skgo/pham#Imatinib
:Imatinib rdf:type owl:NamedIndividual ,
                   :Drug ;
          rdfs:label "Imatinib"@en .


###  https://w3id.org/skgo/pham#Immunosuppressant_cyclosporin_A
:Immunosuppressant_cyclosporin_A rdf:type owl:NamedIndividual ,
                                          :Drug ;
                                 rdfs:label "Immunosuppressant_cyclosporin_A"@en .


###  https://w3id.org/skgo/pham#Indolocarbazole
:Indolocarbazole rdf:type owl:NamedIndividual ,
                          :Drug ;
                 rdfs:label "Indolocarbazole"@en .


###  https://w3id.org/skgo/pham#International_Clinical_Cytometry_Society
:International_Clinical_Cytometry_Society rdf:type owl:NamedIndividual ,
                                                   terms1:Publisher .


###  https://w3id.org/skgo/pham#Invitrogen
:Invitrogen rdf:type owl:NamedIndividual ,
                     foaf:Organization .


###  https://w3id.org/skgo/pham#Jill_K._Paterson
:Jill_K._Paterson rdf:type owl:NamedIndividual ,
                           foaf:Person .


###  https://w3id.org/skgo/pham#John_F._Marcelletti
:John_F._Marcelletti rdf:type owl:NamedIndividual ,
                              foaf:Person .


###  https://w3id.org/skgo/pham#Joseph_A._Ludwig
:Joseph_A._Ludwig rdf:type owl:NamedIndividual ,
                           foaf:Person .


###  https://w3id.org/skgo/pham#K._UEDA
:K._UEDA rdf:type owl:NamedIndividual ,
                  foaf:Person .


###  https://w3id.org/skgo/pham#KB-3-1_KB-8-5_KB-V1
:KB-3-1_KB-8-5_KB-V1 rdf:type owl:NamedIndividual ,
                              :CellLine ;
                     rdfs:label "KB-3-1_KB-8-5_KB-V1"@en .


###  https://w3id.org/skgo/pham#Kazuki_Fukuchi
:Kazuki_Fukuchi rdf:type owl:NamedIndividual ,
                         foaf:Person .


###  https://w3id.org/skgo/pham#Keiichi_Kawai
:Keiichi_Kawai rdf:type owl:NamedIndividual ,
                        foaf:Person .


###  https://w3id.org/skgo/pham#Kodai_Nishi
:Kodai_Nishi rdf:type owl:NamedIndividual ,
                      foaf:Person .


###  https://w3id.org/skgo/pham#L._AUSTIN_DOYLE
:L._AUSTIN_DOYLE rdf:type owl:NamedIndividual ,
                          foaf:Person .


###  https://w3id.org/skgo/pham#LYNNE_V._ABRUZZO
:LYNNE_V._ABRUZZO rdf:type owl:NamedIndividual ,
                           foaf:Person .


###  https://w3id.org/skgo/pham#Larry_D._Cripe
:Larry_D._Cripe rdf:type owl:NamedIndividual ,
                         foaf:Person .


###  https://w3id.org/skgo/pham#Lawrence_D._Mayer
:Lawrence_D._Mayer rdf:type owl:NamedIndividual ,
                            foaf:Person .


###  https://w3id.org/skgo/pham#Leukaemia
:Leukaemia rdf:type owl:NamedIndividual ,
                    :Disease ;
           rdfs:label "Leukaemia"@en .


###  https://w3id.org/skgo/pham#Leukotriene_C4
:Leukotriene_C4 rdf:type owl:NamedIndividual ,
                         :Drug ;
                rdfs:label "Leukotriene_C4"@en .


###  https://w3id.org/skgo/pham#Levels_of_mdrl_mRNA
:Levels_of_mdrl_mRNA rdf:type owl:NamedIndividual ,
                              :levels_of_mdr1_mRNA ;
                     terms:description "Since expression of the mdrl gene is responsible for multidrug resistance in tissue culture systems, we measured levels of mdrl mRNA in normal human tissues and in untreated and treated human cancers." ;
                     rdfs:label "Levels_of_mdrl_mRNA"@en .


###  https://w3id.org/skgo/pham#Lung_cancer
:Lung_cancer rdf:type owl:NamedIndividual ,
                      :Disease ;
             rdfs:label "Lung_cancer"@en .


###  https://w3id.org/skgo/pham#Lymphoma
:Lymphoma rdf:type owl:NamedIndividual ,
                   :Disease ;
          rdfs:label "Lymphoma"@en .


###  https://w3id.org/skgo/pham#M._M._GOTTESMAN
:M._M._GOTTESMAN rdf:type owl:NamedIndividual ,
                          foaf:Person .


###  https://w3id.org/skgo/pham#MCF-7_human_breast_carcinoma_cells
:MCF-7_human_breast_carcinoma_cells rdf:type owl:NamedIndividual ,
                                             :CellLine ;
                                    :obtainedfrom :National_Cancer_Institute ;
                                    rdfs:label "MCF-7_human_breast_carcinoma_cells"@en .


###  https://w3id.org/skgo/pham#MDR2
:MDR2 rdf:type owl:NamedIndividual ,
               :Gene ;
      rdfs:label "MDR2"@en .


###  https://w3id.org/skgo/pham#MRP1
:MRP1 rdf:type owl:NamedIndividual ,
               :Gene ;
      rdfs:label "MRP1"@en .


###  https://w3id.org/skgo/pham#MRP2
:MRP2 rdf:type owl:NamedIndividual ,
               :Gene ;
      rdfs:label "MRP2"@en .


###  https://w3id.org/skgo/pham#MRP3
:MRP3 rdf:type owl:NamedIndividual ,
               :Gene ;
      rdfs:label "MRP3"@en .


###  https://w3id.org/skgo/pham#MRP4
:MRP4 rdf:type owl:NamedIndividual ,
               :Gene ;
      rdfs:label "MRP4"@en .


###  https://w3id.org/skgo/pham#MRP5
:MRP5 rdf:type owl:NamedIndividual ,
               :Gene ;
      rdfs:label "MRP5"@en .


###  https://w3id.org/skgo/pham#MRP6
:MRP6 rdf:type owl:NamedIndividual ,
               :Gene ;
      rdfs:label "MRP6"@en .


###  https://w3id.org/skgo/pham#MRP7
:MRP7 rdf:type owl:NamedIndividual ,
               :Gene ;
      rdfs:label "MRP7"@en .


###  https://w3id.org/skgo/pham#MRP8
:MRP8 rdf:type owl:NamedIndividual ,
               :Gene ;
      rdfs:label "MRP8"@en .


###  https://w3id.org/skgo/pham#Macmillan_Magazines_Ltd
:Macmillan_Magazines_Ltd rdf:type owl:NamedIndividual ,
                                  terms1:Publisher ,
                                  foaf:Agent ;
                         terms1:name "Macmillan Magazines Ltd"^^rdfs:Literal .


###  https://w3id.org/skgo/pham#Masato_Kobayashi
:Masato_Kobayashi rdf:type owl:NamedIndividual ,
                           foaf:Person .


###  https://w3id.org/skgo/pham#Mechanisms_that_enable_the_survival_of_cancer_cells_during_drug_treatment
:Mechanisms_that_enable_the_survival_of_cancer_cells_during_drug_treatment rdf:type owl:NamedIndividual ,
                                                                                    :ClinicalStudy ;
                                                                           :investigate :ALL ,
                                                                                        :Breast_Cancer ,
                                                                                        :CML ,
                                                                                        :Colerectal_cancer ,
                                                                                        :Head_and_neck_cancer ,
                                                                                        :Lymphoma ,
                                                                                        :Melanoma ,
                                                                                        :NSCLC ,
                                                                                        :Ovarian_cancer ,
                                                                                        :Pancreatic_cancer ;
                                                                           :performsExperiment :BH3_profiling ;
                                                                           rdfs:label "Mechanisms_that_enable_the_survival_of_cancer_cells_during_drug_treatment"@en .


###  https://w3id.org/skgo/pham#Melanoma
:Melanoma rdf:type owl:NamedIndividual ,
                   :Disease ;
          rdfs:label "Melanoma"@en .


###  https://w3id.org/skgo/pham#Melanoma_cell_line
:Melanoma_cell_line rdf:type owl:NamedIndividual ,
                             :CellLine ;
                    rdfs:label "Melanoma_cell_line"@en .


###  https://w3id.org/skgo/pham#Methotrexate
:Methotrexate rdf:type owl:NamedIndividual ,
                       :Drug ;
              rdfs:label "Methotrexate"@en .


###  https://w3id.org/skgo/pham#Michael_M._Gottesman
:Michael_M._Gottesman rdf:type owl:NamedIndividual ,
                               foaf:Person .


###  https://w3id.org/skgo/pham#Mitomycin_C
:Mitomycin_C rdf:type owl:NamedIndividual ,
                      :Drug ;
             rdfs:label "Mitomycin_C"@en .


###  https://w3id.org/skgo/pham#Mitoxantrone
:Mitoxantrone rdf:type owl:NamedIndividual ,
                       :Drug ;
              rdfs:label "Mitoxantrone"@en .


###  https://w3id.org/skgo/pham#Multidrug_Resistance_Monitoring_in_Cancer
:Multidrug_Resistance_Monitoring_in_Cancer rdf:type owl:NamedIndividual ,
                                                    :ClinicalStudy ;
                                           rdfs:label "Multidrug_Resistance_Monitoring_in_Cancer"@en .


###  https://w3id.org/skgo/pham#Multidrug_resistance-MDR_in_cancer_Mechanisms
:Multidrug_resistance-MDR_in_cancer_Mechanisms rdf:type owl:NamedIndividual ,
                                                        :ClinicalStudy ;
                                               :investigate :Breast_Cancer ,
                                                            :Colerectal_cancer ,
                                                            :Lung_cancer ,
                                                            :Myeloma ,
                                                            :Ovarian_cancer ,
                                                            :Renal_cell_cancer ;
                                               :investigatesProblem :Role_of_P-GP_in_MDR ;
                                               :performsExperiment :Vesicle_transport_experiments ;
                                               terms1:name "Multidrug resistance (MDR) in cancer Mechanisms, reversal using modulators of MDR and the role of MDR modulators in influencing the pharmacokinetics of anticancer drugs" ;
                                               rdfs:label "Multidrug_resistance-MDR_in_cancer_Mechanisms"@en .


###  https://w3id.org/skgo/pham#Multidrug_resistance_MDR_efflux_pumps_capable_of_eliminating_chemotherapeutic_drugs_from_tumor_cells
:Multidrug_resistance_MDR_efflux_pumps_capable_of_eliminating_chemotherapeutic_drugs_from_tumor_cells rdf:type owl:NamedIndividual ,
                                                                                                               :ClinicalProblem ;
                                                                                                      rdfs:label "Multidrug_resistance_MDR_efflux_pumps_capable_of_eliminating_chemotherapeutic_drugs_from_tumor_cells"@en ;
                                                                                                      skos:definition """Multidrug resistance (MDR) efflux pumps capable of
eliminating chemotherapeutic drugs from tumor cells
contribute to clinical drug resistance in acute myeloid
leukemia (AML) and other cancers."""@en .


###  https://w3id.org/skgo/pham#Multidrug_resistance_MDR_in_cancer_Mechanisms_reversal_using_modulators_of_MDR_and_the_role_of_MDR_modulators_in_influencing_the_pharmacokinetics_of_anticancer_drugs
:Multidrug_resistance_MDR_in_cancer_Mechanisms_reversal_using_modulators_of_MDR_and_the_role_of_MDR_modulators_in_influencing_the_pharmacokinetics_of_anticancer_drugs rdf:type owl:NamedIndividual ,
                                                                                                                                                                                terms1:Publication ,
                                                                                                                                                                                bibo:Article ;
                                                                                                                                                                       :addressesStudy :Multidrug_resistance-MDR_in_cancer_Mechanisms ;
                                                                                                                                                                       terms1:publicationYear "2000"^^xsd:gYear ;
                                                                                                                                                                       bibo:abstract """In recent years, there has been an increased understanding of P-glycoprotein (P-GP)-mediated pharmacokinetic interactions. In addition,
its role in modifying the bioavailability of orally administered drugs via induction or inhibition has been also been demonstrated in
various studies. This overview presents a background on some of the commonly documented mechanisms of multidrug resistance (MDR),
reversal using modulators of MDR, followed by a discussion on the functional aspects of P-GP in the context of the pharmacokinetic
interactions when multiple agents are coadministered. While adverse pharmacokinetic interactions have been documented with first and
second generation MDR modulators, certain newer agents of the third generation class of compounds have been less susceptible in
eliciting pharmacokinetic interactions. Although the review focuses on P-GP and the pharmacology of MDR reversal using MDR
modulators, relevance of these drug transport proteins in the context of pharmacokinetic implications (drug absorption, distribution,
clearance, and interactions) will also be discussed."""@en ;
                                                                                                                                                                       terms:creator :Lawrence_D._Mayer ,
                                                                                                                                                                                     :Rajesh_Krishna ;
                                                                                                                                                                       terms:publisher :European_Journal_of_Pharmaceutical_Sciences ;
                                                                                                                                                                       terms:title "Multidrug resistance (MDR) in cancer Mechanisms, reversal using modulators of MDR and the role of MDR modulators in influencing the pharmacokinetics of anticancer drugs"^^rdfs:Literal .


###  https://w3id.org/skgo/pham#Multidrug_resistance_mediated_by_the_breast_cancer_resistance_protein_BCRP
:Multidrug_resistance_mediated_by_the_breast_cancer_resistance_protein_BCRP rdf:type owl:NamedIndividual ,
                                                                                     terms1:Publication ,
                                                                                     bibo:Article ;
                                                                            :addressesStudy :Identification_of_the_BCRP_gene-Functional_configuration_of_BCRP ;
                                                                            terms1:publicationYear "2003"^^xsd:gYear ;
                                                                            bibo:abstract """Observations of functional adenosine triphosphate (ATP)-dependent drug efflux in certain multidrug-resistant cancer cell lines without overexpression of P-glycoprotein or multidrug resistance protein (MRP) family members
suggested the existence of another ATP-binding cassette (ABC) transporter capable of causing cancer drug resistance. In one such cell line (MCF-7/AdrVp), the overexpression of a novel member of the G subfamily of ABC transporters was found. The new transporter was termed the breast cancer resistance protein (BCRP), because of its identification in MCF-7 human breast carcinoma cells. BCRP is a 655 amino-acid polypeptide, formally designated as ABCG2. Like all members of the ABC G (white) subfamily, BCRP is a half transporter. Transfection and enforced overexpression of BCRP in drug-sensitive MCF-7 or MDA-MB-231 cells recapitulates the drug-resistance phenotype of MCF-7/AdrVp cells, consistent with current evidence suggesting that
functional BCRP is a homodimer. BCRP maps to chromosome 4q22, downstream from a TATA-less promoter. The spectrum of anticancer drugs effluxed by BCRP includes mitoxantrone, camptothecin-derived and
indolocarbazole topoisomerase I inhibitors, methotrexate, flavopiridol, and quinazoline ErbB1 inhibitors. Transport of anthracyclines is variable and appears to depend on the presence of a BCRP mutation at codon 482. Potent and
specific inhibitors of BCRP are now being developed, opening the door to clinical applications of BCRP inhibition. Owing to tissue localization in the placenta, bile canaliculi, colon, small bowel, and brain microvessel endothelium, BCRP may play a role in protecting the organism from potentially harmful xenobiotics. BCRP expression has also been demonstrated in pluripotential side population stem cells, responsible for the characteristic ability of these cells to exclude Hoechst 33342 dye, and possibly for the maintenance of the stem cell
phenotype. Studies are emerging on the role of BCRP expression in drug resistance in clinical cancers. More prospective studies are needed, preferably combining BCRP protein or mRNA quantification with functional
assays, in order to determine the contribution of BCRP to drug resistance in human cancers."""@en ;
                                                                            terms:creator :DOUGLAS_D._ROSS ,
                                                                                          :L._AUSTIN_DOYLE ;
                                                                            terms:publisher :Nature_Publishing_Group ;
                                                                            terms:title "Multidrug resistance mediated by the breast cancer resistance protein BCRP (ABCG2)"^^rdfs:Literal .


###  https://w3id.org/skgo/pham#Multiple_chemotherapeutic_agents
:Multiple_chemotherapeutic_agents rdf:type owl:NamedIndividual ,
                                           :ClinicalProblem ;
                                  rdfs:label "Multiple_chemotherapeutic_agents"@en .


###  https://w3id.org/skgo/pham#MutationResult1
:MutationResult1 rdf:type owl:NamedIndividual .


###  https://w3id.org/skgo/pham#MutationResult10
:MutationResult10 rdf:type owl:NamedIndividual .


###  https://w3id.org/skgo/pham#MutationResult11
:MutationResult11 rdf:type owl:NamedIndividual .


###  https://w3id.org/skgo/pham#MutationResult12
:MutationResult12 rdf:type owl:NamedIndividual .


###  https://w3id.org/skgo/pham#MutationResult13
:MutationResult13 rdf:type owl:NamedIndividual .


###  https://w3id.org/skgo/pham#MutationResult14
:MutationResult14 rdf:type owl:NamedIndividual .


###  https://w3id.org/skgo/pham#MutationResult15
:MutationResult15 rdf:type owl:NamedIndividual .


###  https://w3id.org/skgo/pham#MutationResult16
:MutationResult16 rdf:type owl:NamedIndividual .


###  https://w3id.org/skgo/pham#MutationResult17
:MutationResult17 rdf:type owl:NamedIndividual .


###  https://w3id.org/skgo/pham#MutationResult18
:MutationResult18 rdf:type owl:NamedIndividual .


###  https://w3id.org/skgo/pham#MutationResult19
:MutationResult19 rdf:type owl:NamedIndividual .


###  https://w3id.org/skgo/pham#MutationResult2
:MutationResult2 rdf:type owl:NamedIndividual .


###  https://w3id.org/skgo/pham#MutationResult20
:MutationResult20 rdf:type owl:NamedIndividual .


###  https://w3id.org/skgo/pham#MutationResult3
:MutationResult3 rdf:type owl:NamedIndividual .


###  https://w3id.org/skgo/pham#MutationResult4
:MutationResult4 rdf:type owl:NamedIndividual .


###  https://w3id.org/skgo/pham#MutationResult5
:MutationResult5 rdf:type owl:NamedIndividual .


###  https://w3id.org/skgo/pham#MutationResult6
:MutationResult6 rdf:type owl:NamedIndividual .


###  https://w3id.org/skgo/pham#MutationResult7
:MutationResult7 rdf:type owl:NamedIndividual .


###  https://w3id.org/skgo/pham#MutationResult8
:MutationResult8 rdf:type owl:NamedIndividual .


###  https://w3id.org/skgo/pham#MutationResult9
:MutationResult9 rdf:type owl:NamedIndividual .


###  https://w3id.org/skgo/pham#Myeloma
:Myeloma rdf:type owl:NamedIndividual ,
                  :Disease ;
         rdfs:label "Myeloma"@en .


###  https://w3id.org/skgo/pham#NSCLC
:NSCLC rdf:type owl:NamedIndividual ,
                :Disease ;
       rdfs:label "NSCLC"@en .


###  https://w3id.org/skgo/pham#NSCLC_cell_lines
:NSCLC_cell_lines rdf:type owl:NamedIndividual ,
                           :CellLine ;
                  rdfs:label "NSCLC_cell_lines"@en .


###  https://w3id.org/skgo/pham#NSCLC_sample
:NSCLC_sample rdf:type owl:NamedIndividual ,
                       :Specimen ;
              :obtainedfromPatient :Phase_III_clinical_trials_with_ABC_transporter_inhibitors ;
              rdfs:label "NSCLC_sample"@en .


###  https://w3id.org/skgo/pham#National_Cancer_Institute
:National_Cancer_Institute rdf:type owl:NamedIndividual ,
                                    foaf:Organization .


###  https://w3id.org/skgo/pham#Nature_Publishing_Group
:Nature_Publishing_Group rdf:type owl:NamedIndividual ,
                                  terms1:Publisher ,
                                  foaf:Agent ;
                         terms1:name "Nature Publishing Group"^^rdfs:Literal .


###  https://w3id.org/skgo/pham#Neck_squamous_cell_carcinoma_cell_lines
:Neck_squamous_cell_carcinoma_cell_lines rdf:type owl:NamedIndividual ,
                                                  :CellLine ;
                                         rdfs:label "Neck_squamous_cell_carcinoma_cell_lines"@en .


###  https://w3id.org/skgo/pham#Neuroblastoma
:Neuroblastoma rdf:type owl:NamedIndividual ,
                        :Disease ;
               rdfs:label "Neuroblastoma"@en .


###  https://w3id.org/skgo/pham#Neuroblastoma_Cell
:Neuroblastoma_Cell rdf:type owl:NamedIndividual ,
                             :CellLine ;
                    :obtainedfrom :American_Type_Culture_Collection ;
                    rdfs:label "Neuroblastoma_Cell"@en .


###  https://w3id.org/skgo/pham#Neuroepithelioma
:Neuroepithelioma rdf:type owl:NamedIndividual ,
                           :Disease ;
                  rdfs:label "Neuroepithelioma"@en .


###  https://w3id.org/skgo/pham#Nilotinib
:Nilotinib rdf:type owl:NamedIndividual ,
                    :Drug ;
           rdfs:label "Nilotinib"@en .


###  https://w3id.org/skgo/pham#Non-P-gp_MDR_contributed_to_negative_results_with_zosuquidar
:Non-P-gp_MDR_contributed_to_negative_results_with_zosuquidar rdf:type owl:NamedIndividual ,
                                                                       :levels_of_mdr1_mRNA ;
                                                              rdfs:label "Non-P-gp_MDR_contributed_to_negative_results_with_zosuquidar"@en ;
                                                              skos:definition """Non-P-gp MDR contributed to negative results with zosuquidar in AML trials
like ECOG-ACRIN E3999"""@en .


###  https://w3id.org/skgo/pham#Non_Smallcell_Lung_Cancer
:Non_Smallcell_Lung_Cancer rdf:type owl:NamedIndividual ,
                                    :Disease ;
                           rdfs:label "Non_Smallcell_Lung_Cancer"@en .


###  https://w3id.org/skgo/pham#Northern_analysis_of_the_expression_of_BCRP_mRNA
:Northern_analysis_of_the_expression_of_BCRP_mRNA rdf:type owl:NamedIndividual ,
                                                           :NorthernBlotting ;
                                                  rdfs:label "Northern_analysis_of_the_expression_of_BCRP_mRNA"@en .


###  https://w3id.org/skgo/pham#ObservationalStudy
:ObservationalStudy rdf:type owl:NamedIndividual ;
                    foaf:name "ObservationalStudy"@en .


###  https://w3id.org/skgo/pham#Observational_Study
:Observational_Study rdf:type owl:NamedIndividual ,
                              :ObservationalStudy ;
                     rdfs:label "Observational Study"@en .


###  https://w3id.org/skgo/pham#Ovarian_cancer
:Ovarian_cancer rdf:type owl:NamedIndividual ,
                         :Disease ;
                rdfs:label "Ovarian_cancer"@en .


###  https://w3id.org/skgo/pham#P-GP-mediated_MDR_a_General_overview_of_the_underlying_mechanisms_and_types_of_drug_resistance
:P-GP-mediated_MDR_a_General_overview_of_the_underlying_mechanisms_and_types_of_drug_resistance rdf:type owl:NamedIndividual ,
                                                                                                         :levels_of_mdr1_mRNA ;
                                                                                                terms:description "The focus of this review is P-GP-mediated MDR, a general overview of the underlying mechanisms and types of drug resistance is presented in the context of the overall MDR phenomenon." ;
                                                                                                rdfs:label "P-GP-mediated_MDR_a_General_overview_of_the_underlying_mechanisms_and_types_of_drug_resistance"@en .


###  https://w3id.org/skgo/pham#Paclitaxel
:Paclitaxel rdf:type owl:NamedIndividual ,
                     :Drug ;
            rdfs:label "Paclitaxel"@en .


###  https://w3id.org/skgo/pham#Pancreatic_cancer
:Pancreatic_cancer rdf:type owl:NamedIndividual ,
                            :Disease ;
                   rdfs:label "Pancreatic_cancer"@en .


###  https://w3id.org/skgo/pham#Pancreatic_cancer_cell_lines
:Pancreatic_cancer_cell_lines rdf:type owl:NamedIndividual ,
                                       :CellLine ;
                              rdfs:label "Pancreatic_cancer_cell_lines"@en .


###  https://w3id.org/skgo/pham#Patient_with_adrenocortical_cancer_and_breast_cancer
:Patient_with_adrenocortical_cancer_and_breast_cancer rdf:type owl:NamedIndividual ,
                                                               :Patient ;
                                                      :hasDisease :Adrenocortical_Cancer ,
                                                                  :Breast_Cancer ;
                                                      :has_Treatment :Functions_of_ABC_transporters_in_Chemotherapy ;
                                                      rdfs:label "Patient_with_adrenocortical_cancer_and_breast_cancer"@en .


###  https://w3id.org/skgo/pham#Patrick_G._Johnston
:Patrick_G._Johnston rdf:type owl:NamedIndividual ,
                              foaf:Person .


###  https://w3id.org/skgo/pham#Peripheral_blood_lymphocytes
:Peripheral_blood_lymphocytes rdf:type owl:NamedIndividual ,
                                       :Specimen ;
                              :obtainedfromPatient <https://w3id.org/skgo/pham#10_patients_with_acute_lymphocytic_leukemia> ;
                              rdfs:label "Peripheral_blood_lymphocytes"@en .


###  https://w3id.org/skgo/pham#Phase_III_clinical_trials_with_ABC_transporter_inhibitors
:Phase_III_clinical_trials_with_ABC_transporter_inhibitors rdf:type owl:NamedIndividual ,
                                                                    :Patient ;
                                                           :hasDisease :AML ,
                                                                       :Breast_Cancer ,
                                                                       :Lung_cancer ;
                                                           :has_Treatment :Chemotherapy_with_targeted_inhibitors_of_Pgp-mediated_drug_transport ;
                                                           rdfs:label "Phase_III_clinical_trials_with_ABC_transporter_inhibitors"@en .


###  https://w3id.org/skgo/pham#Phase_II_clinical_trials_in_patients
:Phase_II_clinical_trials_in_patients rdf:type owl:NamedIndividual ,
                                               :Patient ;
                                      :hasDisease :Breast_Cancer ,
                                                  :Colerectal_cancer ,
                                                  :Lung_cancer ,
                                                  :Myeloma ,
                                                  :Ovarian_cancer ,
                                                  :Renal_cell_cancer ;
                                      :has_Treatment :Differential_inhibition_of_various_transporters_by_two_structurally_similar_MDR_modulators ;
                                      rdfs:label "Phase_II_clinical_trials_in_patients"@en .


###  https://w3id.org/skgo/pham#Pheochromocytoma
:Pheochromocytoma rdf:type owl:NamedIndividual ,
                           :Disease ;
                  rdfs:label "Pheochromocytoma"@en .


###  https://w3id.org/skgo/pham#Podophyllotoxin
:Podophyllotoxin rdf:type owl:NamedIndividual ,
                          :Drug ;
                 rdfs:label "Podophyllotoxin"@en .


###  https://w3id.org/skgo/pham#Podophyllotoxin-etoposide_teniposide
:Podophyllotoxin-etoposide_teniposide rdf:type owl:NamedIndividual ,
                                               :Drug ;
                                      rdfs:label "Podophyllotoxin-etoposide_teniposide"@en .


###  https://w3id.org/skgo/pham#Poor-risk_acute_leukaemia_samples
:Poor-risk_acute_leukaemia_samples rdf:type owl:NamedIndividual ,
                                            :Specimen ;
                                   :obtainedfromPatient :Phase_III_clinical_trials_with_ABC_transporter_inhibitors ;
                                   rdfs:label "Poor-risk_acute_leukaemia_samples"@en .


###  https://w3id.org/skgo/pham#Prazocin
:Prazocin rdf:type owl:NamedIndividual ,
                   :Drug ;
          rdfs:label "Prazocin"@en .


###  https://w3id.org/skgo/pham#Proc._Nati._Acad._Sci._USA
:Proc._Nati._Acad._Sci._USA rdf:type owl:NamedIndividual ,
                                     terms1:Publisher ,
                                     foaf:Agent ;
                            terms1:name "Proc. Nati. Acad. Sci. USA"^^rdfs:Literal .


###  https://w3id.org/skgo/pham#Promega_Biotec
:Promega_Biotec rdf:type owl:NamedIndividual ,
                         foaf:Organization .


###  https://w3id.org/skgo/pham#RNA_Fingerprinting
:RNA_Fingerprinting rdf:type owl:NamedIndividual ,
                             :Antibody-mediated_cytolysis_experiment ;
                    :hasBlotAnalysis :Northern_analysis_of_the_expression_of_BCRP_mRNA ;
                    :useAssay :RT-PCR_assay ,
                              :Sulforhodamine-B_cytotoxicity_assay ;
                    rdfs:label "RNA_Fingerprinting"@en .


###  https://w3id.org/skgo/pham#ROLE_OF_ATP-DEPENDENT_TRANSPORTERS_in_chemotherapy_and_A_surrogate_assay_for_PGP_inhibition
:ROLE_OF_ATP-DEPENDENT_TRANSPORTERS_in_chemotherapy_and_A_surrogate_assay_for_PGP_inhibition rdf:type owl:NamedIndividual ,
                                                                                                      :Antibody-mediated_cytolysis_experiment ;
                                                                                             :hasTreatment :Functions_of_ABC_transporters_in_Chemotherapy ;
                                                                                             :useAssay :Surrogate_Assay ;
                                                                                             rdfs:label "ROLE_OF_ATP-DEPENDENT_TRANSPORTERS_in_chemotherapy_and_A_surrogate_assay_for_PGP_inhibition"@en .


###  https://w3id.org/skgo/pham#RT-PCR_assay
:RT-PCR_assay rdf:type owl:NamedIndividual ,
                       :Assay ;
              :useGene :Drosophila_white_gene ;
              rdfs:label "RT-PCR_assay"@en .


###  https://w3id.org/skgo/pham#Rajesh_Krishna
:Rajesh_Krishna rdf:type owl:NamedIndividual ,
                         foaf:Person .


###  https://w3id.org/skgo/pham#Refractory_AML_high-risk_MDS_sample
:Refractory_AML_high-risk_MDS_sample rdf:type owl:NamedIndividual ,
                                              :Specimen ;
                                     :obtainedfromPatient :Phase_III_clinical_trials_with_ABC_transporter_inhibitors ;
                                     rdfs:label "Refractory_AML_high-risk_MDS_sample"@en .


###  https://w3id.org/skgo/pham#Relapsed_and_refractory_AML_sample
:Relapsed_and_refractory_AML_sample rdf:type owl:NamedIndividual ,
                                             :Specimen ;
                                    :obtainedfromPatient :Phase_III_clinical_trials_with_ABC_transporter_inhibitors ;
                                    rdfs:label "Relapsed_and_refractory_AML_sample"@en .


###  https://w3id.org/skgo/pham#Renal_cell_cancer
:Renal_cell_cancer rdf:type owl:NamedIndividual ,
                            :Disease ;
                   rdfs:label "Renal_cell_cancer"@en .


###  https://w3id.org/skgo/pham#Review_Study
:Review_Study rdf:type owl:NamedIndividual ,
                       :ReviewStudy ;
              rdfs:label "Review Study"@en .


###  https://w3id.org/skgo/pham#Rhabdomyosarcoma
:Rhabdomyosarcoma rdf:type owl:NamedIndividual ,
                           :Disease ;
                  rdfs:label "Rhabdomyosarcoma"@en .


###  https://w3id.org/skgo/pham#Role_of_P-GP_in_MDR
:Role_of_P-GP_in_MDR rdf:type owl:NamedIndividual ,
                              :ClinicalProblem ;
                     rdfs:label "Role_of_P-GP_in_MDR"@en .


###  https://w3id.org/skgo/pham#Ryuichi_Nishii
:Ryuichi_Nishii rdf:type owl:NamedIndividual ,
                         foaf:Person .


###  https://w3id.org/skgo/pham#Sandra_Van_Schaeybroeck
:Sandra_Van_Schaeybroeck rdf:type owl:NamedIndividual ,
                                  foaf:Person .


###  https://w3id.org/skgo/pham#Sarcoma
:Sarcoma rdf:type owl:NamedIndividual ,
                  :Disease ;
         rdfs:label "Sarcoma"@en .


###  https://w3id.org/skgo/pham#Slot_Blot_Analysis
:Slot_Blot_Analysis rdf:type owl:NamedIndividual ,
                             :BlotAnalysis .


###  https://w3id.org/skgo/pham#Small_Cell_Lung_Cancer
:Small_Cell_Lung_Cancer rdf:type owl:NamedIndividual ,
                                 :Disease ;
                        rdfs:label "Small_Cell_Lung_Cancer"@en .


###  https://w3id.org/skgo/pham#Southern_Blot_Analysis
:Southern_Blot_Analysis rdf:type owl:NamedIndividual ,
                                 :SouthernBlotting ;
                        rdfs:label "Southern_Blot_Analysis"@en .


###  https://w3id.org/skgo/pham#StatisticalAnalysis
:StatisticalAnalysis rdf:type owl:NamedIndividual ;
                     foaf:name "StatisticalAnalysis"@en .


###  https://w3id.org/skgo/pham#Study
:Study rdf:type owl:NamedIndividual ;
       foaf:name "Study"@en .


###  https://w3id.org/skgo/pham#Sulforhodamine-B_cytotoxicity_assay
:Sulforhodamine-B_cytotoxicity_assay rdf:type owl:NamedIndividual ,
                                              :Assay ;
                                     rdfs:label "Sulforhodamine-B_cytotoxicity_assay"@en .


###  https://w3id.org/skgo/pham#Surrogate_Assay
:Surrogate_Assay rdf:type owl:NamedIndividual ,
                          :Assay ;
                 :hasAssayMethod """This assay uses flow cytometry to test the ability of human CD56+ cells 
which express high levels of the efflux pump P-glycoprotein (PGP)  to retain the PGP substrate rhodamine after exposure to the efflux pump inhibitor PSC-833."""@en ;
                 rdfs:label "Surrogate_Assay"@en .


###  https://w3id.org/skgo/pham#Susan_E._Bates
:Susan_E._Bates rdf:type owl:NamedIndividual ,
                         foaf:Person .


###  https://w3id.org/skgo/pham#TAMMY_KROGMANN
:TAMMY_KROGMANN rdf:type owl:NamedIndividual ,
                         foaf:Person .


###  https://w3id.org/skgo/pham#Takafumi_Tsujiuchi
:Takafumi_Tsujiuchi rdf:type owl:NamedIndividual ,
                             foaf:Person .


###  https://w3id.org/skgo/pham#Takeo_Nakanishi
:Takeo_Nakanishi rdf:type owl:NamedIndividual ,
                          foaf:Person .


###  https://w3id.org/skgo/pham#TargetingMethod1
:TargetingMethod1 rdf:type owl:NamedIndividual .


###  https://w3id.org/skgo/pham#TargetingMethod10
:TargetingMethod10 rdf:type owl:NamedIndividual .


###  https://w3id.org/skgo/pham#TargetingMethod11
:TargetingMethod11 rdf:type owl:NamedIndividual .


###  https://w3id.org/skgo/pham#TargetingMethod12
:TargetingMethod12 rdf:type owl:NamedIndividual .


###  https://w3id.org/skgo/pham#TargetingMethod13
:TargetingMethod13 rdf:type owl:NamedIndividual .


###  https://w3id.org/skgo/pham#TargetingMethod14
:TargetingMethod14 rdf:type owl:NamedIndividual .


###  https://w3id.org/skgo/pham#TargetingMethod15
:TargetingMethod15 rdf:type owl:NamedIndividual .


###  https://w3id.org/skgo/pham#TargetingMethod16
:TargetingMethod16 rdf:type owl:NamedIndividual .


###  https://w3id.org/skgo/pham#TargetingMethod17
:TargetingMethod17 rdf:type owl:NamedIndividual .


###  https://w3id.org/skgo/pham#TargetingMethod18
:TargetingMethod18 rdf:type owl:NamedIndividual .


###  https://w3id.org/skgo/pham#TargetingMethod19
:TargetingMethod19 rdf:type owl:NamedIndividual .


###  https://w3id.org/skgo/pham#TargetingMethod2
:TargetingMethod2 rdf:type owl:NamedIndividual .


###  https://w3id.org/skgo/pham#TargetingMethod20
:TargetingMethod20 rdf:type owl:NamedIndividual .


###  https://w3id.org/skgo/pham#TargetingMethod3
:TargetingMethod3 rdf:type owl:NamedIndividual .


###  https://w3id.org/skgo/pham#TargetingMethod4
:TargetingMethod4 rdf:type owl:NamedIndividual .


###  https://w3id.org/skgo/pham#TargetingMethod5
:TargetingMethod5 rdf:type owl:NamedIndividual .


###  https://w3id.org/skgo/pham#TargetingMethod6
:TargetingMethod6 rdf:type owl:NamedIndividual .


###  https://w3id.org/skgo/pham#TargetingMethod7
:TargetingMethod7 rdf:type owl:NamedIndividual .


###  https://w3id.org/skgo/pham#TargetingMethod8
:TargetingMethod8 rdf:type owl:NamedIndividual .


###  https://w3id.org/skgo/pham#TargetingMethod9
:TargetingMethod9 rdf:type owl:NamedIndividual .


###  https://w3id.org/skgo/pham#Targeting_multidrug_resistance_in_cancer
:Targeting_multidrug_resistance_in_cancer rdf:type owl:NamedIndividual ,
                                                   terms1:Publication ,
                                                   bibo:Article ;
                                          :addressesStudy :Drug_efflux_from_cancer_cells_mediated_by_ATP-binding_cassette_ABC_transporters ;
                                          terms1:publicationYear "2006"^^xsd:gYear ;
                                          bibo:abstract """Effective treatment of metastatic cancers usually requires the use of toxic
chemotherapy. In most cases, multiple drugs are used, as resistance to single agents occurs almost universally. For this reason, elucidation of mechanisms that confer simultaneous resistance to different drugs with different targets and chemical structures  multidrug resistance  has been a major goal of cancer biologists during the past 35 years. Here, we review the most common of these mechanisms, one that relies on drug efflux from cancer cells mediated by ATP-binding cassette (ABC) transporters. We describe various approaches
to combating multidrug-resistant cancer, including the development of drugs that engage, evade or exploit efflux by ABC transporters."""@en ;
                                          terms:creator :Catherine_Booth-Genthe ,
                                                        :Gergely_Szakcs ,
                                                        :Jill_K._Paterson ,
                                                        :Joseph_A._Ludwig ,
                                                        :Michael_M._Gottesman ;
                                          terms:publisher <https://w3id.org/ScienceOnto/phm#Publisher3> ,
                                                          :Nature_Publishing_Group ;
                                          terms:title "Targeting multidrug resistance in cancer"^^rdfs:Literal .


###  https://w3id.org/skgo/pham#Taurocholate
:Taurocholate rdf:type owl:NamedIndividual ,
                       :Drug ;
              rdfs:label "Taurocholate"@en .


###  https://w3id.org/skgo/pham#Taxenes-paclitaxel_docetaxel
:Taxenes-paclitaxel_docetaxel rdf:type owl:NamedIndividual ,
                                       :Drug ;
                              rdfs:label "Taxenes-paclitaxel_docetaxel"@en .


###  https://w3id.org/skgo/pham#Teniopside
:Teniopside rdf:type owl:NamedIndividual ,
                     :Drug ;
            rdfs:label "Teniopside"@en .


###  https://w3id.org/skgo/pham#Testicular_cancer
:Testicular_cancer rdf:type owl:NamedIndividual ,
                            :Disease ;
                   rdfs:label "Testicular_cancer"@en .


###  https://w3id.org/skgo/pham#The_new_transporter_was_termed_the_breast_cancer_resistance_protein_BCRP
:The_new_transporter_was_termed_the_breast_cancer_resistance_protein_BCRP rdf:type owl:NamedIndividual ,
                                                                                   :levels_of_mdr1_mRNA ;
                                                                          rdfs:label "The_new_transporter_was_termed_the_breast_cancer_resistance_protein_BCRP"@en ;
                                                                          skos:definition """The new transporter was
termed the breast cancer resistance protein (BCRP),
because of its identification in MCF-7 human breast
carcinoma cells."""@en .


###  https://w3id.org/skgo/pham#The_physiological_functions_and_structures_of_ABC_transporters
:The_physiological_functions_and_structures_of_ABC_transporters rdf:type owl:NamedIndividual ,
                                                                         :ClinicalStudy ;
                                                                :hasStudyDesign :Review_Study ;
                                                                :investigate :Breast_Cancer ;
                                                                :performsExperiment :Endogenous_and_exogenous_substrates_for_ABC_transporters ;
                                                                rdfs:label "The_physiological_functions_and_structures_of_ABC_transporters"@en .


###  https://w3id.org/skgo/pham#The_physiological_functions_and_structures_of_ABC_transporters_and_development_of_chemosensitizers
:The_physiological_functions_and_structures_of_ABC_transporters_and_development_of_chemosensitizers rdf:type owl:NamedIndividual ,
                                                                                                             :levels_of_mdr1_mRNA ;
                                                                                                    rdfs:label "The_physiological_functions_and_structures_of_ABC_transporters_and_development_of_chemosensitizers"@en ;
                                                                                                    skos:definition """The physiological functions and structures of ABC transporters, and
development of chemosensitizers are described focusing
on well-known proteins including Pgp, MRP, and BCRP."""@en .


###  https://w3id.org/skgo/pham#TissueLocalization1
:TissueLocalization1 rdf:type owl:NamedIndividual .


###  https://w3id.org/skgo/pham#TissueLocalization10
:TissueLocalization10 rdf:type owl:NamedIndividual .


###  https://w3id.org/skgo/pham#TissueLocalization11
:TissueLocalization11 rdf:type owl:NamedIndividual .


###  https://w3id.org/skgo/pham#TissueLocalization12
:TissueLocalization12 rdf:type owl:NamedIndividual .


###  https://w3id.org/skgo/pham#TissueLocalization13
:TissueLocalization13 rdf:type owl:NamedIndividual .


###  https://w3id.org/skgo/pham#TissueLocalization14
:TissueLocalization14 rdf:type owl:NamedIndividual .


###  https://w3id.org/skgo/pham#TissueLocalization15
:TissueLocalization15 rdf:type owl:NamedIndividual .


###  https://w3id.org/skgo/pham#TissueLocalization16
:TissueLocalization16 rdf:type owl:NamedIndividual .


###  https://w3id.org/skgo/pham#TissueLocalization17
:TissueLocalization17 rdf:type owl:NamedIndividual .


###  https://w3id.org/skgo/pham#TissueLocalization18
:TissueLocalization18 rdf:type owl:NamedIndividual .


###  https://w3id.org/skgo/pham#TissueLocalization19
:TissueLocalization19 rdf:type owl:NamedIndividual .


###  https://w3id.org/skgo/pham#TissueLocalization2
:TissueLocalization2 rdf:type owl:NamedIndividual .


###  https://w3id.org/skgo/pham#TissueLocalization20
:TissueLocalization20 rdf:type owl:NamedIndividual .


###  https://w3id.org/skgo/pham#TissueLocalization3
:TissueLocalization3 rdf:type owl:NamedIndividual .


###  https://w3id.org/skgo/pham#TissueLocalization4
:TissueLocalization4 rdf:type owl:NamedIndividual .


###  https://w3id.org/skgo/pham#TissueLocalization5
:TissueLocalization5 rdf:type owl:NamedIndividual .


###  https://w3id.org/skgo/pham#TissueLocalization6
:TissueLocalization6 rdf:type owl:NamedIndividual .


###  https://w3id.org/skgo/pham#TissueLocalization7
:TissueLocalization7 rdf:type owl:NamedIndividual .


###  https://w3id.org/skgo/pham#TissueLocalization8
:TissueLocalization8 rdf:type owl:NamedIndividual .


###  https://w3id.org/skgo/pham#TissueLocalization9
:TissueLocalization9 rdf:type owl:NamedIndividual .


###  https://w3id.org/skgo/pham#Tito_Fojo
:Tito_Fojo rdf:type owl:NamedIndividual ,
                    foaf:Person .


###  https://w3id.org/skgo/pham#Topotecan
:Topotecan rdf:type owl:NamedIndividual ,
                    :Drug ;
           rdfs:label "Topotecan"@en .


###  https://w3id.org/skgo/pham#Trastuzumab
:Trastuzumab rdf:type owl:NamedIndividual ,
                      :Drug ;
             rdfs:label "Trastuzumab"@en .


###  https://w3id.org/skgo/pham#TreatmentOutcome1
:TreatmentOutcome1 rdf:type owl:NamedIndividual .


###  https://w3id.org/skgo/pham#TreatmentOutcome10
:TreatmentOutcome10 rdf:type owl:NamedIndividual .


###  https://w3id.org/skgo/pham#TreatmentOutcome11
:TreatmentOutcome11 rdf:type owl:NamedIndividual .


###  https://w3id.org/skgo/pham#TreatmentOutcome12
:TreatmentOutcome12 rdf:type owl:NamedIndividual .


###  https://w3id.org/skgo/pham#TreatmentOutcome13
:TreatmentOutcome13 rdf:type owl:NamedIndividual .


###  https://w3id.org/skgo/pham#TreatmentOutcome14
:TreatmentOutcome14 rdf:type owl:NamedIndividual .


###  https://w3id.org/skgo/pham#TreatmentOutcome15
:TreatmentOutcome15 rdf:type owl:NamedIndividual .


###  https://w3id.org/skgo/pham#TreatmentOutcome16
:TreatmentOutcome16 rdf:type owl:NamedIndividual .


###  https://w3id.org/skgo/pham#TreatmentOutcome17
:TreatmentOutcome17 rdf:type owl:NamedIndividual .


###  https://w3id.org/skgo/pham#TreatmentOutcome18
:TreatmentOutcome18 rdf:type owl:NamedIndividual .


###  https://w3id.org/skgo/pham#TreatmentOutcome19
:TreatmentOutcome19 rdf:type owl:NamedIndividual .


###  https://w3id.org/skgo/pham#TreatmentOutcome2
:TreatmentOutcome2 rdf:type owl:NamedIndividual .


###  https://w3id.org/skgo/pham#TreatmentOutcome20
:TreatmentOutcome20 rdf:type owl:NamedIndividual .


###  https://w3id.org/skgo/pham#TreatmentOutcome3
:TreatmentOutcome3 rdf:type owl:NamedIndividual .


###  https://w3id.org/skgo/pham#TreatmentOutcome4
:TreatmentOutcome4 rdf:type owl:NamedIndividual .


###  https://w3id.org/skgo/pham#TreatmentOutcome5
:TreatmentOutcome5 rdf:type owl:NamedIndividual .


###  https://w3id.org/skgo/pham#TreatmentOutcome6
:TreatmentOutcome6 rdf:type owl:NamedIndividual .


###  https://w3id.org/skgo/pham#TreatmentOutcome7
:TreatmentOutcome7 rdf:type owl:NamedIndividual .


###  https://w3id.org/skgo/pham#TreatmentOutcome8
:TreatmentOutcome8 rdf:type owl:NamedIndividual .


###  https://w3id.org/skgo/pham#TreatmentOutcome9
:TreatmentOutcome9 rdf:type owl:NamedIndividual .


###  https://w3id.org/skgo/pham#VAD
:VAD rdf:type owl:NamedIndividual ,
              :Drug ;
     rdfs:label "VAD"@en .


###  https://w3id.org/skgo/pham#Vemurafenib
:Vemurafenib rdf:type owl:NamedIndividual ,
                      :Drug ;
             rdfs:label "Vemurafenib"@en .


###  https://w3id.org/skgo/pham#Verapamil
:Verapamil rdf:type owl:NamedIndividual ,
                    :Drug ;
           rdfs:label "Verapamil"@en .


###  https://w3id.org/skgo/pham#Vesicle_transport_experiments
:Vesicle_transport_experiments rdf:type owl:NamedIndividual ,
                                        :Multidrug_resistance_to_cancer_cells ;
                               :hasTreatment :Differential_inhibition_of_various_transporters_by_two_structurally_similar_MDR_modulators ;
                               :useDrug :Daunomycin ;
                               :useProbe :cDNA ;
                               rdfs:label "Vesicle_transport_experiments"@en .


###  https://w3id.org/skgo/pham#Vincristine
:Vincristine rdf:type owl:NamedIndividual ,
                      :Drug ;
             rdfs:label "Vincristine"@en .


###  https://w3id.org/skgo/pham#Vindesine
:Vindesine rdf:type owl:NamedIndividual ,
                    :Drug ;
           rdfs:label "Vindesine"@en .


###  https://w3id.org/skgo/pham#WEIDONG_YANG
:WEIDONG_YANG rdf:type owl:NamedIndividual ,
                       foaf:Person .


###  https://w3id.org/skgo/pham#Western_Blot_Analysis
:Western_Blot_Analysis rdf:type owl:NamedIndividual ,
                                :WesternBlotting ;
                       rdfs:label "Western_Blot_Analysis"@en .


###  https://w3id.org/skgo/pham#YONGMING_GAO
:YONGMING_GAO rdf:type owl:NamedIndividual ,
                       foaf:Person .


###  https://w3id.org/skgo/pham#Yuya_Okui
:Yuya_Okui rdf:type owl:NamedIndividual ,
                    foaf:Person .


###  https://w3id.org/skgo/pham#Zidovudine
:Zidovudine rdf:type owl:NamedIndividual ,
                     :Drug ;
            rdfs:label "Zidovudine"@en .


###  https://w3id.org/skgo/pham#Zosuquidar
:Zosuquidar rdf:type owl:NamedIndividual ,
                     :Drug ;
            rdfs:label "Zosuquidar"@en .


###  https://w3id.org/skgo/pham#Zosuquidar_AML_experiments
:Zosuquidar_AML_experiments rdf:type owl:NamedIndividual ,
                                     :Multidrug_resistance_to_cancer_cells ;
                            :hasExperimentMethod <https://w3id.org/skgo/pham#Comparative_CD34+_blast_responses_were_examined> ;
                            :useCellLine <https://w3id.org/skgo/pham#CD34+_Leukemic_Blasts> ;
                            :useDrug :Zosuquidar ;
                            :useReagent :DiOC2 ,
                                        :Fluorochrome-labeled_anti-CD_antibodies ;
                            :useSpecimen :Bone_marrow_aspirates ;
                            :hasExperimentalResult """50 AML specimens for MDR function
using zosuquidar, a P-gp-selective modulator, and two
ex vivo leukemic blast bioassays confirms the heterogeneous
nature of MDR efflux pump function by AML
blasts. Moreover, it supports the supposition that function
of multiple transporters could have circumvented
or obscured efficacy of P-gp modulators in AML clinical
trials like E3999 with zosuquidar."""@en ;
                            rdfs:label "Zosuquidar_AML_experiments"@en .


###  https://w3id.org/skgo/pham#antibody-mediated_cytolysis_experiment
:antibody-mediated_cytolysis_experiment rdf:type owl:NamedIndividual ,
                                                 :Antibody-mediated_cytolysis_experiment ;
                                        :hasTreatment :Chemotherapy_with_targeted_inhibitors_of_Pgp-mediated_drug_transport ;
                                        :useAssay :Functional_Assay ;
                                        rdfs:label "antibody-mediated_cytolysis_experiment"@en .


###  https://w3id.org/skgo/pham#cDNA
:cDNA rdf:type owl:NamedIndividual ,
               :Probe ;
      rdfs:label "cDNA"@en .


###  https://w3id.org/skgo/pham#ex_vivo
:ex_vivo rdf:type owl:NamedIndividual ,
                  :Exvivo .


###  https://w3id.org/skgo/pham#hasAssayMethod
:hasAssayMethod rdf:type owl:NamedIndividual ;
                foaf:name "hasAssayMethod"@en .


###  https://w3id.org/skgo/pham#hasDrugEffects
:hasDrugEffects rdf:type owl:NamedIndividual ;
                foaf:name "hasDrugEffects"@en .


###  https://w3id.org/skgo/pham#hasEligibilityCriteria
:hasEligibilityCriteria rdf:type owl:NamedIndividual ;
                        foaf:name "hasEligibilityCriteria"@en .


###  https://w3id.org/skgo/pham#hasExperimentalResult
:hasExperimentalResult rdf:type owl:NamedIndividual ;
                       foaf:name "hasExperimentalResult"@en .


###  https://w3id.org/skgo/pham#hasFindings
:hasFindings rdf:type owl:NamedIndividual ;
             foaf:name "hasFindings"@en .


###  https://w3id.org/skgo/pham#hasMutationResult
:hasMutationResult rdf:type owl:NamedIndividual ;
                   foaf:name "hasMutationResult"@en .


###  https://w3id.org/skgo/pham#hasSuggestion
:hasSuggestion rdf:type owl:NamedIndividual ;
               foaf:name "hasSuggestion"@en .


###  https://w3id.org/skgo/pham#hasTissueLocalization
:hasTissueLocalization rdf:type owl:NamedIndividual ;
                       foaf:name "hasTissueLocalization"@en .


###  https://w3id.org/skgo/pham#identify_and_overcome_underlying_mechanisms_of_resistance
:identify_and_overcome_underlying_mechanisms_of_resistance rdf:type owl:NamedIndividual ,
                                                                    :levels_of_mdr1_mRNA ;
                                                           rdfs:label "identify_and_overcome_underlying_mechanisms_of_resistance"@en ;
                                                           skos:definition """this Review focuses on the mechanisms that enable the survival of cancer
cells during drug treatment and on current research
efforts to identify and overcome underlying mechanisms
of resistance to both standard chemotherapeutic agents
and molecularly targeted therapies."""@en .


###  https://w3id.org/skgo/pham#in_silico
:in_silico rdf:type owl:NamedIndividual ,
                    :Insilico .


###  https://w3id.org/skgo/pham#in_vitro
:in_vitro rdf:type owl:NamedIndividual ,
                   :Invitro .


###  https://w3id.org/skgo/pham#in_vivo
:in_vivo rdf:type owl:NamedIndividual ,
                  :Invivo .


###  https://w3id.org/skgo/pham#inhibitors_NB-506_J-107088
:inhibitors_NB-506_J-107088 rdf:type owl:NamedIndividual ,
                                     :Drug ;
                            rdfs:label "inhibitors_NB-506_J-107088"@en .


###  https://w3id.org/skgo/pham#mdr1
:mdr1 rdf:type owl:NamedIndividual ,
               :Gene ;
      rdfs:label "MDR1"@en .


###  https://w3id.org/skgo/pham#mdr1_gene_expression
:mdr1_gene_expression rdf:type owl:NamedIndividual ,
                               :Multidrug_resistance_to_cancer_cells ;
                      :hasBlotAnalysis :Slot_Blot_Analysis ;
                      :hasTreatment :Cancer_chemotherapy_doxorubicin_vinblastine ;
                      :useCellLine :CCL_127__PC12 ,
                                   :Colon_carcinoma ,
                                   :HTB_10_HTB_11_HTB_38 ,
                                   :KB-3-1_KB-8-5_KB-V1 ;
                      :useDrug :Actinomycin_D ,
                               :Doxorubicin ,
                               :Mitomycin_C ,
                               :Vincristine ;
                      :useGene :mdr1 ;
                      :useProbe :cDNA ;
                      :hasExperimentalResult "Expression of mdr1 in Tumors from Untreated and Treated Patients"@en ;
                      :name "Mdr1 Hybridization Probes, RNA Extraction, Electrophoresis"@en ;
                      rdfs:label "mdr1_gene_expression"@en .


###  https://w3id.org/skgo/pham#multidrug_resistance_to_cancer_cells
:multidrug_resistance_to_cancer_cells rdf:type owl:NamedIndividual ,
                                               :Multidrug_resistance_to_cancer_cells ;
                                      :hasExperimentMethod :ROLE_OF_ATP-DEPENDENT_TRANSPORTERS_in_chemotherapy_and_A_surrogate_assay_for_PGP_inhibition ;
                                      :useCellLine <https://w3id.org/skgo/pham#CD56+> ;
                                      :useDrug :Anthranilic-acid-based_drug ,
                                               :Immunosuppressant_cyclosporin_A ,
                                               :Mitoxantrone ,
                                               :Paclitaxel ,
                                               :Verapamil ;
                                      :useGene :ABCA2 ,
                                               :MDR2 ,
                                               :MRP1 ,
                                               :MRP2 ,
                                               :MRP3 ,
                                               :MRP4 ,
                                               :MRP5 ,
                                               :MRP6 ;
                                      :name "Transfection Experiments" ;
                                      rdfs:label "multidrug_resistance_to_cancer_cells"@en .


###  https://w3id.org/skgo/pham#topoisomerase_I
:topoisomerase_I rdf:type owl:NamedIndividual ,
                          :Drug ;
                 rdfs:label "topoisomerase_I"@en .


###  https://w3id.org/skgo/pham#useCellLine
:useCellLine rdf:type owl:NamedIndividual ;
             foaf:name "useCellLine"@en .


###  https://w3id.org/skgo/pham#useDrug
:useDrug rdf:type owl:NamedIndividual ;
         foaf:name "useDrug"@en .


###  https://w3id.org/skgo/pham#useGene
:useGene rdf:type owl:NamedIndividual ;
         foaf:name "useGene"@en .


###  https://w3id.org/skgo/pham#useProbe
:useProbe rdf:type owl:NamedIndividual ;
          foaf:name "useProbe"@en .


###  https://w3id.org/skgo/pham#useReagent
:useReagent rdf:type owl:NamedIndividual ;
            foaf:name "useReagent"@en .


###  https://w3id.org/skgo/pham#useSpecimen
:useSpecimen rdf:type owl:NamedIndividual ;
             foaf:name "Specimen that are used as material in experimental study."@en ,
                       "useSpecimen"@en .


###  https://w3id.org/skgo/pham#useStatisticalAnalysis
:useStatisticalAnalysis rdf:type owl:NamedIndividual ;
                        foaf:name "useStatisticalAnalysis"@en .


###  https://w3id.org/skgo/pham#10_patients_with_acute_lymphocytic_leukemia
<https://w3id.org/skgo/pham#10_patients_with_acute_lymphocytic_leukemia> rdf:type owl:NamedIndividual ,
                                                                                  :Patient ;
                                                                         :hasDisease :Leukaemia ;
                                                                         :has_Treatment :Cancer_chemotherapy_doxorubicin_vinblastine ;
                                                                         rdfs:label "10_patients_with_acute_lymphocytic_leukemia"@en .


###  https://w3id.org/skgo/pham#50_patients_with_newly_diagnosed_AML
<https://w3id.org/skgo/pham#50_patients_with_newly_diagnosed_AML> rdf:type owl:NamedIndividual ,
                                                                           :Patient ;
                                                                  :hasDisease :AML ;
                                                                  rdfs:label "50_patients_with_newly_diagnosed_AML"@en .


###  https://w3id.org/skgo/pham#795-bp_cDNA
<https://w3id.org/skgo/pham#795-bp_cDNA> rdf:type owl:NamedIndividual ,
                                                  :Probe ;
                                         rdfs:label "795-bp_cDNA"@en .


###  https://w3id.org/skgo/pham#99mTc-labeled_compounds_were_exported_via_MRP24_and_BCRP
<https://w3id.org/skgo/pham#99mTc-labeled_compounds_were_exported_via_MRP24_and_BCRP> rdf:type owl:NamedIndividual ,
                                                                                                :levels_of_mdr1_mRNA ;
                                                                                       rdfs:label "99mTc-labeled_compounds_were_exported_via_MRP24_and_BCRP"@en ;
                                                                                       skos:definition """We examinedwhether 99mTc-labeled compounds were
exported via MRP24 and BCRP and whether these compounds
had affinity for these transporters including MDR1
and MRP1 in cancer cells."""@en .


###  https://w3id.org/skgo/pham#ATP_dependent_xenobiotic_transporter_may_contribute_significantly_to_the_MCF-7/AdrVp_cells
<https://w3id.org/skgo/pham#ATP_dependent_xenobiotic_transporter_may_contribute_significantly_to_the_MCF-7/AdrVp_cells> rdf:type owl:NamedIndividual ,
                                                                                                                                 :levels_of_mdr1_mRNA ;
                                                                                                                        terms:description "The hypothesis that an ATPdependent xenobiotic transporter may contribute significantly to the multidrug-resistance phenotype of MCF-7yAdrVp cells." ;
                                                                                                                        rdfs:label "ATP_dependent_xenobiotic_transporter_may_contribute_significantly_to_the_MCF-7/AdrVp_cells"@en .


###  https://w3id.org/skgo/pham#BCRP_substrate/inhibitors
<https://w3id.org/skgo/pham#BCRP_substrate/inhibitors> rdf:type owl:NamedIndividual ,
                                                                :Multidrug_resistance_to_cancer_cells ;
                                                       :useDrug :BBR3390 ,
                                                                :CI1033 ,
                                                                :Daunorubicin ,
                                                                :Doxorubicin ,
                                                                :Epirubicin ,
                                                                :Flavopiridol ,
                                                                :Iamivudine ,
                                                                :Idarubicinol ,
                                                                :Indolocarbazole ,
                                                                :Methotrexate ,
                                                                :Mitoxantrone ,
                                                                :Prazocin ,
                                                                :Topotecan ,
                                                                :Zidovudine ,
                                                                :topoisomerase_I ;
                                                       rdfs:label "BCRP_substrate/inhibitors"@en .


###  https://w3id.org/skgo/pham#CAV/EP
<https://w3id.org/skgo/pham#CAV/EP> rdf:type owl:NamedIndividual ,
                                             :Drug ;
                                    rdfs:label "CAV/EP"@en .


###  https://w3id.org/skgo/pham#CD34+_Leukemic_Blasts
<https://w3id.org/skgo/pham#CD34+_Leukemic_Blasts> rdf:type owl:NamedIndividual ,
                                                            :CellLine ;
                                                   rdfs:label "CD34+_Leukemic_Blasts"@en .


###  https://w3id.org/skgo/pham#CD56+
<https://w3id.org/skgo/pham#CD56+> rdf:type owl:NamedIndividual ,
                                            :CellLine ;
                                   rdfs:label "CD56+"@en .


###  https://w3id.org/skgo/pham#Comparative_CD34+_blast_responses_were_examined
<https://w3id.org/skgo/pham#Comparative_CD34+_blast_responses_were_examined> rdf:type owl:NamedIndividual ,
                                                                                      :Antibody-mediated_cytolysis_experiment ;
                                                                             :useAssay :Accumulation_Bioassay ,
                                                                                       :Efflux_Bioassay ,
                                                                                       :Functional_Bioassay ;
                                                                             :useStatisticalAnalysis :Blast_populations_in_the_two_bioassays ;
                                                                             rdfs:label "Comparative_CD34+_blast_responses_were_examined"@en .


###  https://w3id.org/skgo/pham#Differentially_overexpressed_in_MCF-7/AdrVp_cells_compared_with_MCF-7_cells
<https://w3id.org/skgo/pham#Differentially_overexpressed_in_MCF-7/AdrVp_cells_compared_with_MCF-7_cells> rdf:type owl:NamedIndividual ,
                                                                                                                  :ClinicalStudy ;
                                                                                                         :investigate :Breast_Cancer ;
                                                                                                         :performsExperiment <https://w3id.org/skgo/pham#MCF-7/AdrVp_comparison> ;
                                                                                                         terms1:name "A multidrug resistance transporter from human MCF-7 breast cancer cells" ;
                                                                                                         :hasSuggestion """The presence of the phosphopantetheine attachment site on BCRP suggests
that BCRP may be part of a multiprotein complex."""@en ;
                                                                                                         rdfs:label "Differentially_overexpressed_in_MCF-7/AdrVp_cells_compared_with_MCF-7_cells"@en ;
                                                                                                         skos:definition """MCF-7/AdrVp is a multidrug-resistant human
breast cancer subline that displays an ATP-dependent
reduction in the intracellular accumulation of anthracycline
anticancer drugs in the absence of overexpression of known
multidrug resistance transporters such as P glycoprotein or
the multidrug resistance protein."""@en .


###  https://w3id.org/skgo/pham#ERBB2amplified_breast_cancer_cell_lines
<https://w3id.org/skgo/pham#ERBB2amplified_breast_cancer_cell_lines> rdf:type owl:NamedIndividual ,
                                                                               :CellLine ;
                                                                      rdfs:label "ERBB2_amplified_breast_cancer_cell_lines"@en .


###  https://w3id.org/skgo/pham#MCF-7/AdrVp_comparison
<https://w3id.org/skgo/pham#MCF-7/AdrVp_comparison> rdf:type owl:NamedIndividual ,
                                                             :Multidrug_resistance_to_cancer_cells ;
                                                    :hasExperimentKit :Delta_RNA_Fingerprinting_kit ;
                                                    :hasExperimentMethod :RNA_Fingerprinting ;
                                                    :useCellLine :MCF-7_human_breast_carcinoma_cells ;
                                                    :useDrug :Daunorubicin ,
                                                             :Doxorubicin ,
                                                             :Mitoxantrone ,
                                                             :Paclitaxel ,
                                                             :Vincristine ;
                                                    :useProbe <https://w3id.org/skgo/pham#795-bp_cDNA> ;
                                                    :hasExperimentalResult """Sensitivity of selected MCF-7 sublines to antineoplastic agents determined by sulforhodamine-B cytotoxicity assay (21). Experiments such as those
displayed in Figure 4D were used to obtain the LC50. For each drug and cell type, the table displays the median LC50 and range of LC50 measurements
(nM), the number of experimental determinations of LC50 that were performed (N), and the resistance factor (RF). The RF was calculated by
dividing the median LC50 for a given drug against a transfected cell line by the median LC50 of that drug against nontransfected MCF-7yW cells.
For each drug tested, the LC50 for the BCRP-transfected cells was examined for statistically significant difference from the LC50 of MCF-7yW or
MCF-7ypcDNA3 by the MannWhitney test, using MINITAB statistical software MINITAB release 8 extended, Minitab, State College, PA) and a 95%
confidence interval. The values of P for the statistically significant differences are as follows Mitoxantrone: MCF-7yW vs. MCF-7yBCRPclone6,
P 5 0.0107, MCF-7yW vs. MCF-7yBCRPclone8, P 5 0.0058, MCF-7ypcDNA3 vs. MCF-71BCRPclone6, P 5 0.0142, MCF-7ypcDNA3 vs.
MCF-7yBCRPclone8, P 5 0.0081; daunorubicin: MCF-7yW vs. MCF-7yBCRPclone6, P 5 0.0107, MCF-7yW vs. MCF-7yBCRPclone8, P 5
0.0058, MCF-7ypcDNA3 vs. MCF-7yBCRPclone6, P 5 0.0195, MCF-7ypcDNA3 vs. MCF-7yBCRPclone8, P 5 0.0163; doxorubicin: MCF-7yW
vs. MCF-7yBCRPclone6, P 5 0.0373, MCF-7yW vs. MCF-7yBCRPclone8, P 5 0.02, MCF-7ypcDNA3 vs. MCF-7yBCRPclone8, P 5 0.0304;
cis-platin: MCF-7yW vs. MCF-7yBCRPclone19, P 5 0.0497."""@en ;
                                                    rdfs:label "MCF-7/AdrVp_comparison"@en .


###  https://w3id.org/skgo/pham#MULTIDRUG_RESISTANCE_IN_CANCER:_ROLE_OF_ATP-DEPENDENT_TRANSPORTERS
:_ROLE_OF_ATP-DEPENDENT_TRANSPORTERS rdf:type owl:NamedIndividual ,
                                              terms1:Publication ,
                                              bibo:Article ;
                                     :addressesStudy :ABC_transporters_in_human_cancers ;
                                     terms1:publicationYear "2002"^^xsd:gYear ;
                                     bibo:abstract "Chemotherapeutics are the most effective treatment for metastatic tumours. However, the ability of cancer cells to become simultaneously resistant to different drugs  a trait known as multidrug resistance  remains a significant impediment to successful chemotherapy. Three decades of multidrug-resistance research have identified a myriad of ways in which cancer cells can elude chemotherapy, and it has become apparent that resistance exists against every effective drug, even our newest agents. Therefore, the ability to predict and circumvent drug resistance is likely to improve chemotherapy." ;
                                     :hasTitle "MULTIDRUG RESISTANCE IN CANCER: ROLE OF ATP-DEPENDENT TRANSPORTERS"@en ;
                                     terms:creator :Michael_M._Gottesman ,
                                                   :Susan_E._Bates ,
                                                   :Tito_Fojo ;
                                     terms:publisher :Macmillan_Magazines_Ltd ;
                                     terms:title "MULTIDRUG RESISTANCE IN CANCER: ROLE OF ATP-DEPENDENT TRANSPORTERS"^^rdfs:Literal .


###  https://w3id.org/skgo/pham#PGP/MDR1
<https://w3id.org/skgo/pham#PGP/MDR1> rdf:type owl:NamedIndividual ,
                                               :Gene ;
                                      rdfs:label "PGP/MDR1"@en .


###  https://w3id.org/skgo/pham#Springer_Science+Business_Media_LLC
<https://w3id.org/skgo/pham#Springer_Science+Business_Media_LLC> rdf:type owl:NamedIndividual ,
                                                                          terms1:Publisher .


#################################################################
#    Annotations
#################################################################

terms:AgentClass terms:issued "2008-01-14"^^xsd:date ;
                 rdfs:isDefinedBy terms: ;
                 rdfs:label "Agent Class"@en ;
                 terms:modified "2012-06-14"^^xsd:date ;
                 rdfs:comment "A group of agents."@en ;
                 terms:description "Examples of Agent Class include groups seen as classes, such as students, women, charities, lecturers."@en ;
                 terms:hasVersion <http://dublincore.org/usage/terms/history/#AgentClass-003> .


terms:BibliographicResource rdfs:isDefinedBy terms: ;
                            terms:hasVersion <http://dublincore.org/usage/terms/history/#BibliographicResource-001> ;
                            rdfs:comment "A book, article, or other documentary resource."@en ;
                            rdfs:label "Bibliographic Resource"@en ;
                            terms:issued "2008-01-14"^^xsd:date .


terms:Box terms:issued "2000-07-11"^^xsd:date ;
          rdfs:comment "The set of regions in space defined by their geographic coordinates according to the DCMI Box Encoding Scheme."@en ;
          rdfs:isDefinedBy terms: ;
          terms:modified "2008-01-14"^^xsd:date ;
          rdfs:seeAlso <http://dublincore.org/documents/dcmi-box/> ;
          rdfs:label "DCMI Box"@en ;
          terms:hasVersion <http://dublincore.org/usage/terms/history/#Box-003> .


terms:Frequency rdfs:label "Frequency"@en ;
                terms:hasVersion <http://dublincore.org/usage/terms/history/#Frequency-001> ;
                rdfs:isDefinedBy terms: ;
                rdfs:comment "A rate at which something recurs."@en ;
                terms:issued "2008-01-14"^^xsd:date .


terms:ISO3166 rdfs:comment "The set of codes listed in ISO 3166-1 for the representation of names of countries."@en ;
              terms:issued "2000-07-11"^^xsd:date ;
              rdfs:isDefinedBy terms: ;
              terms:hasVersion <http://dublincore.org/usage/terms/history/#ISO3166-004> ;
              terms:modified "2008-01-14"^^xsd:date ;
              rdfs:label "ISO 3166"@en ;
              rdfs:seeAlso <http://www.iso.org/iso/en/prods-services/iso3166ma/02iso-3166-code-lists/list-en1.html> .


terms:ISO639-2 rdfs:seeAlso <http://lcweb.loc.gov/standards/iso639-2/langhome.html> ;
               terms:modified "2008-01-14"^^xsd:date ;
               terms:issued "2000-07-11"^^xsd:date ;
               rdfs:comment "The three-letter alphabetic codes listed in ISO639-2 for the representation of names of languages."@en ;
               rdfs:isDefinedBy terms: ;
               rdfs:label "ISO 639-2"@en ;
               terms:hasVersion <http://dublincore.org/usage/terms/history/#ISO639-2-003> .


terms:ISO639-3 rdfs:label "ISO 639-3"@en ;
               rdfs:comment "The set of three-letter codes listed in ISO 639-3 for the representation of names of languages."@en ;
               terms:issued "2008-01-14"^^xsd:date ;
               terms:hasVersion <http://dublincore.org/usage/terms/history/#ISO639-3-001> ;
               rdfs:isDefinedBy terms: ;
               rdfs:seeAlso <http://www.sil.org/iso639-3/> .


terms:LicenseDocument rdfs:label "License Document"@en ;
                      rdfs:isDefinedBy terms: ;
                      terms:issued "2008-01-14"^^xsd:date ;
                      rdfs:comment "A legal document giving official permission to do something with a Resource."@en ;
                      terms:hasVersion <http://dublincore.org/usage/terms/history/#LicenseDocument-001> .


terms:LinguisticSystem terms:issued "2008-01-14"^^xsd:date ;
                       terms:hasVersion <http://dublincore.org/usage/terms/history/#LinguisticSystem-001> ;
                       terms:description "Examples include written, spoken, sign, and computer languages."@en ;
                       rdfs:isDefinedBy terms: ;
                       rdfs:comment "A system of signs, symbols, sounds, gestures, or rules used in communication."@en ;
                       rdfs:label "Linguistic System"@en .


terms:MethodOfAccrual rdfs:isDefinedBy terms: ;
                      rdfs:comment "A method by which resources are added to a collection."@en ;
                      terms:hasVersion <http://dublincore.org/usage/terms/history/#MethodOfAccrual-001> ;
                      rdfs:label "Method of Accrual"@en ;
                      terms:issued "2008-01-14"^^xsd:date .


terms:MethodOfInstruction rdfs:label "Method of Instruction"@en ;
                          rdfs:comment "A process that is used to engender knowledge, attitudes, and skills."@en ;
                          rdfs:isDefinedBy terms: ;
                          terms:hasVersion <http://dublincore.org/usage/terms/history/#MethodOfInstruction-001> ;
                          terms:issued "2008-01-14"^^xsd:date .


terms:Period rdfs:seeAlso <http://dublincore.org/documents/dcmi-period/> ;
             rdfs:comment "The set of time intervals defined by their limits according to the DCMI Period Encoding Scheme."@en ;
             terms:modified "2008-01-14"^^xsd:date ;
             terms:issued "2000-07-11"^^xsd:date ;
             rdfs:label "DCMI Period"@en ;
             rdfs:isDefinedBy terms: ;
             terms:hasVersion <http://dublincore.org/usage/terms/history/#Period-003> .


terms:PhysicalResource terms:issued "2008-01-14"^^xsd:date ;
                       rdfs:isDefinedBy terms: ;
                       rdfs:comment "A material thing."@en ;
                       terms:hasVersion <http://dublincore.org/usage/terms/history/#PhysicalResource-001> ;
                       rdfs:label "Physical Resource"@en .


terms:Point rdfs:comment "The set of points in space defined by their geographic coordinates according to the DCMI Point Encoding Scheme."@en ;
            rdfs:label "DCMI Point"@en ;
            terms:modified "2008-01-14"^^xsd:date ;
            terms:issued "2000-07-11"^^xsd:date ;
            terms:hasVersion <http://dublincore.org/usage/terms/history/#Point-003> ;
            rdfs:seeAlso <http://dublincore.org/documents/dcmi-point/> ;
            rdfs:isDefinedBy terms: .


terms:Policy rdfs:isDefinedBy terms: ;
             rdfs:label "Policy"@en ;
             rdfs:comment "A plan or course of action by an authority, intended to influence and determine decisions, actions, and other matters."@en ;
             terms:hasVersion <http://dublincore.org/usage/terms/history/#Policy-001> ;
             terms:issued "2008-01-14"^^xsd:date .


terms:ProvenanceStatement rdfs:label "Provenance Statement"@en ;
                          rdfs:isDefinedBy terms: ;
                          terms:issued "2008-01-14"^^xsd:date ;
                          terms:hasVersion <http://dublincore.org/usage/terms/history/#ProvenanceStatement-001> ;
                          rdfs:comment "A statement of any changes in ownership and custody of a resource since its creation that are significant for its authenticity, integrity, and interpretation."@en .


terms:RFC1766 rdfs:isDefinedBy terms: ;
              terms:issued "2000-07-11"^^xsd:date ;
              terms:modified "2008-01-14"^^xsd:date ;
              terms:hasVersion <http://dublincore.org/usage/terms/history/#RFC1766-003> ;
              rdfs:comment "The set of tags, constructed according to RFC 1766, for the identification of languages."@en ;
              rdfs:seeAlso <http://www.ietf.org/rfc/rfc1766.txt> ;
              rdfs:label "RFC 1766"@en .


terms:RFC3066 terms:issued "2002-07-13"^^xsd:date ;
              rdfs:label "RFC 3066"@en ;
              rdfs:isDefinedBy terms: ;
              terms:description "RFC 3066 has been obsoleted by RFC 4646."@en ;
              rdfs:comment "The set of tags constructed according to RFC 3066 for the identification of languages."@en ;
              terms:modified "2008-01-14"^^xsd:date ;
              rdfs:seeAlso <http://www.ietf.org/rfc/rfc3066.txt> ;
              terms:hasVersion <http://dublincore.org/usage/terms/history/#RFC3066-002> .


terms:RFC4646 terms:description "RFC 4646 obsoletes RFC 3066."@en ;
              terms:issued "2008-01-14"^^xsd:date ;
              terms:hasVersion <http://dublincore.org/usage/terms/history/#RFC4646-001> ;
              rdfs:seeAlso <http://www.ietf.org/rfc/rfc4646.txt> ;
              rdfs:isDefinedBy terms: ;
              rdfs:label "RFC 4646"@en ;
              rdfs:comment "The set of tags constructed according to RFC 4646 for the identification of languages."@en .


terms:RFC5646 terms:issued "2010-10-11"^^xsd:date ;
              rdfs:seeAlso <http://www.ietf.org/rfc/rfc5646.txt> ;
              terms:hasVersion <http://dublincore.org/usage/terms/history/#RFC5646-001> ;
              rdfs:comment "The set of tags constructed according to RFC 5646 for the identification of languages."@en ;
              rdfs:label "RFC 5646"@en ;
              terms:description "RFC 5646 obsoletes RFC 4646."@en ;
              rdfs:isDefinedBy terms: .


terms:RightsStatement rdfs:label "Rights Statement"@en ;
                      rdfs:isDefinedBy terms: ;
                      rdfs:comment "A statement about the intellectual property rights (IPR) held in or over a Resource, a legal document giving official permission to do something with a resource, or a statement about access rights."@en ;
                      terms:issued "2008-01-14"^^xsd:date ;
                      terms:hasVersion <http://dublincore.org/usage/terms/history/#RightsStatement-001> .


terms:Standard rdfs:comment "A basis for comparison; a reference point against which other things can be evaluated."@en ;
               rdfs:label "Standard"@en ;
               rdfs:isDefinedBy terms: ;
               terms:issued "2008-01-14"^^xsd:date ;
               terms:hasVersion <http://dublincore.org/usage/terms/history/#Standard-001> .


terms:URI rdfs:isDefinedBy terms: ;
          rdfs:comment "The set of identifiers constructed according to the generic syntax for Uniform Resource Identifiers as specified by the Internet Engineering Task Force."@en ;
          terms:issued "2000-07-11"^^xsd:date ;
          rdfs:seeAlso <http://www.ietf.org/rfc/rfc3986.txt> ;
          terms:hasVersion <http://dublincore.org/usage/terms/history/#URI-003> ;
          rdfs:label "URI"@en ;
          terms:modified "2008-01-14"^^xsd:date .


terms:W3CDTF rdfs:label "W3C-DTF"@en ;
             rdfs:comment "The set of dates and times constructed according to the W3C Date and Time Formats Specification."@en ;
             rdfs:isDefinedBy terms: ;
             terms:hasVersion <http://dublincore.org/usage/terms/history/#W3CDTF-003> ;
             terms:issued "2000-07-11"^^xsd:date ;
             terms:modified "2008-01-14"^^xsd:date ;
             rdfs:seeAlso <http://www.w3.org/TR/NOTE-datetime> .


terms:abstract rdfs:label "Abstract"@en ;
               terms:modified "2008-01-14"^^xsd:date ;
               terms:hasVersion <http://dublincore.org/usage/terms/history/#abstract-003> ;
               terms:issued "2000-07-11"^^xsd:date ;
               rdfs:isDefinedBy terms: ;
               rdfs:comment "A summary of the resource."@en .


terms:alternative rdfs:comment "An alternative name for the resource."@en ;
                  rdfs:isDefinedBy terms: ;
                  terms:hasVersion <http://dublincore.org/usage/terms/history/#alternative-003> ;
                  dc:description "An alternative name for the resource."@en ;
                  terms:modified "2010-10-11"^^xsd:date ;
                  terms:description "The distinction between titles and alternative titles is application-specific."@en ;
                  terms:issued "2000-07-11"^^xsd:date ;
                  rdfs:label "Alternative Title"@en .


terms:bibliographicCitation terms:modified "2008-01-14"^^xsd:date ;
                            terms:description "Recommended practice is to include sufficient bibliographic detail to identify the resource as unambiguously as possible."@en ;
                            rdfs:label "Bibliographic Citation"@en ;
                            terms:hasVersion <http://dublincore.org/usage/terms/history/#bibliographicCitation-002> ;
                            rdfs:comment "A bibliographic reference for the resource."@en ;
                            rdfs:isDefinedBy terms: ;
                            terms:issued "2003-02-15"^^xsd:date .


terms:contributor terms:modified "2010-10-11"^^xsd:date ;
                  rdfs:comment "An entity responsible for making contributions to the resource."@en ;
                  rdfs:isDefinedBy terms: ;
                  terms:description "Examples of a Contributor include a person, an organization, or a service."@en ;
                  terms:issued "2008-01-14"^^xsd:date ;
                  terms:hasVersion <http://dublincore.org/usage/terms/history/#contributorT-001> ;
                  rdfs:label "Contributor"@en .


terms:coverage rdfs:isDefinedBy terms: ;
               rdfs:label "Coverage"@en ;
               terms:hasVersion <http://dublincore.org/usage/terms/history/#coverageT-001> ;
               terms:description "Spatial topic and spatial applicability may be a named place or a location specified by its geographic coordinates. Temporal topic may be a named period, date, or date range. A jurisdiction may be a named administrative entity or a geographic place to which the resource applies. Recommended best practice is to use a controlled vocabulary such as the Thesaurus of Geographic Names [TGN]. Where appropriate, named places or time periods can be used in preference to numeric identifiers such as sets of coordinates or date ranges."@en ;
               terms:issued "2008-01-14"^^xsd:date ;
               rdfs:comment "The spatial or temporal topic of the resource, the spatial applicability of the resource, or the jurisdiction under which the resource is relevant."@en ;
               terms:modified "2008-01-14"^^xsd:date .


terms:creator rdfs:comment "An entity primarily responsible for making the resource."@en ;
              terms:hasVersion <http://dublincore.org/usage/terms/history/#creatorT-002> ;
              rdfs:isDefinedBy terms: ;
              terms:modified "2010-10-11"^^xsd:date ;
              terms:issued "2008-01-14"^^xsd:date ;
              rdfs:label "Creator"@en ;
              terms:description "Examples of a Creator include a person, an organization, or a service."@en .


terms:description terms:modified "2008-01-14"^^xsd:date ;
                  rdfs:label "Description"@en ;
                  rdfs:isDefinedBy terms: ;
                  terms:issued "2008-01-14"^^xsd:date ;
                  terms:hasVersion <http://dublincore.org/usage/terms/history/#descriptionT-001> ;
                  rdfs:comment "An account of the resource."@en ;
                  terms:description "Description may include but is not limited to: an abstract, a table of contents, a graphical representation, or a free-text account of the resource."@en .


terms:hasPart rdfs:isDefinedBy terms: ;
              skos:note "This term is intended to be used with non-literal values as defined in the DCMI Abstract Model (http://dublincore.org/documents/abstract-model/).  As of December 2007, the DCMI Usage Board is seeking a way to express this intention with a formal range declaration."@en ;
              terms:issued "2000-07-11"^^xsd:date ;
              rdfs:label "Has Part"@en ;
              terms:modified "2008-01-14"^^xsd:date ;
              rdfs:comment "A related resource that is included either physically or logically in the described resource."@en ;
              terms:hasVersion <http://dublincore.org/usage/terms/history/#hasPart-003> .


terms:identifier terms:hasVersion <http://dublincore.org/usage/terms/history/#identifierT-001> ;
                 rdfs:isDefinedBy terms: ;
                 terms:description "Recommended best practice is to identify the resource by means of a string conforming to a formal identification system."@en ;
                 terms:modified "2008-01-14"^^xsd:date ;
                 rdfs:comment "An unambiguous reference to the resource within a given context."@en ;
                 rdfs:label "Identifier"@en ;
                 terms:issued "2008-01-14"^^xsd:date .


terms:isPartOf terms:modified "2008-01-14"^^xsd:date ;
               rdfs:label "Is Part Of"@en ;
               terms:hasVersion <http://dublincore.org/usage/terms/history/#isPartOf-003> ;
               terms:issued "2000-07-11"^^xsd:date ;
               skos:note "This term is intended to be used with non-literal values as defined in the DCMI Abstract Model (http://dublincore.org/documents/abstract-model/).  As of December 2007, the DCMI Usage Board is seeking a way to express this intention with a formal range declaration."@en ;
               rdfs:isDefinedBy terms: ;
               rdfs:comment "A related resource in which the described resource is physically or logically included."@en .


terms:isReferencedBy rdfs:label "Is Referenced By"@en ;
                     rdfs:comment "A related resource that references, cites, or otherwise points to the described resource."@en ;
                     terms:modified "2008-01-14"^^xsd:date ;
                     rdfs:isDefinedBy terms: ;
                     skos:note "This term is intended to be used with non-literal values as defined in the DCMI Abstract Model (http://dublincore.org/documents/abstract-model/).  As of December 2007, the DCMI Usage Board is seeking a way to express this intention with a formal range declaration."@en ;
                     terms:issued "2000-07-11"^^xsd:date ;
                     terms:hasVersion <http://dublincore.org/usage/terms/history/#isReferencedBy-003> .


terms:isVersionOf rdfs:label "Is Version Of"@en ;
                  rdfs:comment "A related resource of which the described resource is a version, edition, or adaptation."@en ;
                  rdfs:isDefinedBy terms: ;
                  terms:issued "2000-07-11"^^xsd:date ;
                  skos:note "This term is intended to be used with non-literal values as defined in the DCMI Abstract Model (http://dublincore.org/documents/abstract-model/).  As of December 2007, the DCMI Usage Board is seeking a way to express this intention with a formal range declaration."@en ;
                  terms:hasVersion <http://dublincore.org/usage/terms/history/#isVersionOf-003> ;
                  terms:modified "2008-01-14"^^xsd:date ;
                  terms:description "Changes in version imply substantive changes in content rather than differences in format."@en .


terms:language rdfs:label "Language"@en ;
               terms:issued "2008-01-14"^^xsd:date ;
               terms:hasVersion <http://dublincore.org/usage/terms/history/#languageT-001> ;
               terms:modified "2008-01-14"^^xsd:date ;
               terms:description "Recommended best practice is to use a controlled vocabulary such as RFC 4646 [RFC4646]."@en ;
               rdfs:isDefinedBy terms: ;
               rdfs:comment "A language of the resource."@en .


terms:publisher terms:modified "2010-10-11"^^xsd:date ;
                terms:issued "2008-01-14"^^xsd:date ;
                rdfs:label "Publisher"@en ;
                terms:description "Examples of a Publisher include a person, an organization, or a service."@en ;
                terms:hasVersion <http://dublincore.org/usage/terms/history/#publisherT-001> ;
                rdfs:isDefinedBy terms: ;
                dc:description "An entity responsible for making the resource available."@en ;
                rdfs:comment "An entity responsible for making the resource available."@en .


terms:references rdfs:comment "A related resource that is referenced, cited, or otherwise pointed to by the described resource."@en ;
                 rdfs:label "References"@en ;
                 terms:modified "2008-01-14"^^xsd:date ;
                 terms:issued "2000-07-11"^^xsd:date ;
                 terms:hasVersion <http://dublincore.org/usage/terms/history/#references-003> ;
                 skos:note "This term is intended to be used with non-literal values as defined in the DCMI Abstract Model (http://dublincore.org/documents/abstract-model/).  As of December 2007, the DCMI Usage Board is seeking a way to express this intention with a formal range declaration."@en ;
                 rdfs:isDefinedBy terms: .


terms:relation terms:issued "2008-01-14"^^xsd:date ;
               skos:note "This term is intended to be used with non-literal values as defined in the DCMI Abstract Model (http://dublincore.org/documents/abstract-model/).  As of December 2007, the DCMI Usage Board is seeking a way to express this intention with a formal range declaration."@en ;
               rdfs:isDefinedBy terms: ;
               terms:hasVersion <http://dublincore.org/usage/terms/history/#relationT-001> ;
               rdfs:label "Relation"@en ;
               rdfs:comment "A related resource."@en ;
               terms:description "Recommended best practice is to identify the related resource by means of a string conforming to a formal identification system."@en ;
               terms:modified "2008-01-14"^^xsd:date .


terms:subject terms:modified "2012-06-14"^^xsd:date ;
              terms:hasVersion <http://dublincore.org/usage/terms/history/#subjectT-002> ;
              skos:note "This term is intended to be used with non-literal values as defined in the DCMI Abstract Model (http://dublincore.org/documents/abstract-model/).  As of December 2007, the DCMI Usage Board is seeking a way to express this intention with a formal range declaration."@en ;
              terms:issued "2008-01-14"^^xsd:date ;
              rdfs:label "Subject"@en ;
              rdfs:comment "The topic of the resource."@en ;
              terms:description "Typically, the subject will be represented using keywords, key phrases, or classification codes. Recommended best practice is to use a controlled vocabulary."@en ;
              rdfs:isDefinedBy terms: .


terms:title rdfs:label "Title"@en ;
            dc:description "A name given to the resource."@en ;
            rdfs:comment "A name given to the resource."@en ;
            terms:issued "2008-01-14"^^xsd:date ;
            terms:hasVersion <http://dublincore.org/usage/terms/history/#titleT-002> ;
            rdfs:isDefinedBy terms: ;
            terms:modified "2010-10-11"^^xsd:date .


terms:type rdfs:isDefinedBy terms: ;
           terms:description "Recommended best practice is to use a controlled vocabulary such as the DCMI Type Vocabulary [DCMITYPE]. To describe the file format, physical medium, or dimensions of the resource, use the Format element."@en ;
           rdfs:comment "The nature or genre of the resource."@en ;
           rdfs:label "Type"@en ;
           terms:modified "2008-01-14"^^xsd:date ;
           terms:hasVersion <http://dublincore.org/usage/terms/history/#typeT-001> ;
           terms:issued "2008-01-14"^^xsd:date .


:AssayKit dc:description "The title of the kit/biologicals used in the assay."@en ;
          rdfs:label "AssayKit"@en .


:AssayMethod dc:description "The methods required to perform typical screening assay. Assay methods include laboratory methods."@en ;
             rdfs:label "AssayMethod"@en .


:EasternBlotting rdfs:label "EasternBlotting"@en ;
                 dc:description "The eastern blot is a biochemical technique used to analyze protein post translational modifications (PTM) including the addition of lipids, phosphates, and glycoconjugates."@en ;
                 rdfs:comment "The eastern blot is a biochemical technique used to analyze protein post translational modifications (PTM) including the addition of lipids, phosphates, and glycoconjugates."@en .


:ExperimentalStudy rdfs:label "ExperimentalStudyDesign"@en ;
                   dc:description "Any Study conducted with a scientific approach, where a set of variables are kept constant while the other set of variables are being measured as the subject of experiment"@en .


:ObservationalStudy rdfs:label "ObservationalStudyDesign"@en ;
                    dc:description "Observational studies are ones where researchers observe the effect of a risk factor, diagnostic test, treatment or other intervention without trying to change who is or isn't exposed to it."@en .


:StatisticalAnalysis dc:description "Statistical methods involved in carrying out a study include planning, designing, collecting data, analysing, drawing meaningful interpretation and reporting of the research findings."@en ;
                     rdfs:label "StatisticalAnalysis"@en .


:Study rdfs:label "Study"@en ;
       dc:description "A detailed investigation and analysis of a subject or situation."@en .


:hasAssayMethod rdfs:comment "Methods used in Assay."@en ;
                dc:description "Methods used in Assay."@en ;
                rdfs:label "hasAssayMethod"@en .


:hasDrugEffects rdfs:label "hasDrugEffects"@en ;
                dc:description "The ability of a drug or treatment to produce a specific result."@en .


:hasEligibilityCriteria rdfs:label "hasEligibilityCriteria"@en ;
                        dc:description "Eligibility criteria for treatment studies often require that patients have a particular type and stage of disease."@en .


:hasExperimentalResult dc:description "Identification of Experimental results that are the set of facts and conclusions."@en ;
                       rdfs:label "hasExperimentalResult"@en .


:hasFindings dc:description "A conclusion reached after examination or investigation."@en ;
             rdfs:label "hasFindings"@en .


:hasMutationResult dc:description "The result of an alteration or change, as in nature, form, or quality."@en ;
                   rdfs:label "hasMutationResult"@en .


:hasSuggestion dc:description "An idea is induced in or adopted by another without argument, command, or coercion."@en ;
               rdfs:label "hasSuggestion"@en .


:hasTissueLocalization dc:description "A determination of the tissue place of proteins, genes."@en ;
                       rdfs:label "hasTissueLocalization"@en .


:useCellLine dc:description "Cell Lines  that are used as material in experimental study."@en ;
             rdfs:label "useCellLine"@en .


:useDrug rdfs:label "useDrug"@en ;
         dc:description "Drugs that are used as material in experimental study."@en .


:useGene rdfs:label "useGene"@en ;
         dc:description "Genes that are used as material in experimental study."@en .


:useProbe rdfs:label "useProbe"@en ;
          dc:description "Probes that are used as material in experimental study."@en .


:useReagent rdfs:label "useReagent"@en ;
            dc:description "Reagents that are used as material in experimental study."@en .


:useSpecimen dc:description "Specimen that are used as material in experimental study."@en ;
             rdfs:label "useSpecimen"@en .


:useStatisticalAnalysis rdfs:label "useStatisticalAnalysis"@en ;
                        dc:description "Study uses statistical analysis involves collecting and scrutinizing every data sample in a set of items from which samples can be drawn."@en .


#################################################################
#    General axioms
#################################################################

[ rdf:type owl:AllDisjointClasses ;
  owl:members ( :AssayKit
                :AssayMethod
                :CellLine
                :Chemical
                :Drug
                :EasternBlotting
                :ExperimentalStudy
                :Exvivo
                :Gene
                :Insilico
                :Invitro
                :Invivo
                :NorthernBlotting
                :ObservationalStudy
                :Probe
                :Reagent
                :ReviewStudy
                :SouthernBlotting
                :WesternBlotting
              )
] .


###  Generated by the OWL API (version 4.5.6.2018-09-06T00:27:41Z) https://github.com/owlcs/owlapi
